Irinotecan Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for Irinotecan comprises 1,086 peer-reviewed publications across 15 journals, 59 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Colorectal Neoplasms, Pancreatic Neoplasms, Neoplasms, and Stomach Neoplasms. Most recent publication: Intermediate Risk Rhabdomyosarcoma in Very Young Children (Less Than or Equal to 24 Months) Treated on the Prior Children's Oncology Group Protocol ARST1431., Pediatr Blood Cancer, 2026.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. Combined Epiregulin and Amphiregulin Expression Levels as a Predictive Biomarker for Panitumumab Therapy Benefit or Lack of Benefit in Patients With RAS Wild-Type Advanced Colorectal Cancer.
    Seligmann JF, Elliott F, Richman SD, et al. · JAMA Oncol · 2025
    PubMed: PMID 26867820 · NCT00389870 · Colorectal Neoplasms
  2. Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children's Hepatic tumors International Collaboration.
    Meyers RL, Maibach R, Hiyama E, et al. · Lancet Oncol · 2017
    PubMed: PMID 27884679 · NCT04478292 · Hepatoblastoma
  3. Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial.
    Labori KJ, Bratlie SO, Andersson B, et al. · Lancet Gastroenterol Hepatol · 2024
    PubMed: PMID 38237621 · NCT02919787 · Pancreatic Neoplasms
  4. Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101.
    Katz MH, Shi Q, Ahmad SA, et al. · JAMA Surg · 2017
    PubMed: PMID 27275632 · NCT03167112 (Folfirinox) · Pancreatic Neoplasms
  5. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
    Goldman JW, Dvorkin M, Chen Y, et al. · Lancet Oncol · 2021
    PubMed: PMID 33285097 · NCT04985201 · Small Cell Lung Carcinoma
  6. Interventions for cisplatin-induced hearing loss in children and adolescents with cancer.
    Freyer DR, Brock P, Knight K, et al. · Lancet Child Adolesc Health · 2020
    PubMed: PMID 31160205 · NCT04478292 · Hepatoblastoma
  7. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial.
    Conroy T, Bosset JF, Etienne PL, et al. · Lancet Oncol · 2021
    PubMed: PMID 33862000 · NCT05868317 · Rectal Neoplasms
  8. Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss.
    Brock PR, Maibach R, Childs M, et al. · N Engl J Med · 2018
    PubMed: PMID 29924955 · NCT04478292 · Hepatoblastoma

Primary-outcome results across pivotal trials

Per-arm reported values from Phase 2/3 and Phase 3 trials with results posted to ClinicalTrials.gov.

TrialIndicationPrimary endpointArmValue
NCT00045162Lung NeoplasmsOverall Survival
Weekly while on treatment, then every 3 months for first year, then every 6 months unitl a maximum of 3 years from enrollment.
Cisplatin + Etoposide9.1 Months
Cisplatin + Irinotecan9.9 Months
NCT00068692Rectal Neoplasms3-year Overall Survival Rate
assessed every 3 months withihn 2 years of study entry, every 6 monhts between years 3-5 and then annually for 5 years, estimated at 3 years
Control (Arm III)0.870 proportion of patients
Irinocetan (Arm I)0.965 proportion of patients
Oxaliplatin (Arm II)0.843 proportion of patients
NCT00079274Colonic NeoplasmsDisease-free Survival (Arms A and D: Wild-type KRAS Patients)
At 3 years
Wild-type KRAS Arm A74.6 percentage of participants
Wild-type KRAS Arm D71.5 percentage of participants
NCT00101686Colorectal NeoplasmsTime to Progression (TTP) at Primary Completion: FOLFIRI and mIFL
every 6 weeks until disease progression
FOLFIRI8.18 months
mIFL6.01 months
NCT00115765Colorectal NeoplasmsObjective Tumor Response Through Week 12 (Irinotecan)
Overall Study
Irinotecan and Bevacizumab Plus Panitumumab29 Participant
Irinotecan and Bevacizumab Without Panitumumab27 Participant
NCT00115765Colorectal NeoplasmsProgression-Free Survival (Oxaliplatin)
Overall study
Oxaliplatin and Bevacizumab Plus Panitumumab10.0 Month
Oxaliplatin and Bevacizumab Without Panitumumab11.4 Month
NCT00143403Colorectal NeoplasmsDisease Free Survival (DFS)
last tumor assessment date or cut-off date, whichever is earlier.
5-FU/FA21.6 months
Irinotecan + 5-FU/FA24.7 months
NCT00143455Small Cell Lung CarcinomaOverall Survival (OS) for the Full Analysis Population (FAP)
Baseline to date of death (every 3 weeks for up to 6 months on study treatment and every 2 months for a minimum of 13 months post study treatment)
Etoposide + Cisplatin (Cohort 2)9.6591 months
Irinotecan + Cisplatin (Cohort 2)10.2177 months
NCT00143455Small Cell Lung CarcinomaOverall Survival for the Per Protocol (PP) Population
Baseline to date of death (every 3 weeks for up to 6 months on study treatment and every 2 months for a minimum of 13 months post study treatment)
Etoposide + Cisplatin (Cohort 2)9.4292 months
Irinotecan + Cisplatin (Cohort 2)10.5791 months
NCT00154102
CRYSTAL
Colorectal NeoplasmsProgression-free Survival (PFS) Time - Independent Review Committee (IRC) Assessments
Time from randomisation to disease progression, death or last tumour assessment, reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006
Cetuximab Plus FOLFIRI8.9 months
FOLFIRI Alone8.0 months
NCT00154102
CRYSTAL
Colorectal NeoplasmsProgression-free Survival Time (Chinese V-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Wild-Type Population) - Independent Review Committee (IRC) Assessments
Time from randomisation to disease progression, death or last tumour assessment, reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006
Cetuximab Plus FOLFIRI9.9 months
FOLFIRI Alone8.4 months
NCT00154102
CRYSTAL
Colorectal NeoplasmsProgression-free Survival Time (KRAS Mutant Population) - Independent Review Committee (IRC) Assessments
Time from randomisation to disease progression, death or last tumour assessment, reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006
Cetuximab Plus FOLFIRI7.4 months
FOLFIRI Alone7.7 months
NCT00193596Neoplasms, Unknown PrimaryOverall Survival (OS), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Death
24 months
Irinotecan/Gemcitabine/Gefitinib8.5 months
Paclitaxel/Carboplatin/Etoposide/Gefitinib7.4 months
NCT00354744SarcomaNumber of Patients With Complete or Partial Response Assessed by RECIST Criteria
Protocol week 6 evaluation
High_Risk_Rhabdomyosarcoma63 percentage of participants
NCT00354744SarcomaPercentage of Patients Experiencing Adverse Events Due to Concurrent Therapy
From enrollment to up to 2 years
High_Risk_Rhabdomyosarcoma68.4 percentage of patients
High_Risk_Rhabdomyosarcoma55.7 percentage of patients
High_Risk_Rhabdomyosarcoma79.3 percentage of patients
High_Risk_Rhabdomyosarcoma53.3 percentage of patients
NCT00354835SarcomaEvent Free Survival (EFS)
4 years
VAC Alternating With Vincristine, Irinotecan (VI)0.5874 Probability
Vincristine, Dactinomycin, Cyclophosphamide (VAC)0.6255 Probability
NCT00354835SarcomaOverall Survival (OS)
4 years
VAC Alternating With Vincristine, Irinotecan (VI)0.7223 Probability
Vincristine, Dactinomycin, Cyclophosphamide (VAC)0.7293 Probability
NCT00354835SarcomaResponse Rate (RR)
Reporting Period 1 (Weeks 1 - 15)
VAC Alternating With Vincristine, Irinotecan (VI)0.6726 Proportion
Vincristine, Dactinomycin, Cyclophosphamide (VAC)0.6667 Proportion
NCT00457691Colorectal NeoplasmsProgression-free Survival (PFS)
First dose of study treatment up to 30 months
FOLFIRI + Placebo36.6 Weeks
FOLFIRI + Sunitinib33.6 Weeks
NCT00499369Rectal NeoplasmsProgression-free Survival (PFS)
Up to 5 years
Cohort I: Chemotherapy + Cetuximab3.2 months
Cohort I: Chemotherapy + Cetuximab + Higher Bevacizumab8.5 months
Cohort I: Chemotherapy + Cetuximab + Lower Bevacizumab4.2 months
Cohort II: Chemotherapy + Bevacizumab5.6 months
Cohort II: Chemotherapy + Cetuximab1.4 months
NCT00561470
VELOUR
Colorectal NeoplasmsOverall Survival (OS)
From the date of the first randomization until the study data cut-off date, 07 February 2011 (approximately three years)
Aflibercept/FOLFIRI13.50 months
Placebo/FOLFIRI12.06 months
NCT00941655Stomach NeoplasmsOverall Survival in Patients With Limited Metastatic Gastric Carcinoma: Arm I
12 weeks up to 3 years
Surgery + HIPEC + Systemic Chemotherapy5 Months
Surgery + HIPEC + Systemic Chemotherapy0 Months
Surgery + HIPEC + Systemic Chemotherapy14 Months
Surgery + HIPEC + Systemic Chemotherapy11 Months
Surgery + HIPEC + Systemic Chemotherapy19 Months
Surgery + HIPEC + Systemic Chemotherapy4 Months
Surgery + HIPEC + Systemic Chemotherapy12 Months
Surgery + HIPEC + Systemic Chemotherapy11 Months
NCT00941655Stomach NeoplasmsOverall Survival in Patients With Limited Metastatic Gastric Carcinoma: Arm II
12 weeks up to 3 years
Systemic Chemotherapy Alone17 Months
Systemic Chemotherapy Alone0 Months
Systemic Chemotherapy Alone8 Months
Systemic Chemotherapy Alone10 Months
Systemic Chemotherapy Alone0 Months
Systemic Chemotherapy Alone6 Months
Systemic Chemotherapy Alone0 Months
NCT00980460—Disease Status at the End of 2 Courses of Therapy
First two cycles of therapy- up to 42 days after enrollment
High-risk Group (Regimen H)3 participants
High-risk Group (Regimen H)18 participants
High-risk Group (Regimen H)4 participants
High-risk Group (Regimen H)10 participants
High-risk Group (Regimen W)5 participants
High-risk Group (Regimen W)16 participants
High-risk Group (Regimen W)3 participants
High-risk Group (Regimen W)6 participants
NCT00980460—Event-free Survival
Time from patient enrollment to progression, treatment failure, death from any cause, diagnosis of a second malignant neoplasm, or last follow-up, assessed up to 5 years
High-risk Group (Regimen H)46.38 Percent Probability
High-risk Group (Regimen W)43.61 Percent Probability
Intermediate-risk Group (Regimen F)87.03 Percent Probability
Low-risk Group (Regimen T)87.21 Percent Probability
Very Low-risk Group100 Percent Probability
NCT00980460—Number of Cycles on Which Grade 3 or Higher Adverse Events Coded According to CTC AE Version 5 Were Observed
During protocol therapy up to 1 year after enrollment
High-risk Group (Regimen H)2 Cycles
High-risk Group (Regimen H)1 Cycles
High-risk Group (Regimen H)2 Cycles
High-risk Group (Regimen H)5 Cycles
High-risk Group (Regimen H)10 Cycles
High-risk Group (Regimen H)4 Cycles
High-risk Group (Regimen H)2 Cycles
High-risk Group (Regimen H)15 Cycles
High-risk Group (Regimen H)0 Cycles
High-risk Group (Regimen H)3 Cycles
High-risk Group (Regimen H)1 Cycles
High-risk Group (Regimen H)0 Cycles
High-risk Group (Regimen H)0 Cycles
High-risk Group (Regimen H)3 Cycles
High-risk Group (Regimen H)0 Cycles
High-risk Group (Regimen H)0 Cycles
High-risk Group (Regimen H)0 Cycles
High-risk Group (Regimen H)0 Cycles
High-risk Group (Regimen H)0 Cycles
High-risk Group (Regimen H)5 Cycles
High-risk Group (Regimen H)3 Cycles
High-risk Group (Regimen H)6 Cycles
High-risk Group (Regimen H)0 Cycles
High-risk Group (Regimen H)0 Cycles
High-risk Group (Regimen H)3 Cycles
High-risk Group (Regimen H)0 Cycles
High-risk Group (Regimen H)6 Cycles
High-risk Group (Regimen H)0 Cycles
High-risk Group (Regimen H)3 Cycles
High-risk Group (Regimen H)0 Cycles
High-risk Group (Regimen H)6 Cycles
High-risk Group (Regimen H)29 Cycles
High-risk Group (Regimen H)0 Cycles
High-risk Group (Regimen H)1 Cycles
High-risk Group (Regimen H)1 Cycles
High-risk Group (Regimen H)0 Cycles
High-risk Group (Regimen H)0 Cycles
High-risk Group (Regimen H)1 Cycles
High-risk Group (Regimen H)1 Cycles
High-risk Group (Regimen H)1 Cycles
High-risk Group (Regimen H)19 Cycles
High-risk Group (Regimen H)1 Cycles
High-risk Group (Regimen H)1 Cycles
High-risk Group (Regimen H)1 Cycles
High-risk Group (Regimen H)0 Cycles
High-risk Group (Regimen H)4 Cycles
High-risk Group (Regimen H)5 Cycles
High-risk Group (Regimen H)0 Cycles
High-risk Group (Regimen H)0 Cycles
High-risk Group (Regimen H)0 Cycles
High-risk Group (Regimen H)5 Cycles
High-risk Group (Regimen H)1 Cycles
High-risk Group (Regimen H)0 Cycles
High-risk Group (Regimen H)0 Cycles
High-risk Group (Regimen H)0 Cycles
High-risk Group (Regimen H)0 Cycles
High-risk Group (Regimen H)0 Cycles
High-risk Group (Regimen H)1 Cycles
High-risk Group (Regimen H)0 Cycles
High-risk Group (Regimen H)0 Cycles
High-risk Group (Regimen H)0 Cycles
High-risk Group (Regimen H)0 Cycles
High-risk Group (Regimen H)4 Cycles
High-risk Group (Regimen H)0 Cycles
High-risk Group (Regimen H)0 Cycles
High-risk Group (Regimen H)10 Cycles
High-risk Group (Regimen H)4 Cycles
High-risk Group (Regimen H)0 Cycles
High-risk Group (Regimen H)1 Cycles
High-risk Group (Regimen H)1 Cycles
High-risk Group (Regimen H)6 Cycles
High-risk Group (Regimen H)0 Cycles
High-risk Group (Regimen H)1 Cycles
High-risk Group (Regimen H)0 Cycles
High-risk Group (Regimen H)1 Cycles
High-risk Group (Regimen H)0 Cycles
High-risk Group (Regimen H)1 Cycles
High-risk Group (Regimen H)0 Cycles
High-risk Group (Regimen H)1 Cycles
High-risk Group (Regimen H)6 Cycles
High-risk Group (Regimen H)0 Cycles
High-risk Group (Regimen H)0 Cycles
High-risk Group (Regimen H)0 Cycles
High-risk Group (Regimen H)1 Cycles
High-risk Group (Regimen H)0 Cycles
High-risk Group (Regimen H)0 Cycles
High-risk Group (Regimen H)1 Cycles
High-risk Group (Regimen H)1 Cycles
High-risk Group (Regimen H)0 Cycles
High-risk Group (Regimen H)0 Cycles
High-risk Group (Regimen H)1 Cycles
High-risk Group (Regimen H)1 Cycles
High-risk Group (Regimen H)0 Cycles
High-risk Group (Regimen H)12 Cycles
High-risk Group (Regimen H)2 Cycles
High-risk Group (Regimen H)0 Cycles
High-risk Group (Regimen H)0 Cycles
High-risk Group (Regimen H)0 Cycles
High-risk Group (Regimen H)0 Cycles
High-risk Group (Regimen H)0 Cycles
High-risk Group (Regimen H)0 Cycles
High-risk Group (Regimen H)0 Cycles
High-risk Group (Regimen H)5 Cycles
High-risk Group (Regimen H)2 Cycles
High-risk Group (Regimen H)1 Cycles
High-risk Group (Regimen H)2 Cycles
High-risk Group (Regimen H)0 Cycles
High-risk Group (Regimen H)0 Cycles
High-risk Group (Regimen H)1 Cycles
High-risk Group (Regimen H)1 Cycles
High-risk Group (Regimen H)0 Cycles
High-risk Group (Regimen H)1 Cycles
High-risk Group (Regimen H)0 Cycles
High-risk Group (Regimen H)6 Cycles
High-risk Group (Regimen H)0 Cycles
High-risk Group (Regimen H)1 Cycles
High-risk Group (Regimen H)1 Cycles
High-risk Group (Regimen H)0 Cycles
High-risk Group (Regimen H)0 Cycles
High-risk Group (Regimen H)7 Cycles
High-risk Group (Regimen H)0 Cycles
High-risk Group (Regimen H)0 Cycles
High-risk Group (Regimen H)2 Cycles
High-risk Group (Regimen H)1 Cycles
High-risk Group (Regimen H)0 Cycles
High-risk Group (Regimen H)3 Cycles
High-risk Group (Regimen H)1 Cycles
High-risk Group (Regimen H)1 Cycles
High-risk Group (Regimen H)0 Cycles
High-risk Group (Regimen H)1 Cycles
High-risk Group (Regimen H)1 Cycles
High-risk Group (Regimen H)0 Cycles
High-risk Group (Regimen H)9 Cycles
High-risk Group (Regimen H)1 Cycles
High-risk Group (Regimen H)0 Cycles
High-risk Group (Regimen H)0 Cycles
High-risk Group (Regimen H)0 Cycles
High-risk Group (Regimen H)0 Cycles
High-risk Group (Regimen H)1 Cycles
High-risk Group (Regimen H)1 Cycles
High-risk Group (Regimen H)1 Cycles
High-risk Group (Regimen H)1 Cycles
High-risk Group (Regimen H)0 Cycles
High-risk Group (Regimen H)0 Cycles
High-risk Group (Regimen H)0 Cycles
High-risk Group (Regimen H)1 Cycles
High-risk Group (Regimen H)9 Cycles
High-risk Group (Regimen H)1 Cycles
High-risk Group (Regimen H)17 Cycles
High-risk Group (Regimen H)0 Cycles
High-risk Group (Regimen H)0 Cycles
High-risk Group (Regimen H)2 Cycles
High-risk Group (Regimen H)4 Cycles
High-risk Group (Regimen H)19 Cycles
High-risk Group (Regimen H)1 Cycles
High-risk Group (Regimen W)2 Cycles
High-risk Group (Regimen W)12 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)10 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)6 Cycles
High-risk Group (Regimen W)2 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)1 Cycles
High-risk Group (Regimen W)1 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)1 Cycles
High-risk Group (Regimen W)1 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)3 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)1 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)1 Cycles
High-risk Group (Regimen W)3 Cycles
High-risk Group (Regimen W)2 Cycles
High-risk Group (Regimen W)3 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)1 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)7 Cycles
High-risk Group (Regimen W)1 Cycles
High-risk Group (Regimen W)2 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)1 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)1 Cycles
High-risk Group (Regimen W)3 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)8 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)1 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)4 Cycles
High-risk Group (Regimen W)1 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)1 Cycles
High-risk Group (Regimen W)1 Cycles
High-risk Group (Regimen W)1 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)2 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)2 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)2 Cycles
High-risk Group (Regimen W)2 Cycles
High-risk Group (Regimen W)3 Cycles
High-risk Group (Regimen W)1 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)3 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)1 Cycles
High-risk Group (Regimen W)1 Cycles
High-risk Group (Regimen W)1 Cycles
High-risk Group (Regimen W)1 Cycles
High-risk Group (Regimen W)1 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)1 Cycles
High-risk Group (Regimen W)4 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)1 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)1 Cycles
High-risk Group (Regimen W)1 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)1 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)2 Cycles
High-risk Group (Regimen W)1 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)2 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)1 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)1 Cycles
High-risk Group (Regimen W)4 Cycles
High-risk Group (Regimen W)1 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)1 Cycles
High-risk Group (Regimen W)1 Cycles
High-risk Group (Regimen W)27 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)1 Cycles
High-risk Group (Regimen W)1 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)1 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)20 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)1 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)4 Cycles
High-risk Group (Regimen W)5 Cycles
High-risk Group (Regimen W)4 Cycles
High-risk Group (Regimen W)1 Cycles
High-risk Group (Regimen W)15 Cycles
High-risk Group (Regimen W)3 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)9 Cycles
High-risk Group (Regimen W)10 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)13 Cycles
High-risk Group (Regimen W)3 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)9 Cycles
High-risk Group (Regimen W)0 Cycles
High-risk Group (Regimen W)3 Cycles
Intermediate-risk Group (Regimen F)2 Cycles
Intermediate-risk Group (Regimen F)4 Cycles
Intermediate-risk Group (Regimen F)0 Cycles
Intermediate-risk Group (Regimen F)1 Cycles
Intermediate-risk Group (Regimen F)2 Cycles
Intermediate-risk Group (Regimen F)1 Cycles
Intermediate-risk Group (Regimen F)1 Cycles
Intermediate-risk Group (Regimen F)0 Cycles
Intermediate-risk Group (Regimen F)1 Cycles
Intermediate-risk Group (Regimen F)28 Cycles
Intermediate-risk Group (Regimen F)37 Cycles
Intermediate-risk Group (Regimen F)5 Cycles
Intermediate-risk Group (Regimen F)2 Cycles
Intermediate-risk Group (Regimen F)1 Cycles
Intermediate-risk Group (Regimen F)7 Cycles
Intermediate-risk Group (Regimen F)3 Cycles
Intermediate-risk Group (Regimen F)7 Cycles
Intermediate-risk Group (Regimen F)7 Cycles
Intermediate-risk Group (Regimen F)6 Cycles
Intermediate-risk Group (Regimen F)0 Cycles
Intermediate-risk Group (Regimen F)0 Cycles
Intermediate-risk Group (Regimen F)0 Cycles
Intermediate-risk Group (Regimen F)0 Cycles
Intermediate-risk Group (Regimen F)0 Cycles
Intermediate-risk Group (Regimen F)0 Cycles
Intermediate-risk Group (Regimen F)0 Cycles
Intermediate-risk Group (Regimen F)0 Cycles
Intermediate-risk Group (Regimen F)30 Cycles
Intermediate-risk Group (Regimen F)2 Cycles
Intermediate-risk Group (Regimen F)15 Cycles
Intermediate-risk Group (Regimen F)12 Cycles
Intermediate-risk Group (Regimen F)4 Cycles
Intermediate-risk Group (Regimen F)1 Cycles
Intermediate-risk Group (Regimen F)48 Cycles
Intermediate-risk Group (Regimen F)1 Cycles
Intermediate-risk Group (Regimen F)22 Cycles
Intermediate-risk Group (Regimen F)7 Cycles
Intermediate-risk Group (Regimen F)3 Cycles
Intermediate-risk Group (Regimen F)10 Cycles
Intermediate-risk Group (Regimen F)11 Cycles
Intermediate-risk Group (Regimen F)21 Cycles
Intermediate-risk Group (Regimen F)2 Cycles
Intermediate-risk Group (Regimen F)0 Cycles
Intermediate-risk Group (Regimen F)2 Cycles
Intermediate-risk Group (Regimen F)1 Cycles
Intermediate-risk Group (Regimen F)0 Cycles
Intermediate-risk Group (Regimen F)0 Cycles
Intermediate-risk Group (Regimen F)6 Cycles
Intermediate-risk Group (Regimen F)1 Cycles
Intermediate-risk Group (Regimen F)3 Cycles
Intermediate-risk Group (Regimen F)2 Cycles
Intermediate-risk Group (Regimen F)1 Cycles
Intermediate-risk Group (Regimen F)2 Cycles
Intermediate-risk Group (Regimen F)1 Cycles
Intermediate-risk Group (Regimen F)0 Cycles
Intermediate-risk Group (Regimen F)0 Cycles
Intermediate-risk Group (Regimen F)2 Cycles
Intermediate-risk Group (Regimen F)1 Cycles
Intermediate-risk Group (Regimen F)0 Cycles
Intermediate-risk Group (Regimen F)1 Cycles
Intermediate-risk Group (Regimen F)0 Cycles
Intermediate-risk Group (Regimen F)1 Cycles
Intermediate-risk Group (Regimen F)1 Cycles
Intermediate-risk Group (Regimen F)0 Cycles
Intermediate-risk Group (Regimen F)9 Cycles
Intermediate-risk Group (Regimen F)1 Cycles
Intermediate-risk Group (Regimen F)3 Cycles
Intermediate-risk Group (Regimen F)0 Cycles
Intermediate-risk Group (Regimen F)0 Cycles
Intermediate-risk Group (Regimen F)1 Cycles
Intermediate-risk Group (Regimen F)2 Cycles
Intermediate-risk Group (Regimen F)1 Cycles
Intermediate-risk Group (Regimen F)1 Cycles
Intermediate-risk Group (Regimen F)1 Cycles
Intermediate-risk Group (Regimen F)3 Cycles
Intermediate-risk Group (Regimen F)4 Cycles
Intermediate-risk Group (Regimen F)9 Cycles
Intermediate-risk Group (Regimen F)1 Cycles
Intermediate-risk Group (Regimen F)0 Cycles
Intermediate-risk Group (Regimen F)0 Cycles
Intermediate-risk Group (Regimen F)0 Cycles
Intermediate-risk Group (Regimen F)0 Cycles
Intermediate-risk Group (Regimen F)1 Cycles
Intermediate-risk Group (Regimen F)0 Cycles
Intermediate-risk Group (Regimen F)0 Cycles
Intermediate-risk Group (Regimen F)0 Cycles
Intermediate-risk Group (Regimen F)0 Cycles
Intermediate-risk Group (Regimen F)1 Cycles
Intermediate-risk Group (Regimen F)1 Cycles
Intermediate-risk Group (Regimen F)6 Cycles
Intermediate-risk Group (Regimen F)8 Cycles
Intermediate-risk Group (Regimen F)1 Cycles
Intermediate-risk Group (Regimen F)0 Cycles
Intermediate-risk Group (Regimen F)20 Cycles
Intermediate-risk Group (Regimen F)15 Cycles
Intermediate-risk Group (Regimen F)1 Cycles
Intermediate-risk Group (Regimen F)0 Cycles
Intermediate-risk Group (Regimen F)10 Cycles
Intermediate-risk Group (Regimen F)1 Cycles
Intermediate-risk Group (Regimen F)24 Cycles
Intermediate-risk Group (Regimen F)1 Cycles
Intermediate-risk Group (Regimen F)1 Cycles
Intermediate-risk Group (Regimen F)10 Cycles
Intermediate-risk Group (Regimen F)3 Cycles
Intermediate-risk Group (Regimen F)1 Cycles
Intermediate-risk Group (Regimen F)5 Cycles
Intermediate-risk Group (Regimen F)1 Cycles
Intermediate-risk Group (Regimen F)0 Cycles
Intermediate-risk Group (Regimen F)0 Cycles
Intermediate-risk Group (Regimen F)0 Cycles
Intermediate-risk Group (Regimen F)2 Cycles
Intermediate-risk Group (Regimen F)1 Cycles
Intermediate-risk Group (Regimen F)2 Cycles
Intermediate-risk Group (Regimen F)2 Cycles
Intermediate-risk Group (Regimen F)0 Cycles
Intermediate-risk Group (Regimen F)1 Cycles
Intermediate-risk Group (Regimen F)0 Cycles
Intermediate-risk Group (Regimen F)0 Cycles
Intermediate-risk Group (Regimen F)1 Cycles
Intermediate-risk Group (Regimen F)1 Cycles
Intermediate-risk Group (Regimen F)1 Cycles
Intermediate-risk Group (Regimen F)1 Cycles
Intermediate-risk Group (Regimen F)0 Cycles
Intermediate-risk Group (Regimen F)1 Cycles
Intermediate-risk Group (Regimen F)1 Cycles
Intermediate-risk Group (Regimen F)2 Cycles
Intermediate-risk Group (Regimen F)1 Cycles
Intermediate-risk Group (Regimen F)4 Cycles
Intermediate-risk Group (Regimen F)1 Cycles
Intermediate-risk Group (Regimen F)0 Cycles
Intermediate-risk Group (Regimen F)3 Cycles
Intermediate-risk Group (Regimen F)1 Cycles
Intermediate-risk Group (Regimen F)0 Cycles
Intermediate-risk Group (Regimen F)13 Cycles
Intermediate-risk Group (Regimen F)3 Cycles
Intermediate-risk Group (Regimen F)1 Cycles
Intermediate-risk Group (Regimen F)1 Cycles
Intermediate-risk Group (Regimen F)1 Cycles
Intermediate-risk Group (Regimen F)44 Cycles
Intermediate-risk Group (Regimen F)0 Cycles
Intermediate-risk Group (Regimen F)4 Cycles
Intermediate-risk Group (Regimen F)2 Cycles
Intermediate-risk Group (Regimen F)2 Cycles
Intermediate-risk Group (Regimen F)0 Cycles
Intermediate-risk Group (Regimen F)1 Cycles
Intermediate-risk Group (Regimen F)1 Cycles
Intermediate-risk Group (Regimen F)1 Cycles
Intermediate-risk Group (Regimen F)8 Cycles
Intermediate-risk Group (Regimen F)38 Cycles
Intermediate-risk Group (Regimen F)0 Cycles
Intermediate-risk Group (Regimen F)0 Cycles
Intermediate-risk Group (Regimen F)0 Cycles
Intermediate-risk Group (Regimen F)0 Cycles
Intermediate-risk Group (Regimen F)3 Cycles
Intermediate-risk Group (Regimen F)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)2 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)2 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)3 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)1 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)1 Cycles
Low-risk Group (Regimen T)4 Cycles
Low-risk Group (Regimen T)1 Cycles
Low-risk Group (Regimen T)1 Cycles
Low-risk Group (Regimen T)1 Cycles
Low-risk Group (Regimen T)2 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)1 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)1 Cycles
Low-risk Group (Regimen T)4 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)1 Cycles
Low-risk Group (Regimen T)1 Cycles
Low-risk Group (Regimen T)1 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)1 Cycles
Low-risk Group (Regimen T)1 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)1 Cycles
Low-risk Group (Regimen T)3 Cycles
Low-risk Group (Regimen T)2 Cycles
Low-risk Group (Regimen T)2 Cycles
Low-risk Group (Regimen T)2 Cycles
Low-risk Group (Regimen T)4 Cycles
Low-risk Group (Regimen T)1 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
Low-risk Group (Regimen T)0 Cycles
NCT00980460—Number of Deaths
During protocol therapy or within 30 days of the termination of protocol therapy up to 1 year after enrollment
Intermediate-risk Group (Regimen F)1 Participants
NCT01183780Colorectal NeoplasmsOverall Survival (OS)
Randomization to Date of Death from Any Cause Up to 39.36 Months
Placebo + FOLFIRI11.7 months
Ramucirumab + FOLFIRI13.3 months
NCT01670721
AFEQT
—Percentage of Participants With Adverse Events (AEs)
Baseline upto 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure:723 days)
Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)40.6 Percentage of participants
Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)100.00 Percentage of participants
Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)16.0 Percentage of participants
Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)23.4 Percentage of participants
Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)9.1 Percentage of participants
Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)21.1 Percentage of participants
NCT01926197Pancreatic NeoplasmsProgression-free Survival (PFS)
38 months
Modified FOLFIRINOX6.5 months (±6.6 Standard Deviation)
Modified FOLFIRINOX Plus Stereotactic Body Radiotherapy8.4 months (±9.5 Standard Deviation)
NCT02564263Esophageal NeoplasmsOverall Survival (OS) in All Participants
Through Final Analysis data cutoff date of 15-Oct-2018 (up to approximately 34 months)
Chemotherapy7.1 Months
Pembrolizumab7.1 Months
NCT02564263Esophageal NeoplasmsOverall Survival (OS) in Participants With Programmed Death-Ligand 1 Combined Positive Score ≥10 (PD-L1 CPS ≥10)
Through Final Analysis data cutoff date of 15-Oct-2018 (up to approximately 34 months)
Chemotherapy6.7 Months
Pembrolizumab9.3 Months
NCT02564263Esophageal NeoplasmsOverall Survival (OS) in Participants With Squamous Cell Carcinoma (SCC) of the Esophagus
Through Final Analysis data cutoff date of 15-Oct-2018 (up to approximately 34 months)
Chemotherapy7.1 Months
Pembrolizumab8.2 Months
NCT02567435RhabdomyosarcomaEvent-free Survival (EFS)
Up to 3 years from study entry
Regimen A (VAC/VI)64.80 Percentage of participants
Regimen B (VAC/VI/Temsirolimus)66.80 Percentage of participants
NCT02625623Stomach NeoplasmsOverall Survival (OS)
From randomization up to 627 days
Avelumab + BSC4.6 months
Physician Choice Chemotherapy + Best Supportive Care (BSC)5.0 months
NCT02753127
CanStem303C
Colorectal NeoplasmsOverall Survival (OS)
Randomization to Date of Death from any cause or database cutoff date (28 Apr 2020) (Approximately 43 months)
FOLFIRI ± Bevacizumab13.83 months
FOLFIRI ± Bevacizumab12.12 months
Napabucasin + FOLFIRI ± Bevacizumab14.29 months
Napabucasin + FOLFIRI ± Bevacizumab13.17 months
NCT02928224
BEACON CRC
Colorectal Neoplasms(Phase 3) Objective Response Rate (ORR) by Blinded Independent Central Review (BICR) Per Response Evaluation Criteria in Solid Tumors (RECIST), v1.1 of Triplet Arm vs. Control Arm
Duration of Phase 3, approximately 6 months (up to 28 days per cycle)
Phase 3: Triplet Arm26.1 Percentage of participants
Phase 3:Control Arm1.9 Percentage of participants
NCT02928224
BEACON CRC
Colorectal Neoplasms(Phase 3) Overall Survival (OS) of Triplet Arm vs. Control Arm - Interim Analysis
From randomization to death due to any cause until 204 deaths were observed (maximum treatment exposure of 89.1 weeks for triplet arm and 52.4 weeks for control arm)
Phase 3: Control Arm5.42 Months
Phase 3: Triplet Arm9.03 Months
NCT02928224
BEACON CRC
Colorectal Neoplasms(Safety Lead-in) Incidence of Dose Interruptions, Dose Modifications and Discontinuations Due to Adverse Events (AEs) - Final Analysis
From start of study treatment until 30 days post last dose of study treatment (maximum treatment exposure of 280 weeks)
Combined Safety Lead-in30 Participants
Combined Safety Lead-in8 Participants
Combined Safety Lead-in16 Participants
NCT02928224
BEACON CRC
Colorectal Neoplasms(Safety Lead-in) Incidence of Dose Interruptions, Dose Modifications and Discontinuations Due to Adverse Events (AEs) - Interim Analysis
Duration of safety lead-in, approximately 6 months (up to 28 days per cycle)
Combined Safety Lead-in26 Participants
NCT02928224
BEACON CRC
Colorectal Neoplasms(Safety Lead-in) Number of Participants With Adverse Events (AEs)
Duration of safety lead-in, approximately 6 months (up to 28 days per cycle)
Combined Safety Lead-in37 Participants
NCT02928224
BEACON CRC
Colorectal Neoplasms(Safety Lead-in) Number of Participants With Dose-Limiting Toxicities (DLTs)
Cycle 1 (up to 28 days)
Combined Safety Lead-in (CSLI)5 Participants
NCT03088813
RESILIENT
Small Cell Lung CarcinomaPart 1: Number of Participants With Dose-Limiting Toxicities (DLT)
From the start of the first study treatment administration (Day 1) up to 14 days after the second dose of study treatment administration, a maximum of 42 days
Part 1: Irinotecan Liposome Injection 70 mg/m^22 Participants
Part 1: Irinotecan Liposome Injection 85 mg/m^24 Participants
NCT03088813
RESILIENT
Small Cell Lung CarcinomaPart 1: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (SAEs)
The TEAEs were reported from the time of first study treatment administration (Day 1) up to 30 days after the date of last study treatment administration, approximately 680 days
Part 1: Irinotecan Liposome Injection 70 mg/m^29 Participants
Part 1: Irinotecan Liposome Injection 70 mg/m^225 Participants
Part 1: Irinotecan Liposome Injection 85 mg/m^25 Participants
Part 1: Irinotecan Liposome Injection 85 mg/m^24 Participants
NCT03088813
RESILIENT
Small Cell Lung CarcinomaPart 2: Overall Survival (OS)
From date of randomization (within 7 days before start of study treatment) until death. Assessed up to Part 2 primary analysis DCO date of 08 February 2022 (approximately 900 days)
Part 2: Irinotecan Liposome Injection 70 mg/m^27.92 months
Part 2: Topotecan 1.5 mg/m^28.31 months
NCT03098030Small Cell Lung CarcinomaOverall Survival (OS)
Up to approximately 2.5 years
Part 2: Dinutuximab + Irinotecan6.9 months
Part 2: Irinotecan7.0 months
Part 2: Topotecan7.4 months
NCT03099382Esophageal NeoplasmsOverall Survival (OS)
approximately 24 months
Camrelizumab8.28 months
Investigator's Choice of Standard Therapy6.24 months
NCT03430843Neoplasm MetastasisOverall Survival (OS) in the Intent-to-Treat (ITT) Analysis Set
Approximately 2 years and 10 months from date of first randomization
Investigator Chosen Chemotherapy6.3 Months
Tislelizumab8.6 Months
NCT03495921
VITA
NeoplasmsProgression Free Survival (PFS)
From date of randomization until the date of first documented progression (assessed up to 3 years).
Group A: Vigil in Combination With Irinotecan and Temozolomide2.8 Months
Group B: Irinotecan and Temozolomide9.1 Months
NCT03665441
Trybeca-1
NeoplasmsOverall Survival (OS)
~12 months
Chemotherapy Alone6.7 months
Eryaspase Plus Chemotherapy7.5 months
NCT03829462
NEXT-REGIRI
Colorectal NeoplasmsOverall Survival
Up to 36 months
Irinotecan + Regorafenib (REGIRI)9 Month
Regorafenib5.5 Month
NCT03933449Esophageal NeoplasmsOverall Survival (OS) in All Participants
From randomization through final analysis data cutoff date of 13-Feb-2019 (Up to ~24 months)
Chemotherapy5.6 Months
Pembrolizumab8.4 Months
NCT03933449Esophageal NeoplasmsOverall Survival (OS) in Participants With Programmed Death-Ligand 1 Combined Positive Score ≥10 (PD-L1 CPS ≥10)
From randomization through final analysis data cutoff date of 13-Feb-2019 (Up to ~24 months)
Chemotherapy5.3 Months
Pembrolizumab12.0 Months
NCT03933449Esophageal NeoplasmsOverall Survival (OS) in Participants With Squamous Cell Carcinoma (SCC) of the Esophagus
From randomization through final analysis data cutoff date of 13-Feb-2019 (Up to ~24 months)
Chemotherapy5.6 Months
Pembrolizumab8.4 Months
NCT04008030
CheckMate 8HW
Colorectal NeoplasmsProgression-free Survival (PFS) by Blinded Independent Review Center (BICR) - Arm B vs. Arm A All Lines Centrally Confirmed MSI-H/dMMR
From date of randomization to the date of first objectively documented disease progression or death due to any cause, whichever occurs first (Up to approximately 60 months)
Arm A - Nivolumab Monotherapy39.26 Months
Arm B - Nivolumab + IpilimumabNA Months
NCT04008030
CheckMate 8HW
Colorectal NeoplasmsProgression-free Survival (PFS) by Blinded Independent Review Center (BICR) - Arm B vs. Arm C 1L Participants Centrally Confirmed MSI-H/dMMR
From date of randomization to the date of first objectively documented disease progression or death due to any cause, whichever occurs first (Up to approximately 32 months)
Arm B - Nivolumab + IpilimumabNA Months
Arm C - Investigator's Choice Chemotherapy5.85 Months
NCT04083235
NAPOLI 3
—Overall Survival (OS)
Assessments performed at baseline (within 28 days before start of study treatment), every 8 weeks after first dose, end of treatment (EoT) visit, then every 2 months thereafter up to primary completion date (PCD) of 23 July 2022 (maximum of 893 days)
Nab-paclitaxel+Gemcitabine9.2 months
NALIRIFOX11.1 months
NCT04094688
SOLARIS
—Progression-free Survival (PFS)
4 years
Arm I (Bevacizumab, Chemotherapy, High-dose Vitamin D3)11.8 months
Arm II (Bevacizumab, Chemotherapy, Standard-dose Vitamin D3)10.3 months
NCT04697628
innovaTV 301
Uterine Cervical NeoplasmsOverall Survival
From randomization to date of death due to any cause or censoring date, whichever occurred first (maximum up to 25 months)
Chemotherapy9.5 Months
Tisotumab Vedotin11.5 Months

Publications by year

1967–2026: 1,086 publications.

1967
1
1971
1
1980
1
1983
1
1985
2
1986
3
1987
1
1988
3
1989
1
1991
3
1992
2
1993
6
1994
5
1995
5
1996
1
1997
6
1998
7
1999
10
2000
12
2001
14
2002
14
2003
15
2004
26
2005
25
2006
28
2007
46
2008
42
2009
44
2010
35
2011
39
2012
46
2013
34
2014
32
2015
34
2016
38
2017
53
2018
20
2019
52
2020
57
2021
78
2022
75
2023
45
2024
58
2025
42
2026
23

Publications by indication

Colorectal Neoplasms (390)

  • Exploratory biomarker analysis of RAS/BRAF somatic mutations and gene expression signatures for predicting treatment effects of aflibercept in the velour trial.
    NPJ Precis Oncol · 2026 · PMID 41530374 · NCT00561470
  • Combination of Lurbinectedin Plus Irinotecan: Preclinical and Early Clinical Results in Patients With Relapsed SCLC.
    J Thorac Oncol · 2026 · PMID 41791703 · NCT02611024
  • Amivantamab Monotherapy in Chemorefractory RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Results From OrigAMI-1, an Open-Label, Phase Ib/II Study.
    J Clin Oncol · 2026 · PMID 42013403 · NCT05379595
  • Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial.
    Nat Med · 2026 · PMID 41981308 · NCT03678883
  • Phase 1b/2 study of BMS-813160, a CCR2/5 dual antagonist, in combination with chemotherapy or nivolumab in patients with advanced pancreatic or colorectal cancer.
    J Immunother Cancer · 2026 · PMID 41571299 · NCT03184870

Pancreatic Neoplasms (90)

  • Predictive criteria for overall survival and treatment duration of 2nd-line chemotherapy in patients with advanced pancreatic adenocarcinoma (AIO-PAK-0216).
    Br J Cancer · 2026 · PMID 41087530 · NCT03468335
  • Perfusion Assessment in CEUS Imaging for Estimating Pancreatic Cancer Response to Sonoporation-Enhanced Chemotherapy.
    Ultrason Imaging · 2026 · PMID 41133726 · NCT04821284
  • A phase III randomized clinical trial of Gemcitabine and Nab-Paclitaxel as switch maintenance versus continuation of modified FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: The PANThEON Study.
    Dig Liver Dis · 2025 · PMID 41318310 · NCT06897644
  • An immune responsive tumor microenvironment imprints into PBMCs and predicts outcome in advanced pancreatic cancer: lessons from the PREDICT trial.
    Mol Cancer · 2025 · PMID 40696453 · NCT03468335
  • PRODIGE 29-UCGI 26 (NEOPAN): A Phase III Randomized Trial Comparing Chemotherapy With FOLFIRINOX or Gemcitabine in Locally Advanced Pancreatic Carcinoma.
    J Clin Oncol · 2025 · PMID 40378359 · NCT02539537

Neoplasms (85)

  • Longitudinal DCE MRI Vascular Textures: Radiologic and Biologic Insights for pCR Prediction in HER2-Negative Breast Cancer.
    Radiol Artif Intell · 2026 · PMID 41879562 · NCT01042379
  • Phase I/II Study of the CDK2/9 Inhibitor Fadraciclib in Combination with Chemotherapy in Children with Advanced Malignancies: Arm K of the AcSé-ESMART Trial.
    Target Oncol · 2026 · PMID 41838385 · NCT02813135
  • Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer.
    NPJ Breast Cancer · 2026 · PMID 36456573 · NCT01042379
  • Detection of serum HER2 in patients treated with neratinib or trastuzumab: analysis of the I-SPY Trial.
    Front Oncol · 2026 · PMID 40777112 · NCT01042379
  • Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial.
    JCO Precis Oncol · 2025 · PMID 40526879 · NCT01042379

Stomach Neoplasms (62)

  • Biomarker-Driven Approach to the Treatment of Metastatic Gastric or Gastroesophageal Adenocarcinoma.
    J Natl Compr Canc Netw · 2025 · PMID 40341124 · NCT06346392
  • Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial.
    Lancet · 2025 · PMID 40460847 · NCT04581473
  • Korean Practice Guideline for Gastric Cancer 2018: an Evidence-based, Multi-disciplinary Approach.
    J Gastric Cancer · 2025 · PMID 30944757 · NCT04915807
  • A prospective phase II single-arm study and predictive factor analysis of irinotecan as third-line treatment in patients with metastatic gastric cancer.
    Ther Adv Med Oncol · 2024 · PMID 38425987 · NCT02662959
  • CMG901, a Claudin18.2-specific antibody-drug conjugate, for the treatment of solid tumors.
    Cell Rep Med · 2024 · PMID 39232496 · NCT06346392

Glioblastoma (57)

  • Depth of Radiographic Response and Time to Tumor Regrowth Predicts Overall Survival Following Anti-VEGF Therapy in Recurrent Glioblastoma.
    Clin Cancer Res · 2023 · PMID 37540556 · NCT00345163
  • Nanoliposomal Irinotecan and Metronomic Temozolomide for Patients With Recurrent Glioblastoma: BrUOG329, A Phase I Brown University Oncology Research Group Trial.
    Am J Clin Oncol · 2021 · PMID 33284237 · NCT03119064
  • Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma.
    Neuro Oncol · 2019 · PMID 29121274 · NCT00967330
  • Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial.
    J Clin Oncol · 2017 · PMID 26976423 · NCT00967330
  • Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials.
    Neuro Oncol · 2017 · PMID 27580889 · NCT00345163

Desmoplastic Small Round Cell Tumor (40)

  • Effectiveness of irinotecan plus trabectedin on a desmoplastic small round cell tumor patient-derived xenograft.
    Dis Model Mech · 2023 · PMID 37158111 · NCT07328425
  • Long-term survivors with desmoplastic small round cell tumor (DSRCT): Results from a retrospective single-institution case series analysis.
    Cancer Med · 2023 · PMID 36951537 · NCT07328425
  • Trabectedin-irinotecan, a potentially promising combination in relapsed desmoplastic small round cell tumor: report of two cases.
    J Chemother · 2023 · PMID 35470779 · NCT07328425
  • Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities.
    Cancer · 2022 · PMID 33910263 · NCT07328425
  • Wnt signaling pathway protein LEF1 in cancer, as a biomarker for prognosis and a target for treatment.
    Am J Cancer Res · 2022 · PMID 28670499 · NCT07328425

Publications by journal

Trial-results highlights

In studies involving lung neoplasms, overall survival was assessed. For lung neoplasms in NCT00045162, the median overall survival was 9.1 months for the Cisplatin + Etoposide arm and 9.9 months for the Cisplatin + Irinotecan arm. For small cell lung carcinoma in NCT00143455, the median overall survival for the Etoposide + Cisplatin (Cohort 2) arm was 9.6591 months, while the Irinotecan + Cisplatin (Cohort 2) arm reported 10.2177 months.

For rectal neoplasms, NCT00068692 reported 3-year overall survival rates. The Control (Arm III) had a 0.870 proportion of patients, the Irinocetan (Arm I) had a 0.965 proportion, and the Oxaliplatin (Arm II) had a 0.843 proportion. In colonic neoplasms, NCT00079274 assessed disease-free survival at 3 years for wild-type KRAS patients. Wild-type KRAS Arm A showed 74.6 percentage of participants, and Wild-type KRAS Arm D showed 71.5 percentage of participants.

Further studies in colorectal neoplasms provided additional insights. In NCT00101686, the median time to progression was 8.18 months for FOLFIRI and 6.01 months for mIFL. NCT00143403 reported a median disease-free survival of 21.6 months for the 5-FU/FA arm and 24.7 months for the Irinotecan + 5-FU/FA arm. In NCT00115765, objective tumor response through week 12 for Irinotecan and Bevacizumab Plus Panitumumab was observed in 29 participants, compared to 27 participants for Irinotecan and Bevacizumab Without Panitumumab. Progression-free survival in the same study was 10.0 months (median) for Oxaliplatin and Bevacizumab Plus Panitumumab, and 11.4 months (median) for Oxaliplatin and Bevacizumab Without Panitumumab. All values are sourced from primary registry reporting; individual papers should be consulted for clinical decisions.

All Irinotecan publications (1,086)

2026 (23 papers)

  1. Intermediate Risk Rhabdomyosarcoma in Very Young Children (Less Than or Equal to 24 Months) Treated on the Prior Children's Oncology Group Protocol ARST1431.
    Winsnes K, Bradley JA, Gao Z, et al. · Pediatr Blood Cancer · 2026 · Derived
    PubMed: PMID 41914453 · NCT02567435 · Rhabdomyosarcoma
  2. Longitudinal DCE MRI Vascular Textures: Radiologic and Biologic Insights for pCR Prediction in HER2-Negative Breast Cancer.
    Teng X, Ma J, Zhang J, et al. · Radiol Artif Intell · 2026 · Derived
    PubMed: PMID 41879562 · NCT01042379 (I-SPY) · Neoplasms
  3. Phase I/II Study of the CDK2/9 Inhibitor Fadraciclib in Combination with Chemotherapy in Children with Advanced Malignancies: Arm K of the AcSé-ESMART Trial.
    Rubio-San-Simón A, Marshall LV, Karamouza E, et al. · Target Oncol · 2026 · Derived
    PubMed: PMID 41838385 · NCT02813135 (ESMART) · Neoplasms
  4. Netrin1 blockade alleviates resistance to chemotherapy in pancreatic cancer.
    Roth G, Artru P, Bouche O, et al. · Nature · 2026 · Derived
    PubMed: PMID 42020751 · NCT05546853 (LAP-NET1)
  5. Exploratory biomarker analysis of RAS/BRAF somatic mutations and gene expression signatures for predicting treatment effects of aflibercept in the velour trial.
    Pu T, Peddle AM, Wirapati P, et al. · NPJ Precis Oncol · 2026 · Derived
    PubMed: PMID 41530374 · NCT00561470 (VELOUR) · Colorectal Neoplasms
  6. Combination of Lurbinectedin Plus Irinotecan: Preclinical and Early Clinical Results in Patients With Relapsed SCLC.
    Ponce S, Ruiz-Torres M, Falcón A, et al. · J Thorac Oncol · 2026 · Derived
    PubMed: PMID 41791703 · NCT02611024 · Colorectal Neoplasms
  7. Setidegrasib in Advanced Non-Small-Cell Lung Cancer and Pancreatic Cancer.
    Park W, Kasi A, Spira AI, et al. · N Engl J Med · 2026 · Derived
    PubMed: PMID 41879829 · NCT05382559 · Neoplasm Metastasis
  8. Amivantamab Monotherapy in Chemorefractory RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Results From OrigAMI-1, an Open-Label, Phase Ib/II Study.
    Oberstein PE, Hecht JR, Raghav K, et al. · J Clin Oncol · 2026 · Derived
    PubMed: PMID 42013403 · NCT05379595 (OrigAMI-1) · Colorectal Neoplasms
  9. Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial.
    Mahalingam D, Shroff RT, Carneiro BA, et al. · Nat Med · 2026 · Derived
    PubMed: PMID 41981308 · NCT03678883 · Colorectal Neoplasms
  10. Predictive criteria for overall survival and treatment duration of 2nd-line chemotherapy in patients with advanced pancreatic adenocarcinoma (AIO-PAK-0216).
    Lutz MP, Ansorge N, Barmashenko G, et al. · Br J Cancer · 2026 · Derived
    PubMed: PMID 41087530 · NCT03468335 (PREDICT) · Pancreatic Neoplasms
  11. Phase 1b/2 study of BMS-813160, a CCR2/5 dual antagonist, in combination with chemotherapy or nivolumab in patients with advanced pancreatic or colorectal cancer.
    Le DT, Folprecht G, Varghese AM, et al. · J Immunother Cancer · 2026 · Derived
    PubMed: PMID 41571299 · NCT03184870 · Colorectal Neoplasms
  12. Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer.
    Lang JE, Forero-Torres A, Yee D, et al. · NPJ Breast Cancer · 2026 · Derived
    PubMed: PMID 36456573 · NCT01042379 (I-SPY) · Neoplasms
  13. Intergroup randomized phase III study of adjuvant FOLFIRI, FOLFOX, or 5-FU/leucovorin for stage II/III rectal cancer: ECOG-ACRIN E3201.
    Kam AE, Zhao F, Meropol NJ, et al. · Oncologist · 2026 · Derived
    PubMed: PMID 41397917 · NCT00068692 · Rectal Neoplasms
  14. Detection of serum HER2 in patients treated with neratinib or trastuzumab: analysis of the I-SPY Trial.
    Hensley M, Lengfeld J, Stoesz S, et al. · Front Oncol · 2026 · Derived
    PubMed: PMID 40777112 · NCT01042379 (I-SPY) · Neoplasms
  15. Trabectedin and low-dose irinotecan to target EWS::FLI1 in Ewing sarcoma: a phase 1/2 trial.
    Grohar PJ, Heise R, Wedekind MF, et al. · Nat Med · 2026 · Derived
    PubMed: PMID 41991689 · NCT04067115 (U01CA236220) · Sarcoma, Ewing
  16. Selinexor (KPT-330) in Combination with Immune Checkpoint Inhibition in Uveal Melanoma: A Phase 1B Trial.
    Gouda MA, Zarifa A, Yang Y, et al. · J Immunother Precis Oncol · 2026 · Derived
    PubMed: PMID 39816915 · NCT02419495 · Neoplasm Metastasis
  17. Pooled safety analysis of lurbinectedin plus irinotecan in patients with advanced solid tumors.
    Falcón A, Cote GM, Molina-Cerrillo J, et al. · Invest New Drugs · 2026 · Derived
    PubMed: PMID 42081171 · NCT02611024 · Colorectal Neoplasms
  18. Upfront Modified FOLFOXIRI Plus Panitumumab for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Results of the Phase III TRIPLETE Study.
    Conca V, Rossini D, Antoniotti C, et al. · J Clin Oncol · 2026 · Derived
    PubMed: PMID 41505697 · NCT03231722 (TRIPLETE) · Colorectal Neoplasms
  19. Treatment Intensification with Hepatic Arterial Infusion Chemotherapy in Patients with Liver-Only Colorectal Metastases Still Unresectable After Systemic Induction Chemotherapy: Exploratory Findings From a Prematurely Closed Multicenter Randomized Phase II Study: SULTAN UCGI 30/PRODIGE 53 (NCT03164655).
    Boilève A, Audemar F, Dupont-Bierre E, et al. · Ann Surg Oncol · 2026 · Derived
    PubMed: PMID 41118066 · NCT03164655 (SULTAN)
  20. Comparative Efficacy and Safety of Tislelizumab in Second-Line Esophageal Squamous Cell Carcinoma: Systematic Literature Review and Simulated Treatment Comparisons.
    Ajani JA, Wang K, Nikolaidis GF, et al. · Adv Ther · 2026 · Derived
    PubMed: PMID 41335329 · NCT03430843 · Neoplasm Metastasis
  21. Perfusion Assessment in CEUS Imaging for Estimating Pancreatic Cancer Response to Sonoporation-Enhanced Chemotherapy.
    Adler O, Machado P, Vu T, et al. · Ultrason Imaging · 2026 · Derived
    PubMed: PMID 41133726 · NCT04821284 · Pancreatic Neoplasms
  22. Impact of UGT1A1*28 polymorphism in patients with metastatic pancreatic ductal adenocarcinoma treated with NALIRIFOX in the NAPOLI 3 trial.
    Abdelrahim M, Khan G, Hatoum H, et al. · Future Oncol · 2026 · Derived
    PubMed: PMID 42080361 · NCT04083235 (NAPOLI 3)
  23. Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles.
    Farshidfar F, Zheng S, Gingras MC, et al. · Cell Rep · 2026 · Background
    PubMed: PMID 28658632 · NCT04059562 (TRITICC) · Cholangiocarcinoma

2025 (42 papers)

  1. Combined Epiregulin and Amphiregulin Expression Levels as a Predictive Biomarker for Panitumumab Therapy Benefit or Lack of Benefit in Patients With RAS Wild-Type Advanced Colorectal Cancer.
    Seligmann JF, Elliott F, Richman SD, et al. · JAMA Oncol · 2025 · Trial result
    PubMed: PMID 26867820 · NCT00389870 · Colorectal Neoplasms
  2. Brief Report: Ivonescimab Combined With Etoposide Plus Carboplatin as First-Line Treatment for Extensive-Stage SCLC: Results of a Phase 1b Clinical Trial.
    Chen Z, Wu L, Wang Q, et al. · J Thorac Oncol · 2025 · Trial result
    PubMed: PMID 39490738 · NCT07258147 · Lung Neoplasms
  3. Neoadjuvant chemoradiotherapy with capecitabine and irinotecan guided by UGT1A1 status in patients with locally advanced rectal cancer: 5-year update of the CinClare trial.
    Zhang Z, Sun X, Liu A, et al. · Cancer Commun (Lond) · 2025 · Derived
    PubMed: PMID 40899645 · NCT02605265 (CinClare)
  4. Combination of anlotinib and irinotecan as second-line therapy in extensive-stage small-cell lung cancer relapsed within six months: a single-arm phase Ⅱ study.
    Zhang M, Tang Y, Liang J, et al. · Lung Cancer · 2025 · Derived
    PubMed: PMID 40555062 · NCT04757779 · Small Cell Lung Carcinoma
  5. Biomarker-Driven Approach to the Treatment of Metastatic Gastric or Gastroesophageal Adenocarcinoma.
    Yu J, Mehta R · J Natl Compr Canc Netw · 2025 · Derived
    PubMed: PMID 40341124 · NCT06346392 · Stomach Neoplasms
  6. Nanoliposomal Irinotecan in Combination With 5-Fluorouracil and Leucovorin for Advanced Head and Neck and Esophageal Squamous Cell Carcinoma After Prior Platinum-Based Chemotherapy or Chemoradiotherapy: A Multicenter Phase II Trial.
    Yang MH, Wu SY, Ho IW, et al. · Cancer Med · 2025 · Derived
    PubMed: PMID 41117518 · NCT03712397 · Head and Neck Neoplasms
  7. Second-line treatment of PD-1 and CTLA-4 blockade combined with liposomal irinotecan plus leucovorin and fluorouracil for advanced cholangiocarcinoma: study protocol of a single-arm, prospective phase II trial.
    Yang H, Li L, Li X, et al. · Ther Adv Med Oncol · 2025 · Derived
    PubMed: PMID 39492841 · NCT06438822 · Cholangiocarcinoma
  8. Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for untreated advanced or metastatic pancreatic ductal adenocarcinoma.
    Xu Q, Zhao X, Wang X, et al. · BMC Med · 2025 · Derived
    PubMed: PMID 40619376 · NCT04796948
  9. Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial.
    Wolf DM, Yau C, Campbell M, et al. · JCO Precis Oncol · 2025 · Derived
    PubMed: PMID 40526879 · NCT01042379 (I-SPY) · Neoplasms
  10. NCI 10211: a phase II, single-arm study of berzosertib in combination with irinotecan in patients with advanced TP53 mutant gastroesophageal cancer.
    Wheless MC, Stockton S, Soares HP, et al. · Oncologist · 2025 · Derived
    PubMed: PMID 41335461 · NCT03641313
  11. Toripalimab, bevacizumab, and irinotecan in dMMR/MSI locally advanced colorectal cancer: First-stage results from a phase 1b/2 trial.
    Wang Z, Wang X, Zhang X, et al. · Cell Rep Med · 2025 · Derived
    PubMed: PMID 40818457 · NCT04988191 · Colorectal Neoplasms
  12. Baseline Liquid Biopsy in Relation to Tissue-Based Parameters in Metastatic Colorectal Cancer: Results From the Randomized FIRE-4 (AIO-KRK-0114) Study.
    Stintzing S, Klein-Scory S, Fischer von Weikersthal L, et al. · J Clin Oncol · 2025 · Derived
    PubMed: PMID 39903881 · NCT02934529 (AIO-KRK-0114) · Colorectal Neoplasms
  13. Individual Patient Data Meta-Analysis of Consensus Molecular Subtypes as Biomarkers of First-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer.
    Stahler A, Modest DP, Stintzing S, et al. · J Clin Oncol · 2025 · Derived
    PubMed: PMID 41252656 · NCT00433927 · Colorectal Neoplasms
  14. First-line treatment of anti-EGFR monoclonal antibody cetuximab β plus FOLFIRI versus FOLFIRI alone in Chinese patients with RAS/BRAF wild-type metastatic colorectal cancer: a randomized, phase 3 trial.
    Shi Y, Ba Y, Wang J, et al. · Signal Transduct Target Ther · 2025 · Derived
    PubMed: PMID 40328753 · NCT03206151 · Colorectal Neoplasms
  15. A phase III randomized clinical trial of Gemcitabine and Nab-Paclitaxel as switch maintenance versus continuation of modified FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: The PANThEON Study.
    Sciortino C, Nichetti F, Bergamo F, et al. · Dig Liver Dis · 2025 · Derived
    PubMed: PMID 41318310 · NCT06897644 (PANThEON) · Pancreatic Neoplasms
  16. BilT03: Phase 1b/2 multicenter trial of nivolumab with 5-fluorouracil and liposomal irinotecan for previously treated advanced biliary tract cancer.
    Sahai V, Griffith KA, Lin BS, et al. · Med · 2025 · Derived
    PubMed: PMID 39701097 · NCT03785873 · Biliary Tract Neoplasms
  17. Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer.
    Rugo HS, Campbell M, Yau C, et al. · Breast Cancer Res Treat · 2025 · Derived
    PubMed: PMID 39625569 · NCT01042379 (I-SPY) · Neoplasms
  18. Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patients With RAS/BRAF Wild-Type, HER2-Positive, Metastatic Colorectal Cancer (S1613): A Randomized Phase II Trial.
    Raghav KPS, Guthrie KA, Tan B, et al. · J Clin Oncol · 2025 · Derived
    PubMed: PMID 39761503 · NCT03365882 · Rectal Neoplasms
  19. In vitro 3D drug sensitivity testing for patient-derived tumor-like cell clusters and whole-exome sequencing to personalize postoperative treatment: A study protocol for a multicenter randomized controlled trial.
    Qiu X, Li R, Xie G, et al. · PLoS One · 2025 · Derived
    PubMed: PMID 40658653 · NCT05424692 · Rectal Neoplasms
  20. Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial.
    Qi C, Liu C, Peng Z, et al. · Lancet · 2025 · Derived
    PubMed: PMID 40460847 · NCT04581473 · Stomach Neoplasms
  21. NET-02: a randomised, non-comparative, phase II trial of nal-IRI/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma.
    McNamara MG, Swain J, Craig Z, et al. · EClinicalMedicine · 2025 · Derived
    PubMed: PMID 37287870 · NCT03837977 (NET02) · Neoplasms
  22. NOTCH1 Mutation and Survival Analysis of Tislelizumab in Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Biomarker Analysis From the Randomized, Phase III, RATIONALE-302 Trial.
    Lu Z, Du W, Jiao X, et al. · J Clin Oncol · 2025 · Derived
    PubMed: PMID 40179324 · NCT03430843 · Neoplasm Metastasis
  23. Combined prognostic impact of initial clinical stage and residual cancer burden after neoadjuvant systemic therapy in triple-negative and HER2-positive breast cancer: an analysis of the I-SPY2 randomized clinical trial.
    Leon-Ferre RA, Dimitroff K, Yau C, et al. · Breast Cancer Res · 2025 · Derived
    PubMed: PMID 40551254 · NCT01042379 (I-SPY) · Neoplasms
  24. An immune responsive tumor microenvironment imprints into PBMCs and predicts outcome in advanced pancreatic cancer: lessons from the PREDICT trial.
    Lahusen A, Lutz MP, Fang R, et al. · Mol Cancer · 2025 · Derived
    PubMed: PMID 40696453 · NCT03468335 (PREDICT) · Pancreatic Neoplasms
  25. Phase I trial of ATR inhibitor elimusertib with FOLFIRI in advanced or metastatic gastrointestinal malignancies (ETCTN 10406).
    Krishnamurthy A, Wang H, Rhee JC, et al. · Cancer Chemother Pharmacol · 2025 · Derived
    PubMed: PMID 39841295 · NCT04535401 · Colorectal Neoplasms
  26. Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial.
    Kopetz S, Yoshino T, Van Cutsem E, et al. · Nat Med · 2025 · Derived
    PubMed: PMID 39863775 · NCT04607421 · Colorectal Neoplasms
  27. BREAKWATER Phase III: results for encorafenib and cetuximab plus mFOLFOX6 in first-line BRAF V600E-mutant metastatic colorectal cancer.
    Kopetz S, Tabernero J, Élez E, et al. · Future Oncol · 2025 · Derived
    PubMed: PMID 41230651 · NCT04607421 · Colorectal Neoplasms
  28. A two-stage dual-task learning strategy for early prediction of pathological complete response to neoadjuvant chemotherapy for breast cancer using dynamic contrast-enhanced magnetic resonance images.
    Jing B, Wang J · Phys Med Biol · 2025 · Derived
    PubMed: PMID 40639409 · NCT01042379 (I-SPY) · Neoplasms
  29. NALIRIFOX in Japanese treatment-naïve patients with metastatic pancreatic adenocarcinoma: an open-label, phase II trial design.
    Ikeda M, Okusaka T, Ueno M, et al. · Future Oncol · 2025 · Derived
    PubMed: PMID 39987459 · NCT06225999
  30. Impact of the tumor immune contexture in microsatellite-stable metastatic colorectal cancer treated with avelumab, cetuximab, and irinotecan.
    Huyghe N, Benidovskaya E, Masoodi T, et al. · Cell Rep Med · 2025 · Derived
    PubMed: PMID 40562041 · NCT03608046 (AVETUXIRI) · Colonic Neoplasms
  31. TRYBECA-1: A Randomized Phase III Study of Eryaspase Combined With Chemotherapy Versus Chemotherapy as Second-Line Treatment in Patients With Advanced Pancreatic Adenocarcinoma.
    Hammel P, Metges JP, Macarulla Mercade T, et al. · J Clin Oncol · 2025 · Derived
    PubMed: PMID 41187298 · NCT03665441 (Trybeca-1) · Neoplasms
  32. Radiomics-based Machine Learning Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Using Physiologically Decomposed Diffusion-weighted MRI.
    Gilad M, Partridge SC, Iima M, et al. · Radiol Imaging Cancer · 2025 · Derived
    PubMed: PMID 40679371 · NCT01042379 (I-SPY) · Neoplasms
  33. Intravenous liposomal irinotecan in metastatic triple-negative breast cancer after ≥ 2 prior lines of chemotherapy: a phase Ib study.
    Fan Y, Zhang Q, Yan M, et al. · Nat Commun · 2025 · Derived
    PubMed: PMID 39746964 · NCT04728035
  34. Phase I results on the efficacy, safety and pharmacokinetics of lurbinectedin and irinotecan in advanced solid tumors.
    Falcón A, Ponce S, Cote GM, et al. · Invest New Drugs · 2025 · Derived
    PubMed: PMID 40963055 · NCT02611024 · Colorectal Neoplasms
  35. Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer.
    Elez E, Yoshino T, Shen L, et al. · N Engl J Med · 2025 · Derived
    PubMed: PMID 40444708 · NCT04607421 · Colorectal Neoplasms
  36. PRODIGE 29-UCGI 26 (NEOPAN): A Phase III Randomized Trial Comparing Chemotherapy With FOLFIRINOX or Gemcitabine in Locally Advanced Pancreatic Carcinoma.
    Ducreux M, Desgrippes R, Rinaldi Y, et al. · J Clin Oncol · 2025 · Derived
    PubMed: PMID 40378359 · NCT02539537 (NEOPAN) · Pancreatic Neoplasms
  37. Locoregional Treatment Options for Locally Advanced Intrahepatic Cholangiocarcinoma.
    Blair AB, Alobuia WM, Palta M, et al. · J Natl Compr Canc Netw · 2025 · Derived
    PubMed: PMID 40812353 · NCT04251715 · Cholangiocarcinoma
  38. Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial.
    André T, Elez E, Lenz HJ, et al. · Lancet · 2025 · Derived
    PubMed: PMID 39874977 · NCT04008030 (CheckMate 8HW) · Colorectal Neoplasms
  39. A Phase IB Trial of Selinexor in Combination With Immune Checkpoint Blockade in Patients With Advanced Renal Cell Carcinoma.
    Alhalabi O, Gouda MA, Milton DR, et al. · Cancer Med · 2025 · Derived
    PubMed: PMID 39945382 · NCT02419495 · Neoplasm Metastasis
  40. Neoadjuvant chemoradiation with or without PD-1 blockade in locally advanced rectal cancer: a randomized phase 2 trial.
    Yang Y, Pang K, Lin G, et al. · Nat Med · 2025 · Background
    PubMed: PMID 39762418 · NCT07521605
  41. 2025 Jan 15
    · 2025 · Background
    PubMed: PMID 29999936 · NCT04059562 (TRITICC) · Cholangiocarcinoma
  42. Korean Practice Guideline for Gastric Cancer 2018: an Evidence-based, Multi-disciplinary Approach.
    Guideline Committee of the Korean Gastric Cancer Association (KGCA), Development Working Group & Review Panel · J Gastric Cancer · 2025 · Background
    PubMed: PMID 30944757 · NCT04915807 · Stomach Neoplasms

2024 (58 papers)

  1. Pancreatic Cancer: An Exocrine Tumor With Endocrine Characteristics.
    Zhu X, Xiao Z, Liu H, et al. · Ann Surg · 2024 · Trial result
    PubMed: PMID 38050737 · NCT06250972 (PTCA199-11)
  2. Preclinical study and phase II trial of adapting low-dose radiotherapy to immunotherapy in small cell lung cancer.
    Wang H, Yao Z, Kang K, et al. · Med · 2024 · Trial result
    PubMed: PMID 38964333 · NCT07258147 · Lung Neoplasms
  3. Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial.
    Labori KJ, Bratlie SO, Andersson B, et al. · Lancet Gastroenterol Hepatol · 2024 · Trial result
    PubMed: PMID 38237621 · NCT02919787 · Pancreatic Neoplasms
  4. Pembrolizumab Plus mFOLFOX7 or FOLFIRI for Microsatellite Stable/Mismatch Repair-Proficient Metastatic Colorectal Cancer: KEYNOTE-651 Cohorts B and D.
    Kim R, Tehfe M, Kavan P, et al. · Clin Colorectal Cancer · 2024 · Trial result
    PubMed: PMID 38762348 · NCT03374254 · Colorectal Neoplasms
  5. GSK-3β inhibitor, 9-ING-41, reduces cell viability and halts proliferation of B-cell lymphoma cell lines as a single agent and in combination with novel agents.
    Karmali R, Chukkapalli V, Gordon LI, et al. · Oncotarget · 2024 · Trial result
    PubMed: PMID 29383130 · NCT03678883 · Colorectal Neoplasms
  6. Pembrolizumab Plus Binimetinib With or Without Chemotherapy for MSS/pMMR Metastatic Colorectal Cancer: Outcomes From KEYNOTE-651 Cohorts A, C, and E.
    Chen EX, Kavan P, Tehfe M, et al. · Clin Colorectal Cancer · 2024 · Trial result
    PubMed: PMID 38653648 · NCT03374254 · Colorectal Neoplasms
  7. A prospective phase II single-arm study and predictive factor analysis of irinotecan as third-line treatment in patients with metastatic gastric cancer.
    Yu N, Huang S, Zhang Z, et al. · Ther Adv Med Oncol · 2024 · Derived
    PubMed: PMID 38425987 · NCT02662959 · Stomach Neoplasms
  8. Circulating tumor DNA: from discovery to clinical application in breast cancer.
    Xu J, Gao H, Guan X, et al. · Front Immunol · 2024 · Derived
    PubMed: PMID 38745646 · NCT01042379 (I-SPY) · Neoplasms
  9. CMG901, a Claudin18.2-specific antibody-drug conjugate, for the treatment of solid tumors.
    Xu G, Liu W, Wang Y, et al. · Cell Rep Med · 2024 · Derived
    PubMed: PMID 39232496 · NCT06346392 · Stomach Neoplasms
  10. Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a valid tool for patient selection?
    Weiss L, Heinemann V, Fischer LE, et al. · Clin Transl Oncol · 2024 · Derived
    PubMed: PMID 37794220 · NCT01729481 (ML22774)
  11. Soluble FLT-1 in angiogenesis: pathophysiological roles and therapeutic implications.
    Wazan LE, Widhibrata A, Liu GS, et al. · Angiogenesis · 2024 · Derived
    PubMed: PMID 39207600 · NCT00561470 (VELOUR) · Colorectal Neoplasms
  12. Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial.
    Wang DS, Ren C, Li SS, et al. · PLoS Med · 2024 · Derived
    PubMed: PMID 38728364 · NCT03493048 · Colorectal Neoplasms
  13. Safety and efficacy of adjuvant FOLFOX/FOLFIRI with versus without hepatic arterial infusion of floxuridine in patients following colorectal cancer liver metastasectomy (HARVEST trial): A randomized controlled trial.
    Wang DS, Pat Fong W, Wen L, et al. · Eur J Cancer · 2024 · Derived
    PubMed: PMID 39644535 · NCT03500874 · Colorectal Neoplasms
  14. Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer.
    Vergote I, González-Martín A, Fujiwara K, et al. · N Engl J Med · 2024 · Derived
    PubMed: PMID 38959480 · NCT04697628 (innovaTV 301) · Uterine Cervical Neoplasms
  15. Intraperitoneal irinotecan with concomitant FOLFOX and bevacizumab for patients with unresectable colorectal peritoneal metastases: protocol of the multicentre, open-label, phase II, INTERACT-II trial.
    van de Vlasakker VCJ, Guchelaar NAD, van den Heuvel TBM, et al. · BMJ Open · 2024 · Derived
    PubMed: PMID 38238055 · NCT06003998 (INTERACT-II) · Colorectal Neoplasms
  16. Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials.
    Tejpar S, Stintzing S, Ciardiello F, et al. · JAMA Oncol · 2024 · Derived
    PubMed: PMID 27722750 · NCT00433927 · Colorectal Neoplasms
  17. RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer.
    Spigel DR, Dowlati A, Chen Y, et al. · J Clin Oncol · 2024 · Derived
    PubMed: PMID 38648575 · NCT03088813 (RESILIENT) · Small Cell Lung Carcinoma
  18. Body composition measurements and clinical outcomes in patients with resectable pancreatic adenocarcinoma - analysis from SWOG S1505.
    Sohal DPS, Boutin RD, Lenchik L, et al. · J Gastrointest Surg · 2024 · Derived
    PubMed: PMID 38445914 · NCT02562716
  19. Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.
    Shatsky RA, Trivedi MS, Yau C, et al. · Nat Med · 2024 · Derived
    PubMed: PMID 39277672 · NCT01042379 (I-SPY) · Neoplasms
  20. Management of Locally Advanced Rectal Cancer: ASCO Guideline.
    Scott AJ, Kennedy EB, Berlin J, et al. · J Clin Oncol · 2024 · Derived
    PubMed: PMID 39116386 · NCT05610163 (JANUS) · Rectal Neoplasms
  21. Efficacy and quality of life for FOLFOX/bevacizumab +/- irinotecan in first-line metastatic colorectal cancer-final results of the AIO CHARTA trial.
    Schmoll HJ, Mann J, Meinert F, et al. · Br J Cancer · 2024 · Derived
    PubMed: PMID 37996507 · NCT01321957 (CHARTA) · Colorectal Neoplasms
  22. Identification of HER2-positive breast cancer molecular subtypes with potential clinical implications in the ALTTO clinical trial.
    Rediti M, Venet D, Joaquin Garcia A, et al. · Nat Commun · 2024 · Derived
    PubMed: PMID 39613746 · NCT01042379 (I-SPY) · Neoplasms
  23. Safety and Efficacy of CT041 in Patients With Refractory Metastatic Pancreatic Cancer: A Pooled Analysis of Two Early-Phase Trials.
    Qi C, Zhang P, Liu C, et al. · J Clin Oncol · 2024 · Derived
    PubMed: PMID 38788174 · NCT04581473 · Stomach Neoplasms
  24. Implementation and impact of an electronic patient reported outcomes system in a phase II multi-site adaptive platform clinical trial for early-stage breast cancer.
    Northrop A, Christofferson A, Umashankar S, et al. · J Am Med Inform Assoc · 2024 · Derived
    PubMed: PMID 39158353 · NCT01042379 (I-SPY) · Neoplasms
  25. Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial.
    Moreno L, Weston R, Owens C, et al. · J Clin Oncol · 2024 · Derived
    PubMed: PMID 38190578 · NCT02308527 (BEACON) · Neuroblastoma
  26. Breast Multiparametric MRI for Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer: The BMMR2 Challenge.
    Li W, Partridge SC, Newitt DC, et al. · Radiol Imaging Cancer · 2024 · Derived
    PubMed: PMID 38180338 · NCT01042379 (I-SPY) · Neoplasms
  27. Raltitrexed Chemotherapy Regimen Plus Bevacizumab as Second-Line Treatment for Metastatic Colorectal Cancer: A Prospective Multicenter Phase II Trial.
    Li S, Li X, Zhu Q, et al. · Cancer Control · 2024 · Derived
    PubMed: PMID 39286935 · NCT03126071
  28. Alternating modified CAPOX/CAPIRI plus bevacizumab in untreated unresectable metastatic colorectal cancer: a phase 2 trial.
    Li S, Li X, Xu H, et al. · Signal Transduct Target Ther · 2024 · Derived
    PubMed: PMID 39658608 · NCT04324476
  29. A phase II study of guadecitabine combined with irinotecan vs regorafenib or TAS-102 in irinotecan-refractory metastatic colorectal cancer patients.
    Lee V, Parkinson R, Zahurak M, et al. · Int J Cancer · 2024 · Derived
    PubMed: PMID 38312102 · NCT01896856 · Neoplasm Metastasis
  30. Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial.
    Kopetz S, Murphy DA, Pu J, et al. · Nat Med · 2024 · Derived
    PubMed: PMID 39313594 · NCT02928224 (BEACON CRC) · Colorectal Neoplasms
  31. Tislelizumab in advanced/metastatic esophageal squamous cell carcinoma: health-related quality of life in Asian patients.
    Kim SB, Van Cutsem E, Ajani J, et al. · Curr Med Res Opin · 2024 · Derived
    PubMed: PMID 37846080 · NCT03430843 · Neoplasm Metastasis
  32. Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.
    Khoury K, Meisel JL, Yau C, et al. · Nat Med · 2024 · Derived
    PubMed: PMID 39277671 · NCT01042379 (I-SPY) · Neoplasms
  33. Liposomal irinotecan (HR070803) in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors: a phase 1b dose-escalation and expansion study.
    Ji D, Shen W, Li T, et al. · Invest New Drugs · 2024 · Derived
    PubMed: PMID 39037543 · NCT05086848
  34. Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: a New Approaches to Neuroblastoma Therapy trial.
    Hogarty MD, Ziegler DS, Franson A, et al. · Br J Cancer · 2024 · Derived
    PubMed: PMID 38200233 · NCT03794349 · Neuroblastoma
  35. Combining antivascular endothelial growth factor and anti-epidermal growth factor receptor antibodies: randomized phase II study of irinotecan and cetuximab with/without ramucirumab in second-line colorectal cancer (ECOG-ACRIN E7208).
    Hochster HS, Catalano P, Weitz M, et al. · J Natl Cancer Inst · 2024 · Derived
    PubMed: PMID 38775718 · NCT01079780 · Colorectal Neoplasms
  36. Circulating tumor DNA serial monitoring of relapse and responses to tislelizumab immunotherapy as second‑line monotherapy for metastatic esophageal squamous cell carcinoma: A prospective study.
    He Q, Shi X, Yan J, et al. · Mol Clin Oncol · 2024 · Derived
    PubMed: PMID 38414510 · NCT03430843 · Neoplasm Metastasis
  37. Second-line tislelizumab versus chemotherapy in Japanese patients with advanced or metastatic esophageal squamous cell carcinoma: subgroup analysis from RATIONALE-302.
    Hara H, Satoh T, Kojima T, et al. · Esophagus · 2024 · Derived
    PubMed: PMID 38240916 · NCT03430843 · Neoplasm Metastasis
  38. Addition of temsirolimus to chemotherapy in children, adolescents, and young adults with intermediate-risk rhabdomyosarcoma (ARST1431): a randomised, open-label, phase 3 trial from the Children's Oncology Group.
    Gupta AA, Xue W, Harrison DJ, et al. · Lancet Oncol · 2024 · Derived
    PubMed: PMID 38936378 · NCT02567435 · Rhabdomyosarcoma
  39. Association of baseline absolute neutrophil counts and survival in patients with metastatic colorectal cancer treated with second-line antiangiogenic therapies: exploratory analyses of the RAISE trial and validation in an electronic medical record data set.
    Grothey A, Yoshino T, Bodoky G, et al. · ESMO Open · 2024 · Derived
    PubMed: PMID 29713498 · NCT01183780 · Colorectal Neoplasms
  40. A phase-II study based on dose adjustment according to UGT1A1 polymorphism: is irinotecan underdosed in first-line FOLFIRI regimen for mCRC?
    Ginzac A, Thivat E, Petorin C, et al. · Cancer Chemother Pharmacol · 2024 · Derived
    PubMed: PMID 37932443 · NCT01963182 (IriGen)
  41. FOLFOXIRI/Bevacizumab Plus Nivolumab as First-Line Treatment in Metastatic Colorectal Cancer RAS/BRAF Mutated: Safety Run-In of Phase II NIVACOR Trial.
    Damato A, Bergamo F, Antonuzzo L, et al. · Front Oncol · 2024 · Derived
    PubMed: PMID 34970487 · NCT04072198 (NIVACOR) · Colorectal Neoplasms
  42. Irinotecan hydrochloride liposome HR070803 in combination with 5-fluorouracil and leucovorin in locally advanced or metastatic pancreatic ductal adenocarcinoma following prior gemcitabine-based therapy (PAN-HEROIC-1): a phase 3 trial.
    Cui J, Qin S, Zhou Y, et al. · Signal Transduct Target Ther · 2024 · Derived
    PubMed: PMID 39300077 · NCT05074589
  43. Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer.
    Cremolini C, Antoniotti C, Stein A, et al. · J Clin Oncol · 2024 · Derived
    PubMed: PMID 32816630 · NCT00719797 (TRIBE) · Colorectal Neoplasms
  44. A Phase 1 Study of ABI-009 (Nab-sirolimus) in Combination With Temozolomide and Irinotecan in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors-A Children's Oncology Group Pediatric Early Phase Clinical Trial Network Study ADVL1514.
    Cramer SL, Reddy AT, Minard CG, et al. · Cancer Med · 2024 · Derived
    PubMed: PMID 39487711 · NCT02975882 · Central Nervous System Neoplasms
  45. Irinotecan and temozolomide in combination with dasatinib and rapamycin versus irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma (RIST-rNB-2011): a multicentre, open-label, randomised, controlled, phase 2 trial.
    Corbacioglu S, Lode H, Ellinger S, et al. · Lancet Oncol · 2024 · Derived
    PubMed: PMID 38936379 · NCT01467986 (RIST-rNB-2011) · Neuroblastoma
  46. Anti-EGFR Rechallenge in Patients With Refractory ctDNA RAS/BRAF wt Metastatic Colorectal Cancer: A Nonrandomized Controlled Trial.
    Ciardiello D, Martinelli E, Troiani T, et al. · JAMA Netw Open · 2024 · Derived
    PubMed: PMID 38592721 · NCT02296203 (CRICKET) · Colorectal Neoplasms
  47. Irinotecan plus raltitrexed as second-line treatment in locally advanced or metastatic colorectal cancer patients: a prospective open-label, single-arm, multi-center, phase II study.
    Cheng Y, Teng Z, Zhang Y, et al. · BMC Cancer · 2024 · Derived
    PubMed: PMID 39223545 · NCT03053167 · Colorectal Neoplasms
  48. Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer: A Nonrandomized Controlled Trial.
    Cecchini M, Salem RR, Robert M, et al. · JAMA Oncol · 2024 · Derived
    PubMed: PMID 38900452 · NCT02047474 · Pancreatic Neoplasms
  49. TAS-102, Irinotecan, and bevacizumab in pre-treated metastatic colorectal cancer (TABAsCO), a phase II clinical trial.
    Boland PM, Mukherjee S, Imanirad I, et al. · Br J Cancer · 2024 · Derived
    PubMed: PMID 39244627 · NCT04109924 · Colorectal Neoplasms
  50. Treatment and outcomes of clear cell sarcoma of the kidney: A report from the Children's Oncology Group studies AREN0321 and AREN03B2.
    Benedetti DJ, Renfro LA, Tfirn I, et al. · Cancer · 2024 · Derived
    PubMed: PMID 38396300 · NCT00335556 · Carcinoma, Renal Cell
  51. QUATTRO-II randomized trial: CAPOXIRI+bevacizumab vs. FOLFOXIRI+bevacizumab as first-line treatment in patients with mCRC.
    Bando H, Kotani D, Satake H, et al. · Med · 2024 · Derived
    PubMed: PMID 38901425 · NCT04097444 (QUATTRO-II) · Colorectal Neoplasms
  52. Upfront Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Bevacizumab With or Without Atezolizumab for Patients With Metastatic Colorectal Cancer: Updated and Overall Survival Results of the ATEZOTRIBE Study.
    Antoniotti C, Rossini D, Pietrantonio F, et al. · J Clin Oncol · 2024 · Derived
    PubMed: PMID 38865678 · NCT03721653 (AtezoTRIBE) · Colorectal Neoplasms
  53. Nivolumab plus Ipilimumab in Microsatellite-Instability-High Metastatic Colorectal Cancer.
    Andre T, Elez E, Van Cutsem E, et al. · N Engl J Med · 2024 · Derived
    PubMed: PMID 39602630 · NCT04008030 (CheckMate 8HW) · Colorectal Neoplasms
  54. Alliance A022104/NRG-GI010: The Janus Rectal Cancer Trial: a randomized phase II/III trial testing the efficacy of triplet versus doublet chemotherapy regarding clinical complete response and disease-free survival in patients with locally advanced rectal cancer.
    Alvarez JA, Shi Q, Dasari A, et al. · BMC Cancer · 2024 · Derived
    PubMed: PMID 39060961 · NCT05610163 (JANUS) · Rectal Neoplasms
  55. ALLIANCE A022104/NRG-GI010: The Janus Rectal Cancer Trial: a randomized phase II/III trial testing the efficacy of triplet versus doublet chemotherapy regarding clinical complete response and disease-free survival in patients with locally advanced rectal cancer.
    Alvarez J, Shi Q, Dasari A, et al. · medRxiv · 2024 · Derived
    PubMed: PMID 38712176 · NCT05610163 (JANUS) · Rectal Neoplasms
  56. Efficacy and safety of PD-1 blockade plus long-course chemoradiotherapy in locally advanced rectal cancer (NECTAR): a multi-center phase 2 study.
    Yang Z, Gao J, Zheng J, et al. · Signal Transduct Target Ther · 2024 · Background
    PubMed: PMID 38462629 · NCT07104604 · Rectal Neoplasms
  57. Resection of colorectal liver metastases with second-line aflibercept plus FOLFIRI: Results from the RESECTION prospective French cohort.
    Tougeron D, Bibeau F, Chibaudel B, et al. · Eur J Cancer · 2024 · Background
    PubMed: PMID 39486163 · NCT05178745 · Colorectal Neoplasms
  58. Clinical sonochemotherapy of inoperable pancreatic cancer using diagnostic ultrasound and microbubbles: a multicentre, open-label, randomised, controlled trial.
    Han F, Wang Y, Dong X, et al. · Eur Radiol · 2024 · Background
    PubMed: PMID 37796294 · NCT07314385

2023 (45 papers)

  1. ROCKET: Phase II Randomized, Active-controlled, Multicenter Trial to Assess the Safety and Efficacy of RRx-001 + Irinotecan vs. Single-agent Regorafenib in Third/Fourth Line Colorectal Cancer.
    Reid TR, Abrouk N, Caroen S, et al. · Clin Colorectal Cancer · 2023 · Trial result
    PubMed: PMID 36529613 · NCT02096354 (ROCKET) · Colorectal Neoplasms
  2. A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer.
    Garralda E, Sukari A, Lakhani NJ, et al. · ESMO Open · 2023 · Trial result
    PubMed: PMID 36493599 · NCT02720068 · Neoplasms
  3. Sintilimab Plus Apatinib and Chemotherapy as Second‑/Third-Line treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a prospective, Single-Arm, phase II trial.
    Zhang L, Wang W, Ge S, et al. · BMC Cancer · 2023 · Derived
    PubMed: PMID 36872337 · NCT05025033 · Stomach Neoplasms
  4. TORCH-R trial protocol: hypofractionated radiotherapy combined with chemotherapy and toripalimab for locally recurrent rectal cancer: a prospective, single-arm, two-cohort, phase II trial.
    Wan J, Wu R, Fu M, et al. · Front Oncol · 2023 · Derived
    PubMed: PMID 38053659 · NCT05628038 (TORCH-R) · Rectal Neoplasms
  5. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial.
    Wainberg ZA, Melisi D, Macarulla T, et al. · Lancet · 2023 · Derived
    PubMed: PMID 37708904 · NCT04083235 (NAPOLI 3)
  6. ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated BRAFV600E-Mutant Metastatic Colorectal Cancer.
    Van Cutsem E, Taieb J, Yaeger R, et al. · J Clin Oncol · 2023 · Derived
    PubMed: PMID 36763936 · NCT04607421 · Colorectal Neoplasms
  7. Vincristine/irinotecan/temsirolimus upfront window treatment of high-risk hepatoblastoma: A report from the Children's Oncology Group AHEP0731 Study Committee.
    Thompson PA, Malogolowkin MH, Furman WL, et al. · Pediatr Blood Cancer · 2023 · Derived
    PubMed: PMID 37073741 · NCT00980460
  8. Phase II Trial of Trifluridine/Tipiracil Plus Irinotecan in Patients with Advanced, Refractory Biliary Tract Carcinoma.
    Tella SH, Foster N, Qian S, et al. · Oncologist · 2023 · Derived
    PubMed: PMID 37339254 · NCT04072445 · Gallbladder Neoplasms
  9. Adverse Events Associated with Encorafenib Plus Cetuximab in Patients with BRAFV600E-mutant Metastatic Colorectal Cancer: An in-depth Analysis of the BEACON CRC Study.
    Taieb J, Lonardi S, Desai J, et al. · Clin Colorectal Cancer · 2023 · Derived
    PubMed: PMID 36653241 · NCT02928224 (BEACON CRC) · Colorectal Neoplasms
  10. Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma.
    Subbiah V, Chawla SP, Conley AP, et al. · Clin Cancer Res · 2023 · Derived
    PubMed: PMID 37265425 · NCT03715933 · Sarcoma
  11. Improving Outcome of Selected Patients With Non-Resectable Hepatic Metastases From Colorectal Cancer With Liver Transplantation: A Prospective Parallel Trial (COLT trial).
    Sposito C, Pietrantonio F, Maspero M, et al. · Clin Colorectal Cancer · 2023 · Derived
    PubMed: PMID 36822922 · NCT03231722 (TRIPLETE) · Colorectal Neoplasms
  12. A phase II study of neoadjuvant liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in pancreatic adenocarcinoma.
    Singhal R, Rogers SC, Lee JH, et al. · Future Oncol · 2023 · Derived
    PubMed: PMID 37753702 · NCT03483038
  13. Multicenter, single-arm, phase II study (CAP) of radiotherapy plus liposomal irinotecan followed by camrelizumab and anti-angiogenic treatment in advanced solid tumors.
    Shen J, Yan J, Du J, et al. · Front Immunol · 2023 · Derived
    PubMed: PMID 37056765 · NCT04569916
  14. Pembrolizumab alone and pembrolizumab plus chemotherapy in previously treated, extrapulmonary poorly differentiated neuroendocrine carcinomas.
    Raj N, Chan JA, Wang SJ, et al. · Br J Cancer · 2023 · Derived
    PubMed: PMID 37208512 · NCT03136055 · Disease
  15. CT041 CAR T cell therapy for Claudin18.2-positive metastatic pancreatic cancer.
    Qi C, Xie T, Zhou J, et al. · J Hematol Oncol · 2023 · Derived
    PubMed: PMID 37689733 · NCT04581473 · Stomach Neoplasms
  16. PANTHER: AZD8931, inhibitor of EGFR, ERBB2 and ERBB3 signalling, combined with FOLFIRI: a Phase I/II study to determine the importance of schedule and activity in colorectal cancer.
    Propper DJ, Gao F, Saunders MP, et al. · Br J Cancer · 2023 · Derived
    PubMed: PMID 36352028 · NCT01862003 (PANTHER) · Colorectal Neoplasms
  17. Sustained Survival Benefit in Recurrent Medulloblastoma by a Metronomic Antiangiogenic Regimen: A Nonrandomized Controlled Trial.
    Peyrl A, Chocholous M, Sabel M, et al. · JAMA Oncol · 2023 · Derived
    PubMed: PMID 37883081 · NCT01356290 (MEMMAT) · Recurrence
  18. Association of baseline ROR1 and ROR2 gene expression with clinical outcomes in the I-SPY2 neoadjuvant breast cancer trial.
    Parker BA, Shatsky RA, Schwab RB, et al. · Breast Cancer Res Treat · 2023 · Derived
    PubMed: PMID 37029329 · NCT01042379 (I-SPY) · Neoplasms
  19. Effect of Longitudinal Variation in Tumor Volume Estimation for MRI-guided Personalization of Breast Cancer Neoadjuvant Treatment.
    Onishi N, Bareng TJ, Gibbs J, et al. · Radiol Imaging Cancer · 2023 · Derived
    PubMed: PMID 37505107 · NCT01042379 (I-SPY) · Neoplasms
  20. Identification of Membrane-expressed CAPRIN-1 as a Novel and Universal Cancer Target, and Generation of a Therapeutic Anti-CAPRIN-1 Antibody TRK-950.
    Okano F, Saito T, Minamida Y, et al. · Cancer Res Commun · 2023 · Derived
    PubMed: PMID 37082579 · NCT03872947 · Colorectal Neoplasms
  21. Breast Conservation Surgery and Mastectomy Have Similar Locoregional Recurrence After Neoadjuvant Chemotherapy: Results From 1462 Patients on the Prospective, Randomized I-SPY2 Trial.
    Mukhtar RA, Chau H, Woriax H, et al. · Ann Surg · 2023 · Derived
    PubMed: PMID 37325931 · NCT01042379 (I-SPY) · Neoplasms
  22. A phase I trial of metformin in combination with vincristine, irinotecan, and temozolomide in children with relapsed or refractory solid and central nervous system tumors: A report from the national pediatric cancer foundation.
    Metts JL, Trucco M, Weiser DA, et al. · Cancer Med · 2023 · Derived
    PubMed: PMID 36151773 · NCT01528046 · Neoplasms
  23. Efficacy and safety of a biomarker-driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RAS/BRAF wild type tumors at start of first line: The CAPRI 2 GOIM trial.
    Martini G, Ciardiello D, Napolitano S, et al. · Front Oncol · 2023 · Derived
    PubMed: PMID 36860319 · NCT05312398
  24. Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials.
    Martini G, Ciardiello D, Famiglietti V, et al. · Cancer Med · 2023 · Derived
    PubMed: PMID 36880426 · NCT02296203 (CRICKET) · Colorectal Neoplasms
  25. Relationship Between Cetuximab Target-Mediated Pharmacokinetics and Progression-Free Survival in Metastatic Colorectal Cancer Patients.
    Lobet S, Paintaud G, Azzopardi N, et al. · Clin Pharmacokinet · 2023 · Derived
    PubMed: PMID 37442917 · NCT00559741 · Colorectal Neoplasms
  26. Inhibition of TCA cycle improves the anti-PD-1 immunotherapy efficacy in melanoma cells via ATF3-mediated PD-L1 expression and glycolysis.
    Liu N, Yan M, Tao Q, et al. · J Immunother Cancer · 2023 · Derived
    PubMed: PMID 37678921 · NCT01835041 · Pancreatic Neoplasms
  27. A Phase I Study of a Combination of Liposomal Irinotecan and Veliparib in Solid Tumors.
    LaRose M, Connolly RM, O'Sullivan CC, et al. · Oncologist · 2023 · Derived
    PubMed: PMID 37010988 · NCT02631733
  28. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Rectal Cancer 2023 Supplement.
    Langenfeld SJ, Davis BR, Vogel JD, et al. · Dis Colon Rectum · 2023 · Derived
    PubMed: PMID 37647138 · NCT05610163 (JANUS) · Rectal Neoplasms
  29. INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG).
    Lam LL, Pavlakis N, Shitara K, et al. · BMC Cancer · 2023 · Derived
    PubMed: PMID 36814222 · NCT04879368 (INTEGRATEIIb) · Neoplasm Metastasis
  30. Study protocol of an open-label, single arm phase II trial investigating the efficacy and safety of Trifluridine/Tipiracil combined with irinotecan as a second line therapy in patients with cholangiocarcinoma (TRITICC).
    Kehmann L, Berres ML, Gonzalez-Carmona M, et al. · BMC Cancer · 2023 · Derived
    PubMed: PMID 37217885 · NCT04059562 (TRITICC) · Cholangiocarcinoma
  31. An expansion study of genotype-driven weekly irinotecan and capecitabine in combination with neoadjuvant radiotherapy for locally advanced rectal cancer with UGT1A1 *1*1 genotype.
    Guan Y, Shen Y, Xu Y, et al. · Ther Adv Gastroenterol · 2023 · Derived
    PubMed: PMID 31217818 · NCT02605265 (CinClare)
  32. Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
    Gallois C, Shi Q, Meyers JP, et al. · J Clin Oncol · 2023 · Derived
    PubMed: PMID 36306483 · NCT00079274 · Colonic Neoplasms
  33. Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 Trial.
    Gallagher RI, Wulfkuhle J, Wolf DM, et al. · Cell Rep Med · 2023 · Derived
    PubMed: PMID 38086377 · NCT01042379 (I-SPY) · Neoplasms
  34. KIR/KIR-ligand genotypes and clinical outcomes following chemoimmunotherapy in patients with relapsed or refractory neuroblastoma: a report from the Children's Oncology Group.
    Erbe AK, Diccianni MB, Mody R, et al. · J Immunother Cancer · 2023 · Derived
    PubMed: PMID 36822669 · NCT01767194 · Neuroblastoma
  35. Depth of Radiographic Response and Time to Tumor Regrowth Predicts Overall Survival Following Anti-VEGF Therapy in Recurrent Glioblastoma.
    Ellingson BM, Hagiwara A, Morris CJ, et al. · Clin Cancer Res · 2023 · Derived
    PubMed: PMID 37540556 · NCT00345163 (BRAIN) · Glioblastoma
  36. The GIANT trial (ECOG-ACRIN EA2186) methods paper: A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer - defining a new treatment option for older vulnerable patients.
    Dotan E, Catalano P, Lenchik L, et al. · J Geriatr Oncol · 2023 · Derived
    PubMed: PMID 36963200 · NCT04233866 · Pancreatic Neoplasms
  37. Cell-free DNA Predicts Prolonged Response to Multi-agent Chemotherapy in Pancreatic Ductal Adenocarcinoma.
    Christenson ES, Lim SJ, Durham J, et al. · Cancer Res Commun · 2023 · Derived
    PubMed: PMID 36970054 · NCT02324543
  38. Pathological response and safety of FOLFOXIRI for neoadjuvant treatment of high-risk relapsed locally advanced colon cancer: study protocol for a single-arm, open-label phase II trial.
    Chen X, Leng W, Zhou Y, et al. · BMJ Open · 2023 · Derived
    PubMed: PMID 36720570 · NCT05018182
  39. Regorafenib plus Vincristine and Irinotecan in Pediatric Patients with Recurrent/Refractory Solid Tumors: An Innovative Therapy for Children with Cancer Study.
    Casanova M, Bautista F, Campbell-Hewson Q, et al. · Clin Cancer Res · 2023 · Derived
    PubMed: PMID 37606641 · NCT02085148 · Neoplasms
  40. Safety, tolerability, and clinical activity of selinexor in combination with pembrolizumab in treatment of metastatic non-small cell lung cancer.
    Altan M, Tu J, Milton DR, et al. · Cancer · 2023 · Derived
    PubMed: PMID 37129197 · NCT02419495 · Neoplasm Metastasis
  41. Effectiveness of irinotecan plus trabectedin on a desmoplastic small round cell tumor patient-derived xenograft.
    Zuco V, Pasquali S, Tortoreto M, et al. · Dis Model Mech · 2023 · Background
    PubMed: PMID 37158111 · NCT07328425 (ISG-TULIPS) · Desmoplastic Small Round Cell Tumor
  42. Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): study protocol for a multicenter randomized controlled trial.
    van Dam JL, Verkolf EMM, Dekker EN, et al. · BMC Cancer · 2023 · Background
    PubMed: PMID 37550634 · NCT04927780 (PREOPANC-3) · Pancreatic Neoplasms
  43. SN-38, an active metabolite of irinotecan, enhances anti-PD-1 treatment efficacy in head and neck squamous cell carcinoma.
    Lee YM, Chen YH, Ou DL, et al. · J Pathol · 2023 · Background
    PubMed: PMID 36641765 · NCT07521605
  44. Long-term survivors with desmoplastic small round cell tumor (DSRCT): Results from a retrospective single-institution case series analysis.
    Giani C, Radaelli S, Miceli R, et al. · Cancer Med · 2023 · Background
    PubMed: PMID 36951537 · NCT07328425 (ISG-TULIPS) · Desmoplastic Small Round Cell Tumor
  45. Trabectedin-irinotecan, a potentially promising combination in relapsed desmoplastic small round cell tumor: report of two cases.
    Ferrari A, Chiaravalli S, Bergamaschi L, et al. · J Chemother · 2023 · Background
    PubMed: PMID 35470779 · NCT07328425 (ISG-TULIPS) · Desmoplastic Small Round Cell Tumor

2022 (75 papers)

  1. Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study.
    Shen L, Kato K, Kim SB, et al. · J Clin Oncol · 2022 · Trial result
    PubMed: PMID 35442766 · NCT03430843 · Neoplasm Metastasis
  2. Pembrolizumab versus chemotherapy for patients with esophageal squamous cell carcinoma enrolled in the randomized KEYNOTE-181 trial in Asia.
    Cao Y, Qin S, Luo S, et al. · ESMO Open · 2022 · Trial result
    PubMed: PMID 34973513 · NCT03933449 · Esophageal Neoplasms
  3. Association Between Three-Dimensional Transrectal Ultrasound Findings and Tumor Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer: An Observational Study.
    Zhang X, Fan J, Zhang L, et al. · Front Oncol · 2022 · Derived
    PubMed: PMID 34178635 · NCT02605265 (CinClare)
  4. FOLFIRI (folinic acid, fluorouracil, and irinotecan) increases not efficacy but toxicity compared with single-agent irinotecan as a second-line treatment in metastatic colorectal cancer patients: a randomized clinical trial.
    Zhang X, Duan R, Wang Y, et al. · Ther Adv Med Oncol · 2022 · Derived
    PubMed: PMID 35069808 · NCT02935764 · Colorectal Neoplasms
  5. Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2).
    Xu J, Li Y, Fan Q, et al. · Nat Commun · 2022 · Derived
    PubMed: PMID 35165274 · NCT03116152 · Esophageal Squamous Cell Carcinoma
  6. Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies.
    Wolf DM, Yau C, Wulfkuhle J, et al. · Cancer Cell · 2022 · Derived
    PubMed: PMID 35623341 · NCT01042379 (I-SPY) · Neoplasms
  7. Results and Molecular Correlates from a Pilot Study of Neoadjuvant Induction FOLFIRINOX Followed by Chemoradiation and Surgery for Gastroesophageal Adenocarcinomas.
    Wo JY, Clark JW, Eyler CE, et al. · Clin Cancer Res · 2022 · Derived
    PubMed: PMID 34330715 · NCT03279237
  8. Efficacy and Safety of Sintilimab in Combination with Concurrent Chemoradiotherapy for Locally Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (SHARED): Study Protocol of a Prospective, Multi-Center, Single-Arm Phase 2 Trial.
    Wei J, Lu X, Liu Q, et al. · Cancer Manag Res · 2022 · Derived
    PubMed: PMID 35747712 · NCT02937116 · Neoplasms
  9. NK cell tumor therapy modulated by UV-inactivated oncolytic herpes simplex virus type 2 and checkpoint inhibitors.
    Wang Y, Jin J, Li Y, et al. · Transl Res · 2022 · Derived
    PubMed: PMID 34757194 · NCT03866525 · Gastrointestinal Neoplasms
  10. Tislelizumab versus chemotherapy as second-line treatment of advanced or metastatic esophageal squamous cell carcinoma (RATIONALE 302): impact on health-related quality of life.
    Van Cutsem E, Kato K, Ajani J, et al. · ESMO Open · 2022 · Derived
    PubMed: PMID 35785595 · NCT03430843 · Neoplasm Metastasis
  11. Small Cell Undifferentiated Histology Does Not Adversely Affect Outcome in Hepatoblastoma: A Report From the Children's Oncology Group (COG) AHEP0731 Study Committee.
    Trobaugh-Lotrario A, Katzenstein HM, Ranganathan S, et al. · J Clin Oncol · 2022 · Derived
    PubMed: PMID 34874751 · NCT00980460
  12. Postneoadjuvant treatment for triple-negative breast cancer.
    Trapani D, Ferraro E, Giugliano F, et al. · Curr Opin Oncol · 2022 · Derived
    PubMed: PMID 35993306 · NCT01042379 (I-SPY) · Neoplasms
  13. In small cell lung cancer patients treated with RRx-001, a downregulator of CD47, decreased expression of PD-L1 on circulating tumor cells significantly correlates with clinical benefit.
    Tomita Y, Oronsky B, Abrouk N, et al. · Transl Lung Cancer Res · 2022 · Derived
    PubMed: PMID 33569311 · NCT02489903 · Lung Neoplasms
  14. Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study.
    Thein KZ, Piha-Paul SA, Tsimberidou A, et al. · Invest New Drugs · 2022 · Derived
    PubMed: PMID 33909232 · NCT02419495 · Neoplasm Metastasis
  15. Selinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumors.
    Thein KZ, Piha-Paul SA, Tsimberidou A, et al. · Exp Hematol Oncol · 2022 · Derived
    PubMed: PMID 34965890 · NCT02419495 · Neoplasm Metastasis
  16. Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study.
    Thein KZ, Karp DD, Tsimberidou A, et al. · Invest New Drugs · 2022 · Derived
    PubMed: PMID 34562230 · NCT02419495 · Neoplasm Metastasis
  17. Evaluation of methylated DCR1 as a biomarker for response to adjuvant irinotecan-based therapy in stage III colon cancer: cancer and leukaemia Group B 89803 (Alliance).
    Symonds L, Yu M, Zhang Y, et al. · Epigenetics · 2022 · Derived
    PubMed: PMID 35412430 · NCT00003835 · Colonic Neoplasms
  18. Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial.
    Symmans WF, Yau C, Chen YY, et al. · JAMA Oncol · 2022 · Derived
    PubMed: PMID 34529000 · NCT01042379 (I-SPY) · Neoplasms
  19. A phase II randomised trial of induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced pancreatic cancer: the Taiwan Cooperative Oncology Group T2212 study.
    Su YY, Chiu YF, Li CP, et al. · Br J Cancer · 2022 · Derived
    PubMed: PMID 34921230 · NCT01867892 · Pancreatic Neoplasms
  20. Efficacy and safety of dilpacimab (ABT-165) versus bevacizumab plus FOLFIRI in metastatic colorectal cancer: a phase II study.
    Strickler JH, Cubillo A, Liang JT, et al. · Future Oncol · 2022 · Derived
    PubMed: PMID 35920133 · NCT03368859 · Colorectal Neoplasms
  21. Encorafenib in Combination With Cetuximab After Systemic Therapy in Patients With BRAFV600E Mutant Metastatic Colorectal Cancer: German Health Technology Assessment-Driven Analyses From the BEACON CRC Study.
    Stintzing S, Seufferlein T, Rosé C, et al. · Clin Colorectal Cancer · 2022 · Derived
    PubMed: PMID 35654691 · NCT02928224 (BEACON CRC) · Colorectal Neoplasms
  22. First-line fluoropyrimidine plus bevacizumab followed by irinotecan-escalation versus initial fluoropyrimidine, irinotecan and bevacizumab in patients with metastatic colorectal cancer - Final survival and per-protocol analysis of the randomised XELAVIRI trial (AIO KRK 0110).
    Stahler A, Modest DP, Fischer von Weikersthal L, et al. · Eur J Cancer · 2022 · Derived
    PubMed: PMID 35940054 · NCT01249638
  23. Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Phase 2 Randomized Clinical Trial.
    Sohal DPS, Duong M, Ahmad SA, et al. · JAMA Oncol · 2022 · Derived
    PubMed: PMID 33475684 · NCT02562716
  24. DNA Damage Repair Inhibitors-Combination Therapies.
    Smith G, Alholm Z, Coleman RL, et al. · Cancer J · 2022 · Derived
    PubMed: PMID 34904813 · NCT02588105 (AToM)
  25. Improved Long-Term Survival of Patients with Recurrent Medulloblastoma Treated with a "MEMMAT-like" Metronomic Antiangiogenic Approach.
    Slavc I, Mayr L, Stepien N, et al. · Cancers (Basel) · 2022 · Derived
    PubMed: PMID 36291912 · NCT01356290 (MEMMAT) · Recurrence
  26. A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pancreatic cancer: the nITRO trial.
    Simionato F, Zecchetto C, Merz V, et al. · Ther Adv Med Oncol · 2022 · Derived
    PubMed: PMID 33403007 · NCT03528785 (nITRo)
  27. Association of tumor-infiltrating lymphocytes with survival depends on primary tumor sidedness in stage III colon cancers (NCCTG N0147) [Alliance].
    Saberzadeh-Ardestani B, Foster NR, Lee HE, et al. · Ann Oncol · 2022 · Derived
    PubMed: PMID 35963480 · NCT00079274 · Colonic Neoplasms
  28. Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies.
    Rossini D, Germani MM, Lonardi S, et al. · Eur J Cancer · 2022 · Derived
    PubMed: PMID 35594613 · NCT00719797 (TRIBE) · Colorectal Neoplasms
  29. Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO.
    Rossini D, Antoniotti C, Lonardi S, et al. · J Clin Oncol · 2022 · Derived
    PubMed: PMID 35666229 · NCT03231722 (TRIPLETE) · Colorectal Neoplasms
  30. Neutrophil extracellular traps have auto-catabolic activity and produce mononucleosome-associated circulating DNA.
    Pisareva E, Mihalovičová L, Pastor B, et al. · Genome Med · 2022 · Derived
    PubMed: PMID 36443816 · NCT02980510 (PANIRINOX) · Colorectal Neoplasms
  31. Phase III randomized trial comparing systemic versus intra-arterial oxaliplatin, combined with LV5FU2 +/- irinotecan and a targeted therapy, in the first-line treatment of metastatic colorectal cancer restricted to the liver (OSCAR): PRODIGE 49.
    Pernot S, Pellerin O, Mineur L, et al. · Dig Liver Dis · 2022 · Derived
    PubMed: PMID 35027324 · NCT02885753 (OSCAR) · Colorectal Neoplasms
  32. RESILIENT part 1: a phase 2 dose-exploration and dose-expansion study of second-line liposomal irinotecan in adults with small cell lung cancer.
    Paz-Ares L, Spigel DR, Chen Y, et al. · Cancer · 2022 · Derived
    PubMed: PMID 35195913 · NCT03088813 (RESILIENT) · Small Cell Lung Carcinoma
  33. The myogenesis program drives clonal selection and drug resistance in rhabdomyosarcoma.
    Patel AG, Chen X, Huang X, et al. · Dev Cell · 2022 · Derived
    PubMed: PMID 35483358 · NCT01871766 · Rhabdomyosarcoma
  34. Association of Residual Ductal Carcinoma In Situ With Breast Cancer Recurrence in the Neoadjuvant I-SPY2 Trial.
    Osdoit M, Yau C, Symmans WF, et al. · JAMA Surg · 2022 · Derived
    PubMed: PMID 36069821 · NCT01042379 (I-SPY) · Neoplasms
  35. Irinotecan combined with oxaliplatin and S-1 in patients with metastatic pancreatic adenocarcinoma: a single-arm, three-centre, prospective study.
    Nie K, Zhang L, You Y, et al. · Ther Adv Med Oncol · 2022 · Derived
    PubMed: PMID 33240399 · NCT03726021
  36. A phase I study of irinotecan and temozolomide with bevacizumab in children with recurrent/refractory central nervous system tumors.
    Metts J, Harrington B, Salman E, et al. · Childs Nerv Syst · 2022 · Derived
    PubMed: PMID 35260913 · NCT00876993 · Central Nervous System Neoplasms
  37. Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors.
    Meany HJ, Widemann BC, Hinds PS, et al. · Pediatr Blood Cancer · 2022 · Derived
    PubMed: PMID 34383370 · NCT01518413 · Neuroblastoma
  38. The Development of Investigator-Initiated Clinical Trials in Surgical Oncology.
    McDonald HG, Cassim EB, Harper MM, et al. · Surg Oncol Clin N Am · 2022 · Derived
    PubMed: PMID 36410913 · NCT04088786 · Colorectal Neoplasms
  39. Cetuximab and Irinotecan With or Without Bevacizumab in Refractory Metastatic Colorectal Cancer: BOND-3, an ACCRU Network Randomized Clinical Trial.
    Lipsyc-Sharf M, Ou FS, Yurgelun MB, et al. · Oncologist · 2022 · Derived
    PubMed: PMID 35380713 · NCT02292758 · Colorectal Neoplasms
  40. Marital Status, Living Arrangement, and Cancer Recurrence and Survival in Patients with Stage III Colon Cancer: Findings from CALGB 89803 (Alliance).
    Lee S, Ma C, Zhang S, et al. · Oncologist · 2022 · Derived
    PubMed: PMID 35641198 · NCT00003835 · Colonic Neoplasms
  41. Genetic Predictors of Severe Skin Toxicity in Patients with Stage III Colon Cancer Treated with Cetuximab: NCCTG N0147 (Alliance).
    Labadie JD, Hua X, Harrison TA, et al. · Cancer Epidemiol Biomarkers Prev · 2022 · Derived
    PubMed: PMID 33203692 · NCT00079274 · Colonic Neoplasms
  42. Combination therapy of capecitabine, irinotecan, oxaliplatin, and bevacizumab as a first-line treatment for metastatic colorectal cancer: Safety lead-in results from the QUATTRO-II study.
    Kotani D, Yoshino T, Kotaka M, et al. · Invest New Drugs · 2022 · Derived
    PubMed: PMID 34019214 · NCT04097444 (QUATTRO-II) · Colorectal Neoplasms
  43. Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC.
    Kopetz S, Grothey A, Van Cutsem E, et al. · ESMO Open · 2022 · Derived
    PubMed: PMID 35653981 · NCT02928224 (BEACON CRC) · Colorectal Neoplasms
  44. Sintilimab in Patients with Previously Treated Metastatic Neuroendocrine Neoplasms.
    Jia R, Li Y, Xu N, et al. · Oncologist · 2022 · Derived
    PubMed: PMID 35647908 · NCT02937116 · Neoplasms
  45. Rh-Endostatin Plus Irinotecan/Cisplatin as Second-Line Therapy for Advanced Esophageal Squamous Cell Carcinoma: An Open-Label, Phase II Study.
    Hu Z, Sun S, Zhao X, et al. · Oncologist · 2022 · Derived
    PubMed: PMID 35380726 · NCT03797625 · Esophageal Squamous Cell Carcinoma
  46. Clinical activity of 9-ING-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, in refractory adult T-Cell leukemia/lymphoma.
    Hsu A, Huntington KE, De Souza A, et al. · Cancer Biol Ther · 2022 · Derived
    PubMed: PMID 35815408 · NCT03678883 · Colorectal Neoplasms
  47. Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3.
    Fischer LE, Stintzing S, von Weikersthal LF, et al. · Br J Cancer · 2022 · Derived
    PubMed: PMID 35637412 · NCT00433927 · Colorectal Neoplasms
  48. Randomized phase 3 study of the anti-disialoganglioside antibody dinutuximab and irinotecan vs irinotecan or topotecan for second-line treatment of small cell lung cancer.
    Edelman MJ, Dvorkin M, Laktionov K, et al. · Lung Cancer · 2022 · Derived
    PubMed: PMID 35278766 · NCT03098030 · Small Cell Lung Carcinoma
  49. PIONEER-Panc: a platform trial for phase II randomized investigations of new and emerging therapies for localized pancreatic cancer.
    Douglas JE, Liu S, Ma J, et al. · BMC Cancer · 2022 · Derived
    PubMed: PMID 34980020 · NCT04481204
  50. Quality of life and Q-TWiST were not adversely affected in Ewing sarcoma patients treated with combined anlotinib, irinotecan, and vincristine: (Peking University People's Hospital Ewing sarcoma trial-02, PKUPH-EWS-02).
    Dong S, Sun K, Xie L, et al. · Medicine (Baltimore) · 2022 · Derived
    PubMed: PMID 34941047 · NCT03416517 · Neoplasm Metastasis
  51. Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO.
    Cremolini C, Antoniotti C, Lonardi S, et al. · Ann Oncol · 2022 · Derived
    PubMed: PMID 29873679 · NCT00719797 (TRIBE) · Colorectal Neoplasms
  52. A phase I/II study of arfolitixorin and 5-fluorouracil in combination with oxaliplatin (plus or minus bevacizumab) or irinotecan in metastatic colorectal cancer.
    Carlsson G, Koumarianou A, Guren TK, et al. · ESMO Open · 2022 · Derived
    PubMed: PMID 36183444 · NCT02244632 · Colorectal Neoplasms
  53. TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer.
    Borelli B, Moretto R, Lonardi S, et al. · ESMO Open · 2022 · Derived
    PubMed: PMID 30018814 · NCT03231722 (TRIPLETE) · Colorectal Neoplasms
  54. The European MAPPYACTS Trial: Precision Medicine Program in Pediatric and Adolescent Patients with Recurrent Malignancies.
    Berlanga P, Pierron G, Lacroix L, et al. · Cancer Discov · 2022 · Derived
    PubMed: PMID 35292802 · NCT02813135 (ESMART) · Neoplasms
  55. Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial.
    Antoniotti C, Rossini D, Pietrantonio F, et al. · Lancet Oncol · 2022 · Derived
    PubMed: PMID 35636444 · NCT03721653 (AtezoTRIBE) · Colorectal Neoplasms
  56. FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies.
    Antoniotti C, Germani MM, Rossini D, et al. · Eur J Cancer · 2022 · Derived
    PubMed: PMID 35366570 · NCT00719797 (TRIBE) · Colorectal Neoplasms
  57. Impact of Pembrolizumab Versus Chemotherapy as Second-Line Therapy for Advanced Esophageal Cancer on Health-Related Quality of Life in KEYNOTE-181.
    Adenis A, Kulkarni AS, Girotto GC, et al. · J Clin Oncol · 2022 · Derived
    PubMed: PMID 34730989 · NCT02564263 · Esophageal Neoplasms
  58. Induction Chemotherapy With FOLFIRINOX Followed by Chemoradiation With Gemcitabine in Patients With Borderline-Resectable Pancreatic Ductal Adenocarcinoma.
    Acuna-Villaorduna A, Shankar V, Wysota M, et al. · Cancer Control · 2022 · Derived
    PubMed: PMID 36221952 · NCT01897454 · Pancreatic Neoplasms
  59. Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities.
    Stacchiotti S, Frezza AM, Blay JY, et al. · Cancer · 2022 · Background
    PubMed: PMID 33910263 · NCT07328425 (ISG-TULIPS) · Desmoplastic Small Round Cell Tumor
  60. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
    Smyth EC, Verheij M, Allum W, et al. · Ann Oncol · 2022 · Background
    PubMed: PMID 27664260 · NCT04915807 · Stomach Neoplasms
  61. Wnt signaling pathway protein LEF1 in cancer, as a biomarker for prognosis and a target for treatment.
    Santiago L, Daniels G, Wang D, et al. · Am J Cancer Res · 2022 · Background
    PubMed: PMID 28670499 · NCT07328425 (ISG-TULIPS) · Desmoplastic Small Round Cell Tumor
  62. Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer.
    Reinert T, Henriksen TV, Christensen E, et al. · JAMA Oncol · 2022 · Background
    PubMed: PMID 31070691 · NCT05031975 (ERASE-TMZ) · Colorectal Neoplasms
  63. Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Initial Results From the Pembrolizumab Arm of a Phase 2 Randomized Clinical Trial.
    Rahma OE, Yothers G, Hong TS, et al. · JAMA Oncol · 2022 · Background
    PubMed: PMID 34196693 · NCT07104604 · Rectal Neoplasms
  64. Rechallenge of immunotherapy beyond progression in patients with extensive-stage small-cell lung cancer.
    Li L, Liu T, Liu Q, et al. · Front Pharmacol · 2022 · Background
    PubMed: PMID 36147357 · NCT06820762
  65. Multicenter, Randomized, Phase III Trial of Short-Term Radiotherapy Plus Chemotherapy Versus Long-Term Chemoradiotherapy in Locally Advanced Rectal Cancer (STELLAR).
    Jin J, Tang Y, Hu C, et al. · J Clin Oncol · 2022 · Background
    PubMed: PMID 35263150 · NCT07521605
  66. Lurbinectedin Inhibits the EWS-WT1 Transcription Factor in Desmoplastic Small Round Cell Tumor.
    Gedminas JM, Kaufman R, Boguslawski EA, et al. · Mol Cancer Ther · 2022 · Background
    PubMed: PMID 35657345 · NCT07328425 (ISG-TULIPS) · Desmoplastic Small Round Cell Tumor
  67. Study protocol of an open-label, single arm phase II trial investigating the efficacy, safety and quality of life of neoadjuvant chemotherapy with liposomal irinotecan combined with Oxaliplatin and 5-fluorouracil/Folinic acid followed by curative surgical resection in patients with hepatic Oligometastatic adenocarcinoma of the pancreas (HOLIPANC).
    Gebauer F, Damanakis AI, Popp F, et al. · BMC Cancer · 2022 · Background
    PubMed: PMID 34794396 · NCT04617457 (HOLIPANC) · Pancreatic Neoplasms
  68. Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy.
    Garcia-Aguilar J, Patil S, Gollub MJ, et al. · J Clin Oncol · 2022 · Background
    PubMed: PMID 35483010 · NCT07173387 (RAD-NALIRIFOX) · Pancreatic Neoplasms
  69. Multiagent chemotherapy including IrIVA regimen and maintenance therapy in the treatment of desmoplastic small round cell tumor.
    Ferrari A, Bergamaschi L, Chiaravalli S, et al. · Tumori · 2022 · Background
    PubMed: PMID 33594944 · NCT07328425 (ISG-TULIPS) · Desmoplastic Small Round Cell Tumor
  70. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
    Chung YM, Khan PP, Wang H, et al. · J Immunother Cancer · 2022 · Background
    PubMed: PMID 34887262 · NCT07521605
  71. PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer.
    Cercek A, Lumish M, Sinopoli J, et al. · N Engl J Med · 2022 · Background
    PubMed: PMID 35660797 · NCT07521605
  72. Advances in the epidemiology of pancreatic cancer: Trends, risk factors, screening, and prognosis.
    Cai J, Chen H, Lu M, et al. · Cancer Lett · 2022 · Background
    PubMed: PMID 34216688 · NCT07173387 (RAD-NALIRIFOX) · Pancreatic Neoplasms
  73. Integrating irinotecan in standard chemotherapy: A novel dose-density combination for high-risk pediatric sarcomas.
    Bisogno G, Ferrari A, Tagarelli A, et al. · Pediatr Blood Cancer · 2022 · Background
    PubMed: PMID 33694265 · NCT07328425 (ISG-TULIPS) · Desmoplastic Small Round Cell Tumor
  74. Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.
    Benson AB, Venook AP, Al-Hawary MM, et al. · J Natl Compr Canc Netw · 2022 · Background
    PubMed: PMID 36240850 · NCT07521605
  75. High-Dose Chemotherapy with Stem Cell Rescue in Desmoplastic Small Round Cell Tumor: A Single-Institution Experience and Review of the Literature.
    Bailey K, Roth M, Weiser D, et al. · Sarcoma · 2022 · Background
    PubMed: PMID 29853779 · NCT07328425 (ISG-TULIPS) · Desmoplastic Small Round Cell Tumor

2021 (78 papers)

  1. Sorafenib Plus Irinotecan Combination in Patients With RAS-mutated Metastatic Colorectal Cancer Refractory To Standard Combined Chemotherapies: A Multicenter, Randomized Phase 2 Trial (NEXIRI-2/PRODIGE 27).
    Samalin E, Fouchardière C, Thézenas S, et al. · Clin Colorectal Cancer · 2021 · Trial result
    PubMed: PMID 32737004 · NCT01715441 (NEXIRI2)
  2. Roles of CA19-9 in pancreatic cancer: Biomarker, predictor and promoter.
    Luo G, Jin K, Deng S, et al. · Biochim Biophys Acta Rev Cancer · 2021 · Trial result
    PubMed: PMID 32827580 · NCT06250972 (PTCA199-11)
  3. Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer.
    Kojima T, Shah MA, Muro K, et al. · J Clin Oncol · 2021 · Trial result
    PubMed: PMID 33026938 · NCT02564263 · Esophageal Neoplasms
  4. Efficacy and safety of sintilimab in combination with chemotherapy in previously untreated advanced or metastatic nonsquamous or squamous NSCLC: two cohorts of an open-label, phase 1b study.
    Jiang H, Zheng Y, Qian J, et al. · Cancer Immunol Immunother · 2021 · Trial result
    PubMed: PMID 33070260 · NCT02937116 · Neoplasms
  5. Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial.
    Jiang H, Zheng Y, Qian J, et al. · BMC Cancer · 2021 · Trial result
    PubMed: PMID 32795349 · NCT02937116 · Neoplasms
  6. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
    Goldman JW, Dvorkin M, Chen Y, et al. · Lancet Oncol · 2021 · Trial result
    PubMed: PMID 33285097 · NCT04985201 · Small Cell Lung Carcinoma
  7. Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL).
    Gelsomino F, Tiseo M, Barbieri F, et al. · Br J Cancer · 2021 · Trial result
    PubMed: PMID 32346071 · NCT04985201 · Small Cell Lung Carcinoma
  8. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial.
    Conroy T, Bosset JF, Etienne PL, et al. · Lancet Oncol · 2021 · Trial result
    PubMed: PMID 33862000 · NCT05868317 · Rectal Neoplasms
  9. Predictive factors for early progression during induction chemotherapy and chemotherapy-free interval: analysis from PRODIGE 9 trial.
    Aparicio T, Bennouna J, Le Malicot K, et al. · Br J Cancer · 2021 · Trial result
    PubMed: PMID 32015513 · NCT00952029 · Colorectal Neoplasms
  10. Multicenter, Randomized, Phase III Trial of Neoadjuvant Chemoradiation With Capecitabine and Irinotecan Guided by UGT1A1 Status in Patients With Locally Advanced Rectal Cancer.
    Zhu J, Liu A, Sun X, et al. · J Clin Oncol · 2021 · Derived
    PubMed: PMID 33119477 · NCT02605265 (CinClare)
  11. A metastatic intrahepatic cholangiocarcinoma treated with programmed cell death 1 inhibitor: a case report and literature review.
    Zhang J, Wu L, Liu J, et al. · Immunotherapy · 2021 · Derived
    PubMed: PMID 32372672 · NCT02937116 · Neoplasms
  12. Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma.
    Zhang B, Qi L, Wang X, et al. · Cancer Commun (Lond) · 2021 · Derived
    PubMed: PMID 33314747 · NCT03603756 · Esophageal Squamous Cell Carcinoma
  13. Patient-Derived Organoids Predict Chemoradiation Responses of Locally Advanced Rectal Cancer.
    Yao Y, Xu X, Yang L, et al. · Cell Stem Cell · 2021 · Derived
    PubMed: PMID 31761724 · NCT02605265 (CinClare)
  14. Zebrafish Patient-Derived Xenografts Identify Chemo-Response in Pancreatic Ductal Adenocarcinoma Patients.
    Usai A, Di Franco G, Piccardi M, et al. · Cancers (Basel) · 2021 · Derived
    PubMed: PMID 34439284 · NCT03668418 (xenoZ) · Colonic Neoplasms
  15. Determination of the UGT1A1 polymorphism as guidance for irinotecan dose escalation in metastatic colorectal cancer treated with first-line bevacizumab and FOLFIRI (PURE FIST).
    Tsai HL, Huang CW, Lin YW, et al. · Eur J Cancer · 2021 · Derived
    PubMed: PMID 32829105 · NCT02256800 · Colorectal Neoplasms
  16. Population pharmacokinetics of ATR inhibitor berzosertib in phase I studies for different cancer types.
    Terranova N, Jansen M, Falk M, et al. · Cancer Chemother Pharmacol · 2021 · Derived
    PubMed: PMID 33145616 · NCT02157792
  17. Clinical development and evaluation of a VEGF-D assay in plasma from patients with metastatic colorectal cancer in the RAISE study.
    Taniguchi H, Yoshino T, Yamaguchi K, et al. · Curr Med Res Opin · 2021 · Derived
    PubMed: PMID 34229554 · NCT01183780 · Colorectal Neoplasms
  18. Plasma deoxyuridine as a surrogate marker for toxicity and early clinical response in patients with metastatic colorectal cancer after 5-FU-based therapy in combination with arfolitixorin.
    Taflin H, Odin E, Carlsson G, et al. · Cancer Chemother Pharmacol · 2021 · Derived
    PubMed: PMID 33099678 · NCT02244632 · Colorectal Neoplasms
  19. Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study.
    Tabernero J, Grothey A, Van Cutsem E, et al. · J Clin Oncol · 2021 · Derived
    PubMed: PMID 33503393 · NCT02928224 (BEACON CRC) · Colorectal Neoplasms
  20. European Medicines Agency approval summary: Zaltrap for the treatment of patients with oxaliplatin-resistant metastatic colorectal cancer.
    Stanel SC, Sjöberg J, Salmonson T, et al. · ESMO Open · 2021 · Derived
    PubMed: PMID 28761750 · NCT00561470 (VELOUR) · Colorectal Neoplasms
  21. Consensus molecular subtypes in metastatic colorectal cancer treated with sequential versus combined fluoropyrimidine, bevacizumab and irinotecan (XELAVIRI trial).
    Stahler A, Heinemann V, Schuster V, et al. · Eur J Cancer · 2021 · Derived
    PubMed: PMID 34507244 · NCT01249638
  22. Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours.
    Shapiro GI, Wesolowski R, Devoe C, et al. · Br J Cancer · 2021 · Derived
    PubMed: PMID 34040174 · NCT02157792
  23. Phase 1 study of alisertib (MLN8237) and weekly irinotecan in adults with advanced solid tumors.
    Semrad TJ, Kim EJ, Gong IY, et al. · Cancer Chemother Pharmacol · 2021 · Derived
    PubMed: PMID 33993383 · NCT01923337 · Colorectal Neoplasms
  24. Atezolizumab in the treatment of metastatic triple-negative breast cancer.
    Pérez-García J, Soberino J, Racca F, et al. · Expert Opin Biol Ther · 2021 · Derived
    PubMed: PMID 32450725 · NCT01042379 (I-SPY) · Neoplasms
  25. Genetic Variant Associated With Survival of Patients With Stage II-III Colon Cancer.
    Penney KL, Banbury BL, Bien S, et al. · Clin Gastroenterol Hepatol · 2021 · Derived
    PubMed: PMID 31811950 · NCT00079274 · Colonic Neoplasms
  26. Phase II and biomarker study of programmed cell death protein 1 inhibitor nivolumab and metronomic cyclophosphamide in paediatric relapsed/refractory solid tumours: Arm G of AcSé-ESMART, a trial of the European Innovative Therapies for Children With Cancer Consortium.
    Pasqualini C, Rubino J, Brard C, et al. · Eur J Cancer · 2021 · Derived
    PubMed: PMID 33892407 · NCT02813135 (ESMART) · Neoplasms
  27. FOLFIRINOX for the Treatment of Advanced Gastroesophageal Cancers: A Phase 2 Nonrandomized Clinical Trial.
    Park H, Jin RU, Wang-Gillam A, et al. · JAMA Oncol · 2021 · Derived
    PubMed: PMID 32469386 · NCT01928290 (FOLFIRINOX) · Stomach Neoplasms
  28. Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial.
    Nanda R, Liu MC, Yau C, et al. · JAMA Oncol · 2021 · Derived
    PubMed: PMID 32053137 · NCT01042379 (I-SPY) · Neoplasms
  29. Phase I Study of Irinotecan/5-Fluorouracil/Leucovorin (FOLFIRI) with Sunitinib for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
    Mukherjee S, Fountzilas C, Boland PM, et al. · Target Oncol · 2021 · Derived
    PubMed: PMID 31802410 · NCT00524186 · Stomach Neoplasms
  30. First-in-child phase I/II study of the dual mTORC1/2 inhibitor vistusertib (AZD2014) as monotherapy and in combination with topotecan-temozolomide in children with advanced malignancies: arms E and F of the AcSé-ESMART trial.
    Morscher RJ, Brard C, Berlanga P, et al. · Eur J Cancer · 2021 · Derived
    PubMed: PMID 34543871 · NCT02813135 (ESMART) · Neoplasms
  31. Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children's Oncology Group.
    Mody R, Yu AL, Naranjo A, et al. · J Clin Oncol · 2021 · Derived
    PubMed: PMID 32343642 · NCT01767194 · Neuroblastoma
  32. Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancer.
    Miyo M, Kato T, Yoshino T, et al. · BMC Cancer · 2021 · Derived
    PubMed: PMID 32703200 · NCT04097444 (QUATTRO-II) · Colorectal Neoplasms
  33. Clinical Impact of a Shortened Infusion Duration of Ramucirumab in Japanese Patients -A Model-Based Approach.
    Mitani S, Chen Y, Inoue K, et al. · Gan To Kagaku Ryoho · 2021 · Derived
    PubMed: PMID 34795131 · NCT01183780 · Colorectal Neoplasms
  34. Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumours.
    Middleton MR, Dean E, Evans TRJ, et al. · Br J Cancer · 2021 · Derived
    PubMed: PMID 34040175 · NCT02157792
  35. Clinical and immune responses to anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (EGFR BATs) in pancreatic cancer patients.
    Lum LG, Thakur A, Choi M, et al. · Oncoimmunology · 2021 · Derived
    PubMed: PMID 32939319 · NCT02620865 · Pancreatic Neoplasms
  36. Deep learning for the prediction of early on-treatment response in metastatic colorectal cancer from serial medical imaging.
    Lu L, Dercle L, Zhao B, et al. · Nat Commun · 2021 · Derived
    PubMed: PMID 34789774 · NCT00561470 (VELOUR) · Colorectal Neoplasms
  37. Phase I study of liposomal irinotecan (LY01610) in patients with advanced esophageal squamous cell carcinoma.
    Liu Y, Zhang B, Xu J, et al. · Cancer Chemother Pharmacol · 2021 · Derived
    PubMed: PMID 34031756 · NCT04088604
  38. Analysis of tumor microenvironmental features to refine prognosis by T, N risk group in patients with stage III colon cancer (NCCTG N0147) (Alliance).
    Lee H, Sha D, Foster NR, et al. · Ann Oncol · 2021 · Derived
    PubMed: PMID 32165096 · NCT00079274 · Colonic Neoplasms
  39. Inter-institutional heterogeneity in outcomes of chemotherapy for metastatic gastric cancer: correlative study in the JCOG9912 phase III trial.
    Kurokawa Y, Boku N, Yamaguchi T, et al. · ESMO Open · 2021 · Derived
    PubMed: PMID 27843586 · NCT00142350 · Stomach Neoplasms
  40. Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406).
    Kopetz S, Guthrie KA, Morris VK, et al. · J Clin Oncol · 2021 · Derived
    PubMed: PMID 33356422 · NCT02164916 · Colorectal Neoplasms
  41. Assessment of TMB, PD-L1, and lymphocyte to monocyte ratio as predictive potential in a phase Ib study of sintilimab in patients with advanced solid tumors.
    Jiang H, Li N, Wang H, et al. · Am J Cancer Res · 2021 · Derived
    PubMed: PMID 34659886 · NCT02937116 · Neoplasms
  42. Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial.
    I-SPY2 Trial Consortium, Yee D, DeMichele AM, et al. · JAMA Oncol · 2021 · Derived
    PubMed: PMID 32701140 · NCT01042379 (I-SPY) · Neoplasms
  43. Gender-dependent survival benefit from first-line irinotecan in metastatic colorectal cancer. Subgroup analysis of a phase III trial (XELAVIRI-study, AIO-KRK-0110).
    Heinrich K, Modest DP, Ricard I, et al. · Eur J Cancer · 2021 · Derived
    PubMed: PMID 33647548 · NCT01249638
  44. FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial.
    Heinemann V, von Weikersthal LF, Decker T, et al. · Br J Cancer · 2021 · Derived
    PubMed: PMID 33154570 · NCT00433927 · Colorectal Neoplasms
  45. Impact of time-varying cumulative bevacizumab exposures on survival: re-analysis of data from randomized clinical trial in patients with metastatic colo-rectal cancer.
    Guilloteau A, Abrahamowicz M, Boussari O, et al. · BMC Med Res Methodol · 2021 · Derived
    PubMed: PMID 33422006 · NCT00952029 · Colorectal Neoplasms
  46. Phase 1 dose-escalation and pharmacokinetic study of regorafenib in paediatric patients with recurrent or refractory solid malignancies.
    Geoerger B, Morland B, Jiménez I, et al. · Eur J Cancer · 2021 · Derived
    PubMed: PMID 34157616 · NCT02085148 · Neoplasms
  47. Impact of Size and Location of Metastases on Early Tumor Shrinkage and Depth of Response in Patients With Metastatic Colorectal Cancer: Subgroup Findings of the Randomized, Open-Label Phase 3 Trial FIRE-3/AIO KRK-0306.
    Froelich MF, Petersen EL, Heinemann V, et al. · Clin Colorectal Cancer · 2021 · Derived
    PubMed: PMID 32917529 · NCT00433927 · Colorectal Neoplasms
  48. RAB5A expression is a predictive biomarker for trastuzumab emtansine in breast cancer.
    Engebraaten O, Yau C, Berg K, et al. · Nat Commun · 2021 · Derived
    PubMed: PMID 34741021 · NCT01042379 (I-SPY) · Neoplasms
  49. Survival benefit of surgical resection after first-line triplet chemotherapy and bevacizumab in patients with initially unresectable metastatic colorectal cancer.
    Elshenawy MA, Badran A, Aljubran A, et al. · World J Surg Oncol · 2021 · Derived
    PubMed: PMID 32641137 · NCT01311050 · Colorectal Neoplasms
  50. Nanoliposomal Irinotecan and Metronomic Temozolomide for Patients With Recurrent Glioblastoma: BrUOG329, A Phase I Brown University Oncology Research Group Trial.
    Elinzano H, Toms S, Robison J, et al. · Am J Clin Oncol · 2021 · Derived
    PubMed: PMID 33284237 · NCT03119064 (329) · Glioblastoma
  51. Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium.
    DuBois SG, Granger MM, Groshen S, et al. · J Clin Oncol · 2021 · Derived
    PubMed: PMID 34270348 · NCT02035137 (N2011-01) · Neuroblastoma
  52. Population pharmacokinetic model of irinotecan and its four main metabolites in patients treated with FOLFIRI or FOLFIRINOX regimen.
    Deyme L, Barbolosi D, Mbatchi LC, et al. · Cancer Chemother Pharmacol · 2021 · Derived
    PubMed: PMID 33912999 · NCT00559676 · Colorectal Neoplasms
  53. Randomized Phase II Trial of Vincristine-Irinotecan With or Without Temozolomide, in Children and Adults With Relapsed or Refractory Rhabdomyosarcoma: A European Paediatric Soft Tissue Sarcoma Study Group and Innovative Therapies for Children With Cancer Trial.
    Defachelles AS, Bogart E, Casanova M, et al. · J Clin Oncol · 2021 · Derived
    PubMed: PMID 34343032 · NCT01355445 (VIT-0910) · Rhabdomyosarcoma
  54. Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated - NIVACOR trial (GOIRC-03-2018).
    Damato A, Iachetta F, Antonuzzo L, et al. · BMC Cancer · 2021 · Derived
    PubMed: PMID 32867715 · NCT04072198 (NIVACOR) · Colorectal Neoplasms
  55. NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC).
    Craig Z, Swain J, Batman E, et al. · BMJ Open · 2021 · Derived
    PubMed: PMID 32029495 · NCT03837977 (NET02) · Neoplasms
  56. Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
    Cohen R, Taieb J, Fiskum J, et al. · J Clin Oncol · 2021 · Derived
    PubMed: PMID 33356421 · NCT00079274 · Colonic Neoplasms
  57. SARC025 arms 1 and 2: A phase 1 study of the poly(ADP-ribose) polymerase inhibitor niraparib with temozolomide or irinotecan in patients with advanced Ewing sarcoma.
    Chugh R, Ballman KV, Helman LJ, et al. · Cancer · 2021 · Derived
    PubMed: PMID 33289920 · NCT02044120 · Sarcoma, Ewing
  58. A randomised phase II study of oxaliplatin/5-FU (mFOLFOX) versus irinotecan/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine/cisplatin chemotherapy.
    Choi IS, Kim KH, Lee JH, et al. · Eur J Cancer · 2021 · Derived
    PubMed: PMID 34303267 · NCT03464968
  59. MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial.
    Chien AJ, Tripathy D, Albain KS, et al. · J Clin Oncol · 2021 · Derived
    PubMed: PMID 32031889 · NCT01042379 (I-SPY) · Neoplasms
  60. Phase I or II Study of Ribociclib in Combination With Topotecan-Temozolomide or Everolimus in Children With Advanced Malignancies: Arms A and B of the AcSé-ESMART Trial.
    Bautista F, Paoletti X, Rubino J, et al. · J Clin Oncol · 2021 · Derived
    PubMed: PMID 34347542 · NCT02813135 (ESMART) · Neoplasms
  61. Can synthetic data be a proxy for real clinical trial data? A validation study.
    Azizi Z, Zheng C, Mosquera L, et al. · BMJ Open · 2021 · Derived
    PubMed: PMID 33863713 · NCT00079274 · Colonic Neoplasms
  62. AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer.
    Antoniotti C, Borelli B, Rossini D, et al. · BMC Cancer · 2021 · Derived
    PubMed: PMID 32698790 · NCT03721653 (AtezoTRIBE) · Colorectal Neoplasms
  63. Surgical Outcome Results From SWOG S1505: A Randomized Clinical Trial of mFOLFIRINOX Versus Gemcitabine/Nab-paclitaxel for Perioperative Treatment of Resectable Pancreatic Ductal Adenocarcinoma.
    Ahmad SA, Duong M, Sohal DPS, et al. · Ann Surg · 2021 · Derived
    PubMed: PMID 32740235 · NCT02562716
  64. Abstracts Presented at the 13th Annual Multidisciplinary Neuroendocrine Tumor Medical Virtual Symposium of the North American Neuroendocrine Tumor Society, October 2-3, 2020.
    Pancreas · 2021 · Derived
    PubMed: PMID 33835977 · NCT03736720 · Somatostatinoma
  65. Efficacy and Long-term Peripheral Sensory Neuropathy of 3 vs 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Colon Cancer: The ACHIEVE Phase 3 Randomized Clinical Trial.
    Yoshino T, Yamanaka T, Oki E, et al. · JAMA Oncol · 2021 · Background
    PubMed: PMID 31513248 · NCT05031975 (ERASE-TMZ) · Colorectal Neoplasms
  66. Patient-derived tumor-like cell clusters for drug testing in cancer therapy.
    Yin S, Xi R, Wu A, et al. · Sci Transl Med · 2021 · Background
    PubMed: PMID 32581131 · NCT05424692 · Rectal Neoplasms
  67. Intra-Abdominal Desmoplastic Small Round Cell Tumor: Current Treatment Options and Perspectives.
    Wei G, Shu X, Zhou Y, et al. · Front Oncol · 2021 · Background
    PubMed: PMID 34604040 · NCT07328425 (ISG-TULIPS) · Desmoplastic Small Round Cell Tumor
  68. Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer.
    Tie J, Cohen JD, Wang Y, et al. · JAMA Oncol · 2021 · Background
    PubMed: PMID 31621801 · NCT05031975 (ERASE-TMZ) · Colorectal Neoplasms
  69. Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer.
    Pietrantonio F, Lobefaro R, Antista M, et al. · Clin Cancer Res · 2021 · Background
    PubMed: PMID 31740551 · NCT05031975 (ERASE-TMZ) · Colorectal Neoplasms
  70. Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer: The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial.
    Meyerhardt JA, Shi Q, Fuchs CS, et al. · JAMA · 2021 · Background
    PubMed: PMID 33821899 · NCT05031975 (ERASE-TMZ) · Colorectal Neoplasms
  71. Desmoplastic Small Round Cell Tumor: A Review of Main Molecular Abnormalities and Emerging Therapy.
    Mello CA, Campos FAB, Santos TG, et al. · Cancers (Basel) · 2021 · Background
    PubMed: PMID 33525546 · NCT07328425 (ISG-TULIPS) · Desmoplastic Small Round Cell Tumor
  72. The use of interval-compressed chemotherapy with the addition of vincristine, irinotecan, and temozolomide for pediatric patients with newly diagnosed desmoplastic small round cell tumor.
    Liu KX, Collins NB, Greenzang KA, et al. · Pediatr Blood Cancer · 2021 · Background
    PubMed: PMID 32686305 · NCT07328425 (ISG-TULIPS) · Desmoplastic Small Round Cell Tumor
  73. Desmoplastic Small Round-cell Tumor: Retrospective Review of Institutional Data and Literature Review.
    Jayakrishnan T, Moll R, Sandhu A, et al. · Anticancer Res · 2021 · Background
    PubMed: PMID 34281846 · NCT07328425 (ISG-TULIPS) · Desmoplastic Small Round Cell Tumor
  74. Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial.
    Janssen QP, van Dam JL, Bonsing BA, et al. · BMC Cancer · 2021 · Background
    PubMed: PMID 33757440 · NCT07173387 (RAD-NALIRIFOX) · Pancreatic Neoplasms
  75. Desmoplastic Small Round Cell Tumors: A review with focus on clinical management and therapeutic options.
    Hendricks A, Boerner K, Germer CT, et al. · Cancer Treat Rev · 2021 · Background
    PubMed: PMID 33388539 · NCT07328425 (ISG-TULIPS) · Desmoplastic Small Round Cell Tumor
  76. Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma.
    Frampton JE · Drugs · 2021 · Background
    PubMed: PMID 32557396 · NCT07173387 (RAD-NALIRIFOX) · Pancreatic Neoplasms
  77. ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper.
    Dasari A, Morris VK, Allegra CJ, et al. · Nat Rev Clin Oncol · 2021 · Background
    PubMed: PMID 32632268 · NCT05031975 (ERASE-TMZ) · Colorectal Neoplasms
  78. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial.
    Bahadoer RR, Dijkstra EA, van Etten B, et al. · Lancet Oncol · 2021 · Background
    PubMed: PMID 33301740 · NCT07521605

2020 (57 papers)

  1. Targeting glycogen synthase kinase 3 for therapeutic benefit in lymphoma.
    Wu X, Stenson M, Abeykoon J, et al. · Blood · 2020 · Trial result
    PubMed: PMID 31101621 · NCT03678883 · Colorectal Neoplasms
  2. Aberrant expression of glycogen synthase kinase-3β in human breast and head and neck cancer.
    Ugolkov AV, Matsangou M, Taxter TJ, et al. · Oncol Lett · 2020 · Trial result
    PubMed: PMID 30405781 · NCT03678883 · Colorectal Neoplasms
  3. Combination Treatment with the GSK-3 Inhibitor 9-ING-41 and CCNU Cures Orthotopic Chemoresistant Glioblastoma in Patient-Derived Xenograft Models.
    Ugolkov A, Qiang W, Bondarenko G, et al. · Transl Oncol · 2020 · Trial result
    PubMed: PMID 28672195 · NCT04239092 · Neoplasms
  4. Glycogen synthase kinase-3 beta inhibitors as novel cancer treatments and modulators of antitumor immune responses.
    Sahin I, Eturi A, De Souza A, et al. · Cancer Biol Ther · 2020 · Trial result
    PubMed: PMID 30975030 · NCT03678883 · Colorectal Neoplasms
  5. 9-ING-41, a small molecule inhibitor of GSK-3beta, potentiates the effects of anticancer therapeutics in bladder cancer.
    Kuroki H, Anraku T, Kazama A, et al. · Sci Rep · 2020 · Trial result
    PubMed: PMID 31882719 · NCT04239092 · Neoplasms
  6. Glycogen Synthase Kinase-3β Inhibition with 9-ING-41 Attenuates the Progression of Pulmonary Fibrosis.
    Jeffers A, Qin W, Owens S, et al. · Sci Rep · 2020 · Trial result
    PubMed: PMID 31831767 · NCT04239092 · Neoplasms
  7. SFCE-RAPIRI Phase I Study of Rapamycin Plus Irinotecan: A New Way to Target Intra-Tumor Hypoxia in Pediatric Refractory Cancers.
    Jannier S, Kemmel V, Sebastia Sancho C, et al. · Cancers (Basel) · 2020 · Trial result
    PubMed: PMID 33092063 · NCT01282697 (RAPIRI)
  8. Interventions for cisplatin-induced hearing loss in children and adolescents with cancer.
    Freyer DR, Brock P, Knight K, et al. · Lancet Child Adolesc Health · 2020 · Trial result
    PubMed: PMID 31160205 · NCT04478292 · Hepatoblastoma
  9. Glycogen Synthase Kinase-3 Inhibition Sensitizes Pancreatic Cancer Cells to Chemotherapy by Abrogating the TopBP1/ATR-Mediated DNA Damage Response.
    Ding L, Madamsetty VS, Kiers S, et al. · Clin Cancer Res · 2020 · Trial result
    PubMed: PMID 31533931 · NCT04239092 · Neoplasms
  10. Clinically relevant GSK‑3β inhibitor 9‑ING‑41 is active as a single agent and in combination with other antitumor therapies in human renal cancer.
    Anraku T, Kuroki H, Kazama A, et al. · Int J Mol Med · 2020 · Trial result
    PubMed: PMID 31894292 · NCT03678883 · Colorectal Neoplasms
  11. Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III study.
    Yoshino T, Portnoy DC, Obermannová R, et al. · Ann Oncol · 2020 · Derived
    PubMed: PMID 30339194 · NCT01183780 · Colorectal Neoplasms
  12. Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study.
    Van Cutsem E, Huijberts S, Grothey A, et al. · J Clin Oncol · 2020 · Derived
    PubMed: PMID 30892987 · NCT02928224 (BEACON CRC) · Colorectal Neoplasms
  13. A Model of a Zebrafish Avatar for Co-Clinical Trials.
    Usai A, Di Franco G, Colucci P, et al. · Cancers (Basel) · 2020 · Derived
    PubMed: PMID 32183229 · NCT03668418 (xenoZ) · Colonic Neoplasms
  14. Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
    Taieb J, Shi Q, Pederson L, et al. · Ann Oncol · 2020 · Derived
    PubMed: PMID 31268130 · NCT00026273 · Colorectal Neoplasms
  15. Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial.
    Stintzing S, Wirapati P, Lenz HJ, et al. · Ann Oncol · 2020 · Derived
    PubMed: PMID 31868905 · NCT00433927 · Colorectal Neoplasms
  16. CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial.
    Shi Y, Li J, Xu J, et al. · Cancer Commun (Lond) · 2020 · Derived
    PubMed: PMID 31126331 · NCT01550055 (CRC009) · Colorectal Neoplasms
  17. A Phase II Study of Irinotecan and Etoposide as Treatment for Refractory Metastatic Breast Cancer.
    Segar JM, Reed D, Stopeck A, et al. · Oncologist · 2020 · Derived
    PubMed: PMID 31383812 · NCT00693719 · Breast Neoplasms
  18. Sequential or combined designs for Phase I/II clinical trials? A simulation study.
    Rossoni C, Bardet A, Geoerger B, et al. · Clin Trials · 2020 · Derived
    PubMed: PMID 31538815 · NCT02813135 (ESMART) · Neoplasms
  19. Pharmacology of the ATM Inhibitor AZD0156: Potentiation of Irradiation and Olaparib Responses Preclinically.
    Riches LC, Trinidad AG, Hughes G, et al. · Mol Cancer Ther · 2020 · Derived
    PubMed: PMID 31534013 · NCT02588105 (AToM)
  20. Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313.
    Ramanathan RK, McDonough SL, Philip PA, et al. · J Clin Oncol · 2020 · Derived
    PubMed: PMID 30817250 · NCT01959139
  21. RRx-001 followed by platinum plus etoposide in patients with previously treated small-cell lung cancer.
    Morgensztern D, Rose M, Waqar SN, et al. · Br J Cancer · 2020 · Derived
    PubMed: PMID 31231122 · NCT02489903 · Lung Neoplasms
  22. MINOAS: A Single-arm Translational Phase II Trial of FOLFIRI Plus Aflibercept as First-line Therapy in Unresectable, Metastatic Colorectal Cancer.
    Matikas A, Souglakos J, Katsaounis P, et al. · Target Oncol · 2020 · Derived
    PubMed: PMID 31203498 · NCT02624726 (MINOAS) · Colorectal Neoplasms
  23. Effect of Early Adverse Events on Survival Outcomes of Patients with Metastatic Colorectal Cancer Treated with Ramucirumab.
    Lim HH, Hopkins AM, Rowland A, et al. · Target Oncol · 2020 · Derived
    PubMed: PMID 31676953 · NCT01183780 · Colorectal Neoplasms
  24. A Phase III Study to Compare the Efficacy and Safety of Paclitaxel Versus Irinotecan in Patients with Metastatic or Recurrent Gastric Cancer Who Failed in First-line Therapy (KCSG ST10-01).
    Lee KW, Maeng CH, Kim TY, et al. · Oncologist · 2020 · Derived
    PubMed: PMID 30126861 · NCT01224652 · Stomach Neoplasms
  25. Prognostic association of PTGS2 (COX-2) over-expression according to BRAF mutation status in colorectal cancer: Results from two prospective cohorts and CALGB 89803 (Alliance) trial.
    Kosumi K, Hamada T, Zhang S, et al. · Eur J Cancer · 2020 · Derived
    PubMed: PMID 30826660 · NCT00003835 · Colonic Neoplasms
  26. ACORN: Observational Study of Bevacizumab in Combination With First-Line Chemotherapy for Treatment of Metastatic Colorectal Cancer in the UK.
    Khakoo S, Chau I, Pedley I, et al. · Clin Colorectal Cancer · 2020 · Derived
    PubMed: PMID 31451367 · NCT01506167 · Colorectal Neoplasms
  27. Minimal adjuvant chemotherapy for children with hepatoblastoma resected at diagnosis (AHEP0731): a Children's Oncology Group, multicentre, phase 3 trial.
    Katzenstein HM, Langham MR, Malogolowkin MH, et al. · Lancet Oncol · 2020 · Derived
    PubMed: PMID 30975630 · NCT00980460
  28. Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM).
    Hurwitz HI, Tan BR, Reeves JA, et al. · Oncologist · 2020 · Derived
    PubMed: PMID 30552157 · NCT01765582 (STEAM) · Colorectal Neoplasms
  29. Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study.
    Huang J, Xu J, Chen Y, et al. · Lancet Oncol · 2020 · Derived
    PubMed: PMID 32416073 · NCT03099382 · Esophageal Neoplasms
  30. An update on emerging drugs in osteosarcoma: towards tailored therapies?
    Hattinger CM, Patrizio MP, Magagnoli F, et al. · Expert Opin Emerg Drugs · 2020 · Derived
    PubMed: PMID 31401903 · NCT02013336 · Neuroblastoma
  31. Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab.
    Dohan A, Gallix B, Guiu B, et al. · Gut · 2020 · Derived
    PubMed: PMID 31101691 · NCT00952029 · Colorectal Neoplasms
  32. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.
    Cremolini C, Antoniotti C, Rossini D, et al. · Lancet Oncol · 2020 · Derived
    PubMed: PMID 32164906 · NCT02339116 (TRIBE2) · Colorectal Neoplasms
  33. The prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab: A translational study [ASCENT].
    Clarke SJ, Burge M, Feeney K, et al. · PLoS One · 2020 · Derived
    PubMed: PMID 32142532 · NCT01588990 (ASCENT) · Colorectal Neoplasms
  34. A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adenocarcinoma-TCOG T1211 study.
    Chiang NJ, Tsai KK, Hsiao CF, et al. · Eur J Cancer · 2020 · Derived
    PubMed: PMID 31765987 · NCT03443492 (Pancreas) · Pancreatic Neoplasms
  35. Safety and Effectiveness of Aflibercept + Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) for the Treatment of Patients with Metastatic Colorectal Cancer (mCRC) in Current Clinical Practice: OZONE Study.
    Chau I, Fakih M, García-Alfonso P, et al. · Cancers (Basel) · 2020 · Derived
    PubMed: PMID 32168980 · NCT00561470 (VELOUR) · Colorectal Neoplasms
  36. Evaluation of the Association of Perioperative UGT1A1 Genotype-Dosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients With Locally Advanced Gastroesophageal Adenocarcinoma: A Phase 2 Clinical Trial.
    Catenacci DVT, Chase L, Lomnicki S, et al. · JAMA Netw Open · 2020 · Derived
    PubMed: PMID 32058557 · NCT02366819 · Stomach Neoplasms
  37. Increased local failure for patients with intermediate-risk rhabdomyosarcoma on ARST0531: A report from the Children's Oncology Group.
    Casey DL, Chi YY, Donaldson SS, et al. · Cancer · 2020 · Derived
    PubMed: PMID 31174239 · NCT00354835 · Sarcoma
  38. Treatment intensification with hepatic arterial infusion chemotherapy in patients with liver-only colorectal metastases still unresectable after systemic induction chemotherapy - a randomized phase II study -- SULTAN UCGI 30/PRODIGE 53 (NCT03164655)- study protocol.
    Boilève A, Maillard A, Wagner M, et al. · BMC Cancer · 2020 · Derived
    PubMed: PMID 32000724 · NCT03164655 (SULTAN)
  39. No evidence for changes in skeletal muscle mass or weight during first-line chemotherapy for metastatic colorectal cancer.
    Antoun S, Bayar MA, Dyevre V, et al. · BMC Cancer · 2020 · Derived
    PubMed: PMID 31462288 · NCT00423696 · Colorectal Neoplasms
  40. Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
    Abdel-Rahman O · Clin Colorectal Cancer · 2020 · Derived
    PubMed: PMID 30679026 · NCT00115765 · Colorectal Neoplasms
  41. Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
    Abdel-Rahman O · Clin Colorectal Cancer · 2020 · Derived
    PubMed: PMID 31378656 · NCT00115765 · Colorectal Neoplasms
  42. Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study.
    Xu J, Zhang Y, Jia R, et al. · Clin Cancer Res · 2020 · Background
    PubMed: PMID 30348638 · NCT05025033 · Stomach Neoplasms
  43. Apatinib for Advanced Osteosarcoma after Failure of Standard Multimodal Therapy: An Open Label Phase II Clinical Trial.
    Xie L, Xu J, Sun X, et al. · Oncologist · 2020 · Background
    PubMed: PMID 30559126 · NCT07479732 · Osteosarcoma
  44. Three- versus six-month adjuvant FOLFOX or CAPOX for high-risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) project.
    Souglakos J, Boukovinas I, Kakolyris S, et al. · Ann Oncol · 2020 · Background
    PubMed: PMID 31228203 · NCT05031975 (ERASE-TMZ) · Colorectal Neoplasms
  45. Mathematical and computational modeling of nano-engineered drug delivery systems.
    Shamsi M, Mohammadi A, Manshadi MKD, et al. · J Control Release · 2020 · Background
    PubMed: PMID 31229474 · NCT07173387 (RAD-NALIRIFOX) · Pancreatic Neoplasms
  46. Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase.
    Schwartz S, Szeto C, Tian Y, et al. · Eur J Cancer · 2020 · Background
    PubMed: PMID 30579113 · NCT05031975 (ERASE-TMZ) · Colorectal Neoplasms
  47. Desmoplastic small round cell tumors: Multimodality treatment and new risk factors.
    Scheer M, Vokuhl C, Blank B, et al. · Cancer Med · 2020 · Background
    PubMed: PMID 30652419 · NCT07328425 (ISG-TULIPS) · Desmoplastic Small Round Cell Tumor
  48. Biosensors for early diagnosis of pancreatic cancer: a review.
    Qian L, Li Q, Baryeh K, et al. · Transl Res · 2020 · Background
    PubMed: PMID 31442419 · NCT07173387 (RAD-NALIRIFOX) · Pancreatic Neoplasms
  49. Biomarker-guided implementation of the old drug temozolomide as a novel treatment option for patients with metastatic colorectal cancer.
    Pietrantonio F, Randon G, Romagnoli D, et al. · Cancer Treat Rev · 2020 · Background
    PubMed: PMID 31821983 · NCT04689347 · Colorectal Neoplasms
  50. Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.
    Petrelli F, Labianca R, Zaniboni A, et al. · JAMA Oncol · 2020 · Background
    PubMed: PMID 32053133 · NCT05031975 (ERASE-TMZ) · Colorectal Neoplasms
  51. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS.
    Muro K, Van Cutsem E, Narita Y, et al. · Ann Oncol · 2020 · Background
    PubMed: PMID 30475956 · NCT04915807 · Stomach Neoplasms
  52. Epigenetic priming sensitizes gastric cancer cells to irinotecan and cisplatin by restoring multiple pathways.
    Moro H, Hattori N, Nakamura Y, et al. · Gastric Cancer · 2020 · Background
    PubMed: PMID 31555951 · NCT05381038 · Neoplasms
  53. Negative Hyperselection of Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy.
    Morano F, Corallo S, Lonardi S, et al. · J Clin Oncol · 2020 · Background
    PubMed: PMID 31539295 · NCT05031975 (ERASE-TMZ) · Colorectal Neoplasms
  54. Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial.
    Kawazoe A, Fukuoka S, Nakamura Y, et al. · Lancet Oncol · 2020 · Background
    PubMed: PMID 32589866 · NCT05025033 · Stomach Neoplasms
  55. Trabectedin Inhibits EWS-FLI1 and Evicts SWI/SNF from Chromatin in a Schedule-dependent Manner.
    Harlow ML, Chasse MH, Boguslawski EA, et al. · Clin Cancer Res · 2020 · Background
    PubMed: PMID 30723142 · NCT07328425 (ISG-TULIPS) · Desmoplastic Small Round Cell Tumor
  56. Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study.
    Duffaud F, Mir O, Boudou-Rouquette P, et al. · Lancet Oncol · 2020 · Background
    PubMed: PMID 30477937 · NCT07479732 · Osteosarcoma
  57. Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study.
    Bang YJ, Li CP, Lee KH, et al. · Cancer Sci · 2020 · Background
    PubMed: PMID 31789476 · NCT07104604 · Rectal Neoplasms

2019 (52 papers)

  1. 9-ING-41, a small-molecule glycogen synthase kinase-3 inhibitor, is active in neuroblastoma.
    Ugolkov AV, Bondarenko GI, Dubrovskyi O, et al. · Anticancer Drugs · 2019 · Trial result
    PubMed: PMID 29846250 · NCT03678883 · Colorectal Neoplasms
  2. Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study.
    Shah MA, Starodub A, Sharma S, et al. · Clin Cancer Res · 2019 · Trial result
    PubMed: PMID 29691300 · NCT01803282 · Colorectal Neoplasms
  3. Effects of statin exposure and lung cancer survival: A meta-analysis of observational studies.
    Chen Y, Li X, Zhang R, et al. · Pharmacol Res · 2019 · Trial result
    PubMed: PMID 30641276 · NCT04985201 · Small Cell Lung Carcinoma
  4. Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300.
    Bang YJ, Ruiz EY, Van Cutsem E, et al. · Ann Oncol · 2019 · Trial result
    PubMed: PMID 30052729 · NCT02625623 · Stomach Neoplasms
  5. Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9).
    Aparicio T, Ghiringhelli F, Boige V, et al. · J Clin Oncol · 2019 · Trial result
    PubMed: PMID 29346040 · NCT00952029 · Colorectal Neoplasms
  6. Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials.
    Zaanan A, Shi Q, Taieb J, et al. · JAMA Oncol · 2019 · Derived
    PubMed: PMID 28983557 · NCT00079274 · Colonic Neoplasms
  7. Influence of genetic variation in the vitamin D pathway on plasma 25-hydroxyvitamin D3 levels and survival among patients with metastatic colorectal cancer.
    Yuan C, Renfro L, Ambadwar PB, et al. · Cancer Causes Control · 2019 · Derived
    PubMed: PMID 31104167 · NCT00003594 · Colorectal Neoplasms
  8. Phase II Study of Irinotecan Plus Panitumumab as Second-Line Therapy for Patients with Advanced Esophageal Adenocarcinoma.
    Yoon H, Karapetyan L, Choudhary A, et al. · Oncologist · 2019 · Derived
    PubMed: PMID 29769385 · NCT00836277 · Esophageal Neoplasms
  9. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.
    Xu RH, Muro K, Morita S, et al. · Lancet Oncol · 2019 · Derived
    PubMed: PMID 29555258 · NCT01996306 (AXEPT) · Colorectal Neoplasms
  10. Dietary Fat Intake after Colon Cancer Diagnosis in Relation to Cancer Recurrence and Survival: CALGB 89803 (Alliance).
    Van Blarigan EL, Ou FS, Niedzwiecki D, et al. · Cancer Epidemiol Biomarkers Prev · 2019 · Derived
    PubMed: PMID 30038051 · NCT00003835 · Colonic Neoplasms
  11. Association of Survival With Adherence to the American Cancer Society Nutrition and Physical Activity Guidelines for Cancer Survivors After Colon Cancer Diagnosis: The CALGB 89803/Alliance Trial.
    Van Blarigan EL, Fuchs CS, Niedzwiecki D, et al. · JAMA Oncol · 2019 · Derived
    PubMed: PMID 29710284 · NCT00003835 · Colonic Neoplasms
  12. Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based Chemotherapy.
    Tokunaga R, Cao S, Naseem M, et al. · Clin Colorectal Cancer · 2019 · Derived
    PubMed: PMID 30293873 · NCT00433927 · Colorectal Neoplasms
  13. Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study.
    Tabernero J, Hozak RR, Yoshino T, et al. · Ann Oncol · 2019 · Derived
    PubMed: PMID 29228087 · NCT01183780 · Colorectal Neoplasms
  14. Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer.
    Siena S, Sartore-Bianchi A, Garcia-Carbonero R, et al. · Ann Oncol · 2019 · Derived
    PubMed: PMID 28945848 · NCT00891930 · Colorectal Neoplasms
  15. Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma.
    Schäfer N, Proescholdt M, Steinbach JP, et al. · Neuro Oncol · 2019 · Derived
    PubMed: PMID 29121274 · NCT00967330 · Glioblastoma
  16. Observed benefit and safety of aflibercept in elderly patients with metastatic colorectal cancer: An age-based analysis from the randomized placebo-controlled phase III VELOUR trial.
    Ruff P, Van Cutsem E, Lakomy R, et al. · J Geriatr Oncol · 2019 · Derived
    PubMed: PMID 28807738 · NCT00561470 (VELOUR) · Colorectal Neoplasms
  17. Sequential Versus Combination Therapy of Metastatic Colorectal Cancer Using Fluoropyrimidines, Irinotecan, and Bevacizumab: A Randomized, Controlled Study-XELAVIRI (AIO KRK0110).
    Modest DP, Fischer von Weikersthal L, Decker T, et al. · J Clin Oncol · 2019 · Derived
    PubMed: PMID 30388045 · NCT01249638
  18. Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer.
    Kopetz S, Grothey A, Yaeger R, et al. · N Engl J Med · 2019 · Derived
    PubMed: PMID 31566309 · NCT02928224 (BEACON CRC) · Colorectal Neoplasms
  19. Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open-labeled phase 3 trial.
    Huang J, Xu B, Liu Y, et al. · Cancer Commun (Lond) · 2019 · Derived
    PubMed: PMID 30940189 · NCT02319187 · Esophageal Neoplasms
  20. Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line RAS Wild-Type Metastatic Colorectal Cancer.
    Hill AG, Findlay MP, Burge ME, et al. · Clin Cancer Res · 2019 · Derived
    PubMed: PMID 29506988 · NCT01652482 · Colorectal Neoplasms
  21. Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.
    Hawkins DS, Chi YY, Anderson JR, et al. · J Clin Oncol · 2019 · Derived
    PubMed: PMID 30091945 · NCT00354835 · Sarcoma
  22. Exploration of potential prognostic biomarkers in aflibercept plus FOLFIRI in Japanese patients with metastatic colorectal cancer.
    Hamaguchi T, Denda T, Kudo T, et al. · Cancer Sci · 2019 · Derived
    PubMed: PMID 31520559 · NCT01882868
  23. Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the 'Arbeitsgemeinschaft Internistische Onkologie'.
    Haas M, Siveke JT, Schenk M, et al. · Eur J Cancer · 2019 · Derived
    PubMed: PMID 29549862 · NCT01729481 (ML22774)
  24. Nut Consumption and Survival in Patients With Stage III Colon Cancer: Results From CALGB 89803 (Alliance).
    Fadelu T, Zhang S, Niedzwiecki D, et al. · J Clin Oncol · 2019 · Derived
    PubMed: PMID 29489429 · NCT00003835 · Colonic Neoplasms
  25. Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma.
    DuBois SG, Mosse YP, Fox E, et al. · Clin Cancer Res · 2019 · Derived
    PubMed: PMID 30093449 · NCT01601535 · Neuroblastoma
  26. Impact of Variability in Portal Venous Phase Acquisition Timing in Tumor Density Measurement and Treatment Response Assessment: Metastatic Colorectal Cancer as a Paradigm.
    Dercle L, Lu L, Lichtenstein P, et al. · JCO Clin Cancer Inform · 2019 · Derived
    PubMed: PMID 30657405 · NCT00154102 (CRYSTAL) · Colorectal Neoplasms
  27. Phase II trial of aflibercept with FOLFIRI as a second-line treatment for Japanese patients with metastatic colorectal cancer.
    Denda T, Sakai D, Hamaguchi T, et al. · Cancer Sci · 2019 · Derived
    PubMed: PMID 30657223 · NCT01882868
  28. A Phase I Dose-Escalation Study of Linsitinib (OSI-906), a Small-Molecule Dual Insulin-Like Growth Factor-1 Receptor/Insulin Receptor Kinase Inhibitor, in Combination with Irinotecan in Patients with Advanced Cancer.
    Davis SL, Eckhardt SG, Diamond JR, et al. · Oncologist · 2019 · Derived
    PubMed: PMID 30139840 · NCT01016860 · Colorectal Neoplasms
  29. Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial.
    Cremolini C, Rossini D, Dell'Aquila E, et al. · JAMA Oncol · 2019 · Derived
    PubMed: PMID 30476968 · NCT02296203 (CRICKET) · Colorectal Neoplasms
  30. DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer.
    Cremolini C, Del Re M, Antoniotti C, et al. · Oncotarget · 2019 · Derived
    PubMed: PMID 29487697 · NCT00719797 (TRIBE) · Colorectal Neoplasms
  31. Circulating Tumor Cells and Circulating Tumor DNA Detection in Potentially Resectable Metastatic Colorectal Cancer: A Prospective Ancillary Study to the Unicancer Prodige-14 Trial.
    Bidard FC, Kiavue N, Ychou M, et al. · Cells · 2019 · Derived
    PubMed: PMID 31142037 · NCT01442935 · Colorectal Neoplasms
  32. Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial.
    Bennouna J, Hiret S, Bertaut A, et al. · JAMA Oncol · 2019 · Derived
    PubMed: PMID 30422156 · NCT01442649 · Colorectal Neoplasms
  33. Rationale and Design of the IROCAS Study: Multicenter, International, Randomized Phase 3 Trial Comparing Adjuvant Modified (m) FOLFIRINOX to mFOLFOX6 in Patients With High-Risk Stage III (pT4 and/or N2) Colon Cancer-A UNICANCER GI-PRODIGE Trial.
    Bennouna J, André T, Campion L, et al. · Clin Colorectal Cancer · 2019 · Derived
    PubMed: PMID 30415988 · NCT02967289 (IROCAS) · Colonic Neoplasms
  34. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS.
    Yoshino T, Arnold D, Taniguchi H, et al. · Ann Oncol · 2019 · Background
    PubMed: PMID 29155929 · NCT04689347 · Colorectal Neoplasms
  35. [Study of clinical outcome and prognosis in pediatric core binding factor-acute myeloid leukemia].
    Wu J, Lu AD, Zhang LP, et al. · Zhonghua Xue Ye Xue Za Zhi · 2019 · Background
    PubMed: PMID 30704229 · NCT07521605
  36. FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant Trial.
    Sobrero A, Lonardi S, Rosati G, et al. · J Clin Oncol · 2019 · Background
    PubMed: PMID 29620994 · NCT05031975 (ERASE-TMZ) · Colorectal Neoplasms
  37. Malnutrition is associated with adverse postoperative outcome in patients undergoing elective colorectal cancer resections.
    Seretis C, Kaisari P, Wanigasooriya K, et al. · J BUON · 2019 · Background
    PubMed: PMID 29552757 · NCT07521605
  38. Optimizing drug combinations against multiple myeloma using a quadratic phenotypic optimization platform (QPOP).
    Rashid MBMA, Toh TB, Hooi L, et al. · Sci Transl Med · 2019 · Background
    PubMed: PMID 30089632 · NCT05381038 · Neoplasms
  39. Perioperative Bevacizumab-based Triplet Chemotherapy in Patients With Potentially Resectable Colorectal Cancer Liver Metastases.
    Pietrantonio F, Cotsoglou C, Fucà G, et al. · Clin Colorectal Cancer · 2019 · Background
    PubMed: PMID 30558859 · NCT04689347 · Colorectal Neoplasms
  40. RRx-001 protects normal tissues but not tumors via Nrf2 induction and Bcl-2 inhibition.
    Oronsky B, Scribner C, Aggarwal R, et al. · J Cancer Res Clin Oncol · 2019 · Background
    PubMed: PMID 31250159 · NCT02096354 (ROCKET) · Colorectal Neoplasms
  41. Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation.
    Morano F, Corallo S, Niger M, et al. · Ann Oncol · 2019 · Background
    PubMed: PMID 29860358 · NCT04689347 · Colorectal Neoplasms
  42. Targeting minimal residual disease: a path to cure?
    Luskin MR, Murakami MA, Manalis SR, et al. · Nat Rev Cancer · 2019 · Background
    PubMed: PMID 29376520 · NCT05031975 (ERASE-TMZ) · Colorectal Neoplasms
  43. A Phase I Trial of a Guadecitabine (SGI-110) and Irinotecan in Metastatic Colorectal Cancer Patients Previously Exposed to Irinotecan.
    Lee V, Wang J, Zahurak M, et al. · Clin Cancer Res · 2019 · Background
    PubMed: PMID 30097434 · NCT05381038 · Neoplasms
  44. Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2016.
    Jung KW, Won YJ, Kong HJ, et al. · Cancer Res Treat · 2019 · Background
    PubMed: PMID 30913865 · NCT04915807 · Stomach Neoplasms
  45. 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial.
    Iveson TJ, Kerr RS, Saunders MP, et al. · Lancet Oncol · 2019 · Background
    PubMed: PMID 29611518 · NCT05031975 (ERASE-TMZ) · Colorectal Neoplasms
  46. Desmoplastic Small Round Cell Tumor Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Results of a Phase 2 Trial.
    Hayes-Jordan AA, Coakley BA, Green HL, et al. · Ann Surg Oncol · 2019 · Background
    PubMed: PMID 29383611 · NCT07328425 (ISG-TULIPS) · Desmoplastic Small Round Cell Tumor
  47. Neoadjuvant Chemotherapy Followed by Radical Surgery Versus Concomitant Chemotherapy and Radiotherapy in Patients With Stage IB2, IIA, or IIB Squamous Cervical Cancer: A Randomized Controlled Trial.
    Gupta S, Maheshwari A, Parab P, et al. · J Clin Oncol · 2019 · Background
    PubMed: PMID 29432076 · NCT04789941
  48. Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial.
    Fuchs CS, Doi T, Jang RW, et al. · JAMA Oncol · 2019 · Background
    PubMed: PMID 29543932 · NCT05025033 · Stomach Neoplasms
  49. The genomics of desmoplastic small round cell tumor reveals the deregulation of genes related to DNA damage response, epithelial-mesenchymal transition, and immune response.
    Devecchi A, De Cecco L, Dugo M, et al. · Cancer Commun (Lond) · 2019 · Background
    PubMed: PMID 30486883 · NCT07328425 (ISG-TULIPS) · Desmoplastic Small Round Cell Tumor
  50. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
    Bray F, Ferlay J, Soerjomataram I, et al. · CA Cancer J Clin · 2019 · Background
    PubMed: PMID 30207593 · NCT04915807 · Stomach Neoplasms
  51. Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study.
    Bang YJ, Kang YK, Catenacci DV, et al. · Gastric Cancer · 2019 · Background
    PubMed: PMID 30911859 · NCT05025033 · Stomach Neoplasms
  52. Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial.
    André T, Vernerey D, Mineur L, et al. · J Clin Oncol · 2019 · Background
    PubMed: PMID 29620995 · NCT05031975 (ERASE-TMZ) · Colorectal Neoplasms

2018 (20 papers)

  1. Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss.
    Brock PR, Maibach R, Childs M, et al. · N Engl J Med · 2018 · Trial result
    PubMed: PMID 29924955 · NCT04478292 · Hepatoblastoma
  2. Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer.
    Yarchoan M, Myzak MC, Johnson BA, et al. · Oncotarget · 2018 · Derived
    PubMed: PMID 28454122 · NCT01296763 · Pancreatic Neoplasms
  3. Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma.
    Weiss GJ, Blaydorn L, Beck J, et al. · Invest New Drugs · 2018 · Derived
    PubMed: PMID 29119276 · NCT02331251 · Pancreatic Neoplasms
  4. The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting.
    Severson TM, Wolf DM, Yau C, et al. · Breast Cancer Res · 2018 · Derived
    PubMed: PMID 28851423 · NCT01042379 (I-SPY) · Neoplasms
  5. Surgical treatment options following chemotherapy plus cetuximab or bevacizumab in metastatic colorectal cancer-central evaluation of FIRE-3.
    Modest DP, Denecke T, Pratschke J, et al. · Eur J Cancer · 2018 · Derived
    PubMed: PMID 29195117 · NCT00433927 · Colorectal Neoplasms
  6. Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial - 1 (NorPACT-1)) - study protocol for a national multicentre randomized controlled trial.
    Labori KJ, Lassen K, Hoem D, et al. · BMC Surg · 2018 · Derived
    PubMed: PMID 28841916 · NCT02919787 · Pancreatic Neoplasms
  7. Phase II study of oxaliplatin, irinotecan and S-1 therapy in patients with advanced gastric cancer: the Korean Cancer Study Group ST14-11.
    Kim HS, Ryu MH, Zang DY, et al. · Gastric Cancer · 2018 · Derived
    PubMed: PMID 29372461 · NCT02527785 · Stomach Neoplasms
  8. A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Simtuzumab in Combination with FOLFIRI for the Second-Line Treatment of Metastatic KRAS Mutant Colorectal Adenocarcinoma.
    Hecht JR, Benson AB, Vyushkov D, et al. · Oncologist · 2018 · Derived
    PubMed: PMID 28246207 · NCT01479465 · Colorectal Neoplasms
  9. Predicted vitamin D status and colon cancer recurrence and mortality in CALGB 89803 (Alliance).
    Fuchs MA, Yuan C, Sato K, et al. · Ann Oncol · 2018 · Derived
    PubMed: PMID 28327908 · NCT00003835 · Colonic Neoplasms
  10. TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group.
    Cremolini C, Marmorino F, Loupakis F, et al. · BMC Cancer · 2018 · Derived
    PubMed: PMID 28599628 · NCT02339116 (TRIBE2) · Colorectal Neoplasms
  11. Mechanism of action of trabectedin in desmoplastic small round cell tumor cells.
    Uboldi S, Craparotta I, Colella G, et al. · BMC Cancer · 2018 · Background
    PubMed: PMID 28166781 · NCT07328425 (ISG-TULIPS) · Desmoplastic Small Round Cell Tumor
  12. Desmoplastic small round cell tumor: A nationwide study of a rare sarcoma.
    Stiles ZE, Dickson PV, Glazer ES, et al. · J Surg Oncol · 2018 · Background
    PubMed: PMID 29878371 · NCT07328425 (ISG-TULIPS) · Desmoplastic Small Round Cell Tumor
  13. The Development Of RRx-001, A Novel Nitric-Oxide-Mediated Epigenetically Active Anticancer Agent.
    Scicinski J, Fisher G, Carter C, et al. · Redox Biol · 2018 · Background
    PubMed: PMID 28162292 · NCT02096354 (ROCKET) · Colorectal Neoplasms
  14. Safety and efficacy of combining capecitabine and temozolomide (CAPTEM) to treat advanced neuroendocrine neoplasms: A meta-analysis.
    Lu Y, Zhao Z, Wang J, et al. · Medicine (Baltimore) · 2018 · Background
    PubMed: PMID 30313101 · NCT04689347 · Colorectal Neoplasms
  15. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Kang YK, Boku N, Satoh T, et al. · Lancet · 2018 · Background
    PubMed: PMID 28993052 · NCT05025033 · Stomach Neoplasms
  16. Duration of Adjuvant Chemotherapy for Stage III Colon Cancer.
    Grothey A, Sobrero AF, Shields AF, et al. · N Engl J Med · 2018 · Background
    PubMed: PMID 29590544 · NCT07521605
  17. Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth.
    Germano G, Lamba S, Rospo G, et al. · Nature · 2018 · Background
    PubMed: PMID 29186113 · NCT04689347 · Colorectal Neoplasms
  18. A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: a systematic review and meta-analysis.
    Dossa F, Chesney TR, Acuna SA, et al. · Lancet Gastroenterol Hepatol · 2018 · Background
    PubMed: PMID 28479372 · NCT07521605
  19. A novel three‑miRNA signature predicts survival in cholangiocarcinoma based on RNA‑Seq data.
    Cao J, Sun L, Li J, et al. · Oncol Rep · 2018 · Background
    PubMed: PMID 29956786 · NCT04059562 (TRITICC) · Cholangiocarcinoma
  20. Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer.
    Barault L, Amatu A, Siravegna G, et al. · Gut · 2018 · Background
    PubMed: PMID 28982739 · NCT05031975 (ERASE-TMZ) · Colorectal Neoplasms

2017 (53 papers)

  1. Molecular Pathways: Revisiting Glycogen Synthase Kinase-3β as a Target for the Treatment of Cancer.
    Walz A, Ugolkov A, Chandra S, et al. · Clin Cancer Res · 2017 · Trial result
    PubMed: PMID 28053024 · NCT04239092 · Neoplasms
  2. GSK-3 inhibition overcomes chemoresistance in human breast cancer.
    Ugolkov A, Gaisina I, Zhang JS, et al. · Cancer Lett · 2017 · Trial result
    PubMed: PMID 27424289 · NCT03678883 · Colorectal Neoplasms
  3. Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children's Hepatic tumors International Collaboration.
    Meyers RL, Maibach R, Hiyama E, et al. · Lancet Oncol · 2017 · Trial result
    PubMed: PMID 27884679 · NCT04478292 · Hepatoblastoma
  4. CA19-9-Low&Lewis (+) pancreatic cancer: A unique subtype.
    Luo G, Liu C, Guo M, et al. · Cancer Lett · 2017 · Trial result
    PubMed: PMID 27840089 · NCT06250972 (PTCA199-11)
  5. Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101.
    Katz MH, Shi Q, Ahmad SA, et al. · JAMA Surg · 2017 · Trial result
    PubMed: PMID 27275632 · NCT03167112 (Folfirinox) · Pancreatic Neoplasms
  6. Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial.
    Freyer DR, Chen L, Krailo MD, et al. · Lancet Oncol · 2017 · Trial result
    PubMed: PMID 27914822 · NCT04478292 · Hepatoblastoma
  7. Modulation of tumor eIF4E by antisense inhibition: A phase I/II translational clinical trial of ISIS 183750-an antisense oligonucleotide against eIF4E-in combination with irinotecan in solid tumors and irinotecan-refractory colorectal cancer.
    Duffy AG, Makarova-Rusher OV, Ulahannan SV, et al. · Int J Cancer · 2017 · Trial result
    PubMed: PMID 27194579 · NCT01675128 · Colorectal Neoplasms
  8. Neoadjuvant irinotecan, cisplatin, and concurrent radiation therapy with celecoxib for patients with locally advanced esophageal cancer.
    Cleary JM, Mamon HJ, Szymonifka J, et al. · BMC Cancer · 2017 · Trial result
    PubMed: PMID 27412386 · NCT00137852 · Esophageal Neoplasms
  9. A Phase I study of olaparib and irinotecan in patients with colorectal cancer: Canadian Cancer Trials Group IND 187.
    Chen EX, Jonker DJ, Siu LL, et al. · Invest New Drugs · 2017 · Trial result
    PubMed: PMID 27075016 · NCT00535353 · Colorectal Neoplasms
  10. A pilot clinical study of apatinib plus irinotecan in patients with recurrent high-grade glioma: Clinical Trial/Experimental Study.
    Wang L, Liang L, Yang T, et al. · Medicine (Baltimore) · 2017 · Derived
    PubMed: PMID 29245310 · NCT02848794 · Glioma
  11. Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy.
    Van Cutsem E, Joulain F, Hoff PM, et al. · Target Oncol · 2017 · Derived
    PubMed: PMID 26706237 · NCT00561470 (VELOUR) · Colorectal Neoplasms
  12. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.
    Stintzing S, Modest DP, Rossius L, et al. · Lancet Oncol · 2017 · Derived
    PubMed: PMID 27575024 · NCT00433927 · Colorectal Neoplasms
  13. Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials.
    Sinicrope FA, Shi Q, Allegra CJ, et al. · JAMA Oncol · 2017 · Derived
    PubMed: PMID 28006055 · NCT00079274 · Colonic Neoplasms
  14. Hypomethylating agents synergize with irinotecan to improve response to chemotherapy in colorectal cancer cells.
    Sharma A, Vatapalli R, Abdelfatah E, et al. · PLoS One · 2017 · Derived
    PubMed: PMID 28445481 · NCT01896856 · Neoplasm Metastasis
  15. Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression.
    Obermannová R, Van Cutsem E, Yoshino T, et al. · Ann Oncol · 2017 · Derived
    PubMed: PMID 27573561 · NCT01183780 · Colorectal Neoplasms
  16. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial.
    Nywening TM, Wang-Gillam A, Sanford DE, et al. · Lancet Oncol · 2017 · Derived
    PubMed: PMID 27055731 · NCT01413022 · Pancreatic Neoplasms
  17. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.
    Mody R, Naranjo A, Van Ryn C, et al. · Lancet Oncol · 2017 · Derived
    PubMed: PMID 28549783 · NCT01767194 · Neuroblastoma
  18. Combination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma: Results of a phase II study.
    Modak S, Kushner BH, Basu E, et al. · Pediatr Blood Cancer · 2017 · Derived
    PubMed: PMID 28111925 · NCT01114555 · Neuroblastoma
  19. CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).
    Michl M, Stintzing S, Fischer von Weikersthal L, et al. · Ann Oncol · 2017 · Derived
    PubMed: PMID 27234640 · NCT00433927 · Colorectal Neoplasms
  20. Response to FOLFIRINOX by gender in patients with metastatic pancreatic cancer: Results from the PRODIGE 4/ ACCORD 11 randomized trial.
    Lambert A, Jarlier M, Gourgou Bourgade S, et al. · PLoS One · 2017 · Derived
    PubMed: PMID 28931010 · NCT00112658 · Pancreatic Neoplasms
  21. Study protocol of the Asian XELIRI ProjecT (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab.
    Kotaka M, Xu R, Muro K, et al. · Chin J Cancer · 2017 · Derived
    PubMed: PMID 28007025 · NCT01996306 (AXEPT) · Colorectal Neoplasms
  22. Salvage treatment with irinotecan/cisplatin versus pemetrexed/cisplatin in patients with non-small cell lung cancer pre-treated with a non-platinum-based regimen in the first-line setting: a randomized phase II study of the Hellenic Oncology Research Group (HORG).
    Kentepozidis N, Economopoulou P, Christofyllakis C, et al. · Clin Transl Oncol · 2017 · Derived
    PubMed: PMID 27492015 · NCT00614965 · Neoplasms
  23. Prognostic value of baseline seric Syndecan-1 in initially unresectable metastatic colorectal cancer patients: a simple biological score.
    Jary M, Lecomte T, Bouché O, et al. · Int J Cancer · 2017 · Derived
    PubMed: PMID 27472156 · NCT00544011 · Colorectal Neoplasms
  24. Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation.
    Hong DS, Morris VK, El Osta B, et al. · Cancer Discov · 2017 · Derived
    PubMed: PMID 27729313 · NCT01787500 · Colorectal Neoplasms
  25. Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial.
    Herrlinger U, Schäfer N, Steinbach JP, et al. · J Clin Oncol · 2017 · Derived
    PubMed: PMID 26976423 · NCT00967330 · Glioblastoma
  26. Time to Definitive Health-Related Quality of Life Score Deterioration in Patients with Resectable Metastatic Colorectal Cancer Treated with FOLFOX4 versus Sequential Dose-Dense FOLFOX7 followed by FOLFIRI: The MIROX Randomized Phase III Trial.
    Hamidou Z, Chibaudel B, Hebbar M, et al. · PLoS One · 2017 · Derived
    PubMed: PMID 27310205 · NCT00268398 (MIROX) · Colorectal Neoplasms
  27. Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials.
    Ellingson BM, Harris RJ, Woodworth DC, et al. · Neuro Oncol · 2017 · Derived
    PubMed: PMID 27580889 · NCT00345163 (BRAIN) · Glioblastoma
  28. FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials.
    Cremolini C, Loupakis F, Masi G, et al. · Ann Oncol · 2017 · Derived
    PubMed: PMID 26861604 · NCT00719797 (TRIBE) · Colorectal Neoplasms
  29. Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
    Cremolini C, Casagrande M, Loupakis F, et al. · Eur J Cancer · 2017 · Derived
    PubMed: PMID 27986363 · NCT00719797 (TRIBE) · Colorectal Neoplasms
  30. Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial.
    Alistar A, Morris BB, Desnoyer R, et al. · Lancet Oncol · 2017 · Derived
    PubMed: PMID 28495639 · NCT01835041 · Pancreatic Neoplasms
  31. The gut microbiome and liver cancer: mechanisms and clinical translation.
    Yu LX, Schwabe RF · Nat Rev Gastroenterol Hepatol · 2017 · Background
    PubMed: PMID 28676707 · NCT04059562 (TRITICC) · Cholangiocarcinoma
  32. Trabectedin in advanced desmoplastic round cell tumors: a retrospective single-center series.
    Verret B, Honore C, Dumont S, et al. · Anticancer Drugs · 2017 · Background
    PubMed: PMID 27782906 · NCT07328425 (ISG-TULIPS) · Desmoplastic Small Round Cell Tumor
  33. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer.
    Tie J, Wang Y, Tomasetti C, et al. · Sci Transl Med · 2017 · Background
    PubMed: PMID 27384348 · NCT05031975 (ERASE-TMZ) · Colorectal Neoplasms
  34. Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer.
    Shitara K, Muro K, Shimada Y, et al. · Gastric Cancer · 2017 · Background
    PubMed: PMID 26510663 · NCT04770623 · Stomach Neoplasms
  35. Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients.
    Sartore-Bianchi A, Pietrantonio F, Amatu A, et al. · Eur J Cancer · 2017 · Background
    PubMed: PMID 27997874 · NCT05031975 (ERASE-TMZ) · Colorectal Neoplasms
  36. Dose-Dense Temozolomide in Patients with MGMT-Silenced Chemorefractory Colorectal Cancer.
    Pietrantonio F, de Braud F, Milione M, et al. · Target Oncol · 2017 · Background
    PubMed: PMID 26538496 · NCT05031975 (ERASE-TMZ) · Colorectal Neoplasms
  37. Second line with oxaliplatin- or irinotecan-based chemotherapy for gemcitabine-pretreated pancreatic cancer: A systematic review.
    Petrelli F, Inno A, Ghidini A, et al. · Eur J Cancer · 2017 · Background
    PubMed: PMID 28633088 · NCT04059562 (TRITICC) · Cholangiocarcinoma
  38. Stereotactic Body Radiation Therapy for Locally Advanced Pancreatic Cancer: A Systematic Review and Pooled Analysis of 19 Trials.
    Petrelli F, Comito T, Ghidini A, et al. · Int J Radiat Oncol Biol Phys · 2017 · Background
    PubMed: PMID 28068239 · NCT07173387 (RAD-NALIRIFOX) · Pancreatic Neoplasms
  39. Immune biomarkers for chronic inflammation related complications in non-cancerous and cancerous diseases.
    Meirow Y, Baniyash M · Cancer Immunol Immunother · 2017 · Background
    PubMed: PMID 28674756 · NCT04059562 (TRITICC) · Cholangiocarcinoma
  40. Dual inhibition of ATR and ATM potentiates the activity of trabectedin and lurbinectedin by perturbing the DNA damage response and homologous recombination repair.
    Lima M, Bouzid H, Soares DG, et al. · Oncotarget · 2017 · Background
    PubMed: PMID 27029031 · NCT07328425 (ISG-TULIPS) · Desmoplastic Small Round Cell Tumor
  41. Japanese gastric cancer treatment guidelines 2014 (ver. 4).
    Japanese Gastric Cancer Association · Gastric Cancer · 2017 · Background
    PubMed: PMID 27342689 · NCT04915807 · Stomach Neoplasms
  42. Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer.
    Hughes PE, Caenepeel S, Wu LC, et al. · Trends Immunol · 2017 · Background
    PubMed: PMID 27216414 · NCT05025033 · Stomach Neoplasms
  43. Adjuvant sunitinib following chemoradiotherapy and surgery for locally advanced esophageal cancer: a phase II trial.
    Horgan AM, Darling G, Wong R, et al. · Dis Esophagus · 2017 · Background
    PubMed: PMID 26663741 · NCT00400114 · Neoplasms
  44. The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials.
    Holch JW, Ricard I, Stintzing S, et al. · Eur J Cancer · 2017 · Background
    PubMed: PMID 27907852 · NCT04689347 · Colorectal Neoplasms
  45. Lurbinectedin Inactivates the Ewing Sarcoma Oncoprotein EWS-FLI1 by Redistributing It within the Nucleus.
    Harlow ML, Maloney N, Roland J, et al. · Cancer Res · 2017 · Background
    PubMed: PMID 27697767 · NCT07328425 (ISG-TULIPS) · Desmoplastic Small Round Cell Tumor
  46. Case Report: Immune-mediated Complete Response in a Patient With Recurrent Advanced Ewing Sarcoma (EWS) After Vigil Immunotherapy.
    Ghisoli M, Rutledge M, Stephens PJ, et al. · J Pediatr Hematol Oncol · 2017 · Background
    PubMed: PMID 28338569 · NCT02511132 · Sarcoma
  47. Three-year Follow up of GMCSF/bi-shRNA(furin) DNA-transfected Autologous Tumor Immunotherapy (Vigil) in Metastatic Advanced Ewing's Sarcoma.
    Ghisoli M, Barve M, Mennel R, et al. · Mol Ther · 2017 · Background
    PubMed: PMID 27109631 · NCT02511132 · Sarcoma
  48. A genomic case study of desmoplastic small round cell tumor: comprehensive analysis reveals insights into potential therapeutic targets and development of a monitoring tool for a rare and aggressive disease.
    Ferreira EN, Barros BD, de Souza JE, et al. · Hum Genomics · 2017 · Background
    PubMed: PMID 27863505 · NCT07328425 (ISG-TULIPS) · Desmoplastic Small Round Cell Tumor
  49. A human clinical trial using ultrasound and microbubbles to enhance gemcitabine treatment of inoperable pancreatic cancer.
    Dimcevski G, Kotopoulis S, Bjånes T, et al. · J Control Release · 2017 · Background
    PubMed: PMID 27744037 · NCT07314385
  50. Stereotactic body radiotherapy for unresected pancreatic cancer: A nationwide review.
    de Geus SWL, Eskander MF, Kasumova GG, et al. · Cancer · 2017 · Background
    PubMed: PMID 28708929 · NCT07173387 (RAD-NALIRIFOX) · Pancreatic Neoplasms
  51. A phase I trial of azacitidine and nanoparticle albumin bound paclitaxel in patients with advanced or metastatic solid tumors.
    Cohen AL, Ray A, Van Brocklin M, et al. · Oncotarget · 2017 · Background
    PubMed: PMID 28881739 · NCT05381038 · Neoplasms
  52. A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.
    Calegari MA, Inno A, Monterisi S, et al. · Br J Cancer · 2017 · Background
    PubMed: PMID 28427088 · NCT05031975 (ERASE-TMZ) · Colorectal Neoplasms
  53. Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer.
    Amatu A, Barault L, Moutinho C, et al. · Ann Oncol · 2017 · Background
    PubMed: PMID 26916096 · NCT05031975 (ERASE-TMZ) · Colorectal Neoplasms

2016 (38 papers)

  1. Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors.
    Tolcher AW, LoRusso P, Arzt J, et al. · Cancer Chemother Pharmacol · 2016 · Trial result
    PubMed: PMID 26420235 · NCT01009073
  2. Selective Allosteric Inhibition of MMP9 Is Efficacious in Preclinical Models of Ulcerative Colitis and Colorectal Cancer.
    Marshall DC, Lyman SK, McCauley S, et al. · PLoS One · 2016 · Trial result
    PubMed: PMID 25961845 · NCT01803282 · Colorectal Neoplasms
  3. High-Dose FOLFIRI plus Bevacizumab in the Treatment of Metastatic Colorectal Cancer Patients with Two Different UGT1A1 Genotypes: FFCD 0504 Study.
    Manfredi S, Bouché O, Rougier P, et al. · Mol Cancer Ther · 2016 · Trial result
    PubMed: PMID 26494856 · NCT00628810 · Colorectal Neoplasms
  4. GRECCAR 8: impact on survival of the primary tumor resection in rectal cancer with unresectable synchronous metastasis: a randomized multicentre study.
    Cotte E, Villeneuve L, Passot G, et al. · BMC Cancer · 2016 · Trial result
    PubMed: PMID 25849254 · NCT02314182 (GRECCAR8) · Rectal Neoplasms
  5. Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001-02).
    Aparicio T, Lavau-Denes S, Phelip JM, et al. · Ann Oncol · 2016 · Trial result
    PubMed: PMID 26487578 · NCT00303771 · Colorectal Neoplasms
  6. Prospective analysis of UGT1A1 promoter polymorphism for irinotecan dose escalation in metastatic colorectal cancer patients treated with bevacizumab plus FOLFIRI as the first-line setting: study protocol for a randomized controlled trial.
    Yeh YS, Tsai HL, Huang CW, et al. · Trials · 2016 · Derived
    PubMed: PMID 26811156 · NCT02256800 · Colorectal Neoplasms
  7. Phase II/III study of second-line chemotherapy comparing irinotecan-alone with S-1 plus irinotecan in advanced gastric cancer refractory to first-line treatment with S-1 (JACCRO GC-05).
    Tanabe K, Fujii M, Nishikawa K, et al. · Ann Oncol · 2016 · Derived
    PubMed: PMID 26109630 · NCT00639327 · Stomach Neoplasms
  8. Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.
    Rugo HS, Olopade OI, DeMichele A, et al. · N Engl J Med · 2016 · Derived
    PubMed: PMID 27406347 · NCT01042379 (I-SPY) · Neoplasms
  9. Significant effect of VEGFA polymorphisms on the clinical outcome of metastatic colorectal cancer patients treated with FOLFIRI-cetuximab.
    Rollin J, Payancé A, Gouilleux-Gruart V, et al. · Pharmacogenomics · 2016 · Derived
    PubMed: PMID 26615857 · NCT00559741 · Colorectal Neoplasms
  10. Phase II Trial of Upfront Bevacizumab, Irinotecan, and Temozolomide for Unresectable Glioblastoma.
    Peters KB, Lou E, Desjardins A, et al. · Oncologist · 2016 · Derived
    PubMed: PMID 26025933 · NCT00979017 · Glioblastoma
  11. Adaptive Randomization of Neratinib in Early Breast Cancer.
    Park JW, Liu MC, Yee D, et al. · N Engl J Med · 2016 · Derived
    PubMed: PMID 27406346 · NCT01042379 (I-SPY) · Neoplasms
  12. Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal Cancer.
    Modest DP, Stintzing S, von Weikersthal LF, et al. · J Clin Oncol · 2016 · Derived
    PubMed: PMID 26261259 · NCT00433927 · Colorectal Neoplasms
  13. Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial.
    Masi G, Salvatore L, Boni L, et al. · Ann Oncol · 2016 · Derived
    PubMed: PMID 25600568 · NCT00720512 (BEBYP) · Colorectal Neoplasms
  14. FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized phase III trial.
    Hebbar M, Chibaudel B, André T, et al. · Ann Oncol · 2016 · Derived
    PubMed: PMID 25403578 · NCT00268398 (MIROX) · Colorectal Neoplasms
  15. Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial.
    Gruenberger T, Bridgewater J, Chau I, et al. · Ann Oncol · 2016 · Derived
    PubMed: PMID 25538173 · NCT00778102 · Colorectal Neoplasms
  16. Bevacizumab and Combination Chemotherapy in rectal cancer Until Surgery (BACCHUS): a phase II, multicentre, open-label, randomised study of neoadjuvant chemotherapy alone in patients with high-risk cancer of the rectum.
    Glynne-Jones R, Hava N, Goh V, et al. · BMC Cancer · 2016 · Derived
    PubMed: PMID 26493588 · NCT01650428 (BACCHUS) · Rectal Neoplasms
  17. Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study.
    Garcia-Alfonso P, Chaves M, Muñoz A, et al. · BMC Cancer · 2016 · Derived
    PubMed: PMID 25925749 · NCT00875771 (AVAXIRI) · Colorectal Neoplasms
  18. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
    Cremolini C, Loupakis F, Antoniotti C, et al. · Lancet Oncol · 2016 · Derived
    PubMed: PMID 26338525 · NCT00719797 (TRIBE) · Colorectal Neoplasms
  19. Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest.
    Cremolini C, Loupakis F, Antoniotti C, et al. · Ann Oncol · 2016 · Derived
    PubMed: PMID 25712456 · NCT00719797 (TRIBE) · Colorectal Neoplasms
  20. Prospective evaluation of 18F-fluorodeoxyglucose positron emission tomography in patients receiving hepatic arterial and systemic chemotherapy for unresectable colorectal liver metastases.
    Correa-Gallego C, Gavane S, Grewal R, et al. · HPB (Oxford) · 2016 · Derived
    PubMed: PMID 26010778 · NCT00492999 · Colorectal Neoplasms
  21. STRATEGIC-1: A multiple-lines, randomized, open-label GERCOR phase III study in patients with unresectable wild-type RAS metastatic colorectal cancer.
    Chibaudel B, Bonnetain F, Tournigand C, et al. · BMC Cancer · 2016 · Derived
    PubMed: PMID 26141683 · NCT01910610 (STRATEGIC-1)
  22. A Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection in Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only.
    Bendell JC, Zakari A, Peyton JD, et al. · Oncologist · 2016 · Derived
    PubMed: PMID 26911408 · NCT01226719 · Colorectal Neoplasms
  23. Phase I/II trial of capecitabine, oxaliplatin, and irinotecan in combination with bevacizumab in first line treatment of metastatic colorectal cancer.
    Bazarbashi S, Aljubran A, Alzahrani A, et al. · Cancer Med · 2016 · Derived
    PubMed: PMID 26207614 · NCT01311050 · Colorectal Neoplasms
  24. Pharmacokinetics of Irinotecan With and Without Panitumumab Coadministration in Patients With Metastatic Colorectal Cancer.
    Yang BB, Wu CY, Chen E, et al. · Clin Pharmacol Drug Dev · 2016 · Background
    PubMed: PMID 27121781 · NCT00563316 · Colorectal Neoplasms
  25. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
    Wang-Gillam A, Li CP, Bodoky G, et al. · Lancet · 2016 · Background
    PubMed: PMID 26615328 · NCT07173387 (RAD-NALIRIFOX) · Pancreatic Neoplasms
  26. A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer.
    Sclafani F, Kim TY, Cunningham D, et al. · J Natl Cancer Inst · 2016 · Background
    PubMed: PMID 26405092 · NCT00614393 · Colorectal Neoplasms
  27. Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial.
    Schmoll HJ, Tabernero J, Maroun J, et al. · J Clin Oncol · 2016 · Background
    PubMed: PMID 26324362 · NCT05031975 (ERASE-TMZ) · Colorectal Neoplasms
  28. Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance).
    Pachman DR, Qin R, Seisler DK, et al. · J Clin Oncol · 2016 · Background
    PubMed: PMID 26282635 · NCT07521605
  29. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma.
    Mellon EA, Hoffe SE, Springett GM, et al. · Acta Oncol · 2016 · Background
    PubMed: PMID 25734581 · NCT07173387 (RAD-NALIRIFOX) · Pancreatic Neoplasms
  30. SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer.
    Hecht JR, Cohn A, Dakhil S, et al. · Clin Colorectal Cancer · 2016 · Background
    PubMed: PMID 25982297 · NCT00418938 · Colorectal Neoplasms
  31. Bevacizumab dosing strategy in paediatric cancer patients based on population pharmacokinetic analysis with external validation.
    Han K, Peyret T, Quartino A, et al. · Br J Clin Pharmacol · 2016 · Background
    PubMed: PMID 26345283 · NCT00381797 · Oligodendroglioma
  32. Pilot Trial of FANG Immunotherapy in Ewing's Sarcoma.
    Ghisoli M, Barve M, Schneider R, et al. · Mol Ther · 2016 · Background
    PubMed: PMID 25917459 · NCT03495921 (VITA) · Neoplasms
  33. High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response.
    Gao H, Korn JM, Ferretti S, et al. · Nat Med · 2016 · Background
    PubMed: PMID 26479923 · NCT05424692 · Rectal Neoplasms
  34. Patient-reported outcomes in the evaluation of toxicity of anticancer treatments.
    Di Maio M, Basch E, Bryce J, et al. · Nat Rev Clin Oncol · 2016 · Background
    PubMed: PMID 26787278 · NCT07328425 (ISG-TULIPS) · Desmoplastic Small Round Cell Tumor
  35. Risk of recurrence in patients with colon cancer stage II and III: a systematic review and meta-analysis of recent literature.
    Böckelman C, Engelmann BE, Kaprio T, et al. · Acta Oncol · 2016 · Background
    PubMed: PMID 25430983 · NCT05031975 (ERASE-TMZ) · Colorectal Neoplasms
  36. MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.
    Arena S, Siravegna G, Mussolin B, et al. · Sci Transl Med · 2016 · Background
    PubMed: PMID 26843189 · NCT05031975 (ERASE-TMZ) · Colorectal Neoplasms
  37. Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?
    Apetoh L, Ladoire S, Coukos G, et al. · Ann Oncol · 2016 · Background
    PubMed: PMID 25922066 · NCT05025033 · Stomach Neoplasms
  38. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
    André T, de Gramont A, Vernerey D, et al. · J Clin Oncol · 2016 · Background
    PubMed: PMID 26527776 · NCT05031975 (ERASE-TMZ) · Colorectal Neoplasms

2015 (34 papers)

  1. The impact of postoperative complications on the administration of adjuvant therapy following pancreaticoduodenectomy for adenocarcinoma.
    Wu W, He J, Cameron JL, et al. · Ann Surg Oncol · 2015 · Trial result
    PubMed: PMID 24770680 · NCT03167112 (Folfirinox) · Pancreatic Neoplasms
  2. Neoadjuvant therapy for non-metastatic pancreatic ductal adenocarcinoma.
    Winner M, Goff SL, Chabot JA, et al. · Semin Oncol · 2015 · Trial result
    PubMed: PMID 25726054 · NCT03167112 (Folfirinox) · Pancreatic Neoplasms
  3. Neoadjuvant FOLFIRINOX application in borderline resectable pancreatic adenocarcinoma: a retrospective cohort study.
    Paniccia A, Edil BH, Schulick RD, et al. · Medicine (Baltimore) · 2015 · Trial result
    PubMed: PMID 25501072 · NCT03167112 (Folfirinox) · Pancreatic Neoplasms
  4. Inhibition of GSK-3 induces differentiation and impaired glucose metabolism in renal cancer.
    Pal K, Cao Y, Gaisina IN, et al. · Mol Cancer Ther · 2015 · Trial result
    PubMed: PMID 24327518 · NCT04239092 · Neoplasms
  5. Phase II trial of bortezomib alone or in combination with irinotecan in patients with adenocarcinoma of the gastroesophageal junction or stomach.
    Ocean AJ, Christos P, Sparano JA, et al. · Invest New Drugs · 2015 · Trial result
    PubMed: PMID 24526575 · NCT00061932 · Stomach Neoplasms
  6. Postoperative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer.
    Merkow RP, Bilimoria KY, Tomlinson JS, et al. · Ann Surg · 2015 · Trial result
    PubMed: PMID 24374509 · NCT03167112 (Folfirinox) · Pancreatic Neoplasms
  7. A randomized, phase II study of the anti-insulin-like growth factor receptor type 1 (IGF-1R) monoclonal antibody robatumumab (SCH 717454) in patients with advanced colorectal cancer.
    Lin EH, Lenz HJ, Saleh MN, et al. · Cancer Med · 2015 · Trial result
    PubMed: PMID 24905030 · NCT00551213 · Colorectal Neoplasms
  8. FOLFIRI® and bevacizumab in first-line treatment for colorectal cancer patients: safety, efficacy and genetic polymorphisms.
    Bécouarn Y, Cany L, Pulido M, et al. · BMC Res Notes · 2015 · Trial result
    PubMed: PMID 24758527 · NCT00467142 (OMEGA) · Colorectal Neoplasms
  9. A study of docetaxel and irinotecan in children and young adults with recurrent or refractory Ewing sarcoma family of tumors.
    Yoon JH, Kwon MM, Park HJ, et al. · BMC Cancer · 2015 · Derived
    PubMed: PMID 25164234 · NCT01380275 · Sarcoma
  10. Determination of prognostic factors in Japanese patients with advanced gastric cancer using the data from a randomized controlled trial, Japan clinical oncology group 9912.
    Takahari D, Boku N, Mizusawa J, et al. · Oncologist · 2015 · Derived
    PubMed: PMID 24668328 · NCT00142350 · Stomach Neoplasms
  11. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.
    Tabernero J, Yoshino T, Cohn AL, et al. · Lancet Oncol · 2015 · Derived
    PubMed: PMID 25877855 · NCT01183780 · Colorectal Neoplasms
  12. Upfront FOLFOXIRI+bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer.
    Stein A, Atanackovic D, Hildebrandt B, et al. · Br J Cancer · 2015 · Derived
    PubMed: PMID 26335608 · NCT00940303 · Colorectal Neoplasms
  13. MRE11-deficiency associated with improved long-term disease free survival and overall survival in a subset of stage III colon cancer patients in randomized CALGB 89803 trial.
    Pavelitz T, Renfro L, Foster NR, et al. · PLoS One · 2015 · Derived
    PubMed: PMID 25310185 · NCT00003835 · Colonic Neoplasms
  14. Phase II study of weekly irinotecan and capecitabine treatment in metastatic colorectal cancer patients.
    Li W, Xu J, Shen L, et al. · BMC Cancer · 2015 · Derived
    PubMed: PMID 25527007 · NCT01322152 · Colorectal Neoplasms
  15. Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial.
    Klingbiel D, Saridaki Z, Roth AD, et al. · Ann Oncol · 2015 · Derived
    PubMed: PMID 25361982 · NCT00026273 · Colorectal Neoplasms
  16. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
    Heinemann V, von Weikersthal LF, Decker T, et al. · Lancet Oncol · 2015 · Derived
    PubMed: PMID 25088940 · NCT00433927 · Colorectal Neoplasms
  17. Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial.
    Élez E, Kocáková I, Höhler T, et al. · Ann Oncol · 2015 · Derived
    PubMed: PMID 25319061 · NCT01008475 (POSEIDON) · Colorectal Neoplasms
  18. Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes.
    DʼAngelica MI, Correa-Gallego C, Paty PB, et al. · Ann Surg · 2015 · Derived
    PubMed: PMID 24646562 · NCT00492999 · Colorectal Neoplasms
  19. Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer.
    Bajetta E, Floriani I, Di Bartolomeo M, et al. · Ann Oncol · 2015 · Derived
    PubMed: PMID 24728035 · NCT01640782 (ITACA-S)
  20. KRAS and BRAF gene mutations and DNA mismatch repair status in Chinese colorectal carcinoma patients.
    Ye JX, Liu Y, Qin Y, et al. · World J Gastroenterol · 2015 · Background
    PubMed: PMID 25663779 · NCT07521605
  21. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.
    Wilke H, Muro K, Van Cutsem E, et al. · Lancet Oncol · 2015 · Background
    PubMed: PMID 25240821 · NCT04915807 · Stomach Neoplasms
  22. Outcome of patients with bulky IB (≥ 6 cm) cervical squamous cell carcinoma with and without cisplatin-based neoadjuvant chemotherapy.
    Wang PH, Chang YH, Yang YH, et al. · Taiwan J Obstet Gynecol · 2015 · Background
    PubMed: PMID 25286786 · NCT04789941
  23. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials.
    Sorich MJ, Wiese MD, Rowland A, et al. · Ann Oncol · 2015 · Background
    PubMed: PMID 25115304 · NCT04689347 · Colorectal Neoplasms
  24. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.
    Siravegna G, Mussolin B, Buscarino M, et al. · Nat Med · 2015 · Background
    PubMed: PMID 26151329 · NCT05031975 (ERASE-TMZ) · Colorectal Neoplasms
  25. Phase I/II study of azacitidine, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy.
    Singal R, Ramachandran K, Gordian E, et al. · Clin Genitourin Cancer · 2015 · Background
    PubMed: PMID 25178642 · NCT05381038 · Neoplasms
  26. Clinical presentation, risk factors and staging systems of cholangiocarcinoma.
    Plentz RR, Malek NP · Best Pract Res Clin Gastroenterol · 2015 · Background
    PubMed: PMID 25966425 · NCT04059562 (TRITICC) · Cholangiocarcinoma
  27. Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation.
    Pietrantonio F, Perrone F, de Braud F, et al. · Ann Oncol · 2015 · Background
    PubMed: PMID 24379162 · NCT04689347 · Colorectal Neoplasms
  28. A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study.
    Lin XJ, Chong Y, Guo ZW, et al. · Lancet Oncol · 2015 · Background
    PubMed: PMID 26088272 · NCT04059562 (TRITICC) · Cholangiocarcinoma
  29. Second-line chemotherapy in advanced biliary cancer: a systematic review.
    Lamarca A, Hubner RA, David Ryder W, et al. · Ann Oncol · 2015 · Background
    PubMed: PMID 24769639 · NCT04059562 (TRITICC) · Cholangiocarcinoma
  30. Osteosarcoma: Current Treatment and a Collaborative Pathway to Success.
    Isakoff MS, Bielack SS, Meltzer P, et al. · J Clin Oncol · 2015 · Background
    PubMed: PMID 26304877 · NCT07479732 · Osteosarcoma
  31. Abdominal desmoplastic small round cell tumor: multimodal treatment combining chemotherapy, surgery, and radiotherapy is the best option.
    Honoré C, Amroun K, Vilcot L, et al. · Ann Surg Oncol · 2015 · Background
    PubMed: PMID 25300608 · NCT07328425 (ISG-TULIPS) · Desmoplastic Small Round Cell Tumor
  32. Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma.
    Herman JM, Chang DT, Goodman KA, et al. · Cancer · 2015 · Background
    PubMed: PMID 25538019 · NCT07173387 (RAD-NALIRIFOX) · Pancreatic Neoplasms
  33. FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma.
    Guion-Dusserre JF, Lorgis V, Vincent J, et al. · World J Gastroenterol · 2015 · Background
    PubMed: PMID 25717243 · NCT04059562 (TRITICC) · Cholangiocarcinoma
  34. FOLFIRI+bevacizumab induction chemotherapy followed by bevacizumab or observation in metastatic colorectal cancer, a phase III trial (PRODIGE 9--FFCD 0802).
    Aparicio T, Linot B, Le Malicot K, et al. · Dig Liver Dis · 2015 · Background
    PubMed: PMID 25677925 · NCT00952029 · Colorectal Neoplasms

2014 (32 papers)

  1. Aggressive surgery for borderline resectable pancreatic cancer: evaluation of National Comprehensive Cancer Network guidelines.
    Yamada S, Fujii T, Sugimoto H, et al. · Pancreas · 2014 · Trial result
    PubMed: PMID 23532000 · NCT03167112 (Folfirinox) · Pancreatic Neoplasms
  2. A phase I study of vincristine, irinotecan, temozolomide and bevacizumab (vitb) in pediatric patients with relapsed solid tumors.
    Venkatramani R, Malogolowkin M, Davidson TB, et al. · PLoS One · 2014 · Trial result
    PubMed: PMID 23894304 · NCT00993044 (VIT-B)
  3. Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial.
    Samalin E, Bouché O, Thézenas S, et al. · Br J Cancer · 2014 · Trial result
    PubMed: PMID 24407191 · NCT00989469 (NEXIRI) · Colorectal Neoplasms
  4. Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: results of the GYMSSA trial.
    Rudloff U, Langan RC, Mullinax JE, et al. · J Surg Oncol · 2014 · Trial result
    PubMed: PMID 25042700 · NCT00941655 · Stomach Neoplasms
  5. Two Case Reports of Resensitization to Previous Chemotherapy with the Novel Hypoxia-Activated Hypomethylating Anticancer Agent RRx-001 in Metastatic Colorectal Cancer Patients.
    Reid T, Dad S, Korn R, et al. · Case Rep Oncol · 2014 · Trial result
    PubMed: PMID 24575021 · NCT02096354 (ROCKET) · Colorectal Neoplasms
  6. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States.
    Rahib L, Smith BD, Aizenberg R, et al. · Cancer Res · 2014 · Trial result
    PubMed: PMID 24840647 · NCT03167112 (Folfirinox) · Pancreatic Neoplasms
  7. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial.
    Oettle H, Riess H, Stieler JM, et al. · J Clin Oncol · 2014 · Trial result
    PubMed: PMID 24982456 · NCT02558868 · Pancreatic Neoplasms
  8. A single-arm, nonrandomized phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinoma.
    OʼReilly EM, Perelshteyn A, Jarnagin WR, et al. · Ann Surg · 2014 · Trial result
    PubMed: PMID 24901360 · NCT03167112 (Folfirinox) · Pancreatic Neoplasms
  9. Radiological heterogeneity in response to chemotherapy is associated with poor survival in patients with colorectal liver metastases.
    van Kessel CS, Samim M, Koopman M, et al. · Eur J Cancer · 2014 · Derived
    PubMed: PMID 23692811 · NCT00312000 · Neoplasms
  10. Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial.
    Tabernero J, Van Cutsem E, Lakomý R, et al. · Eur J Cancer · 2014 · Derived
    PubMed: PMID 24140268 · NCT00561470 (VELOUR) · Colorectal Neoplasms
  11. A phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinoma.
    Sohal DP, Mykulowycz K, Uehara T, et al. · Ann Oncol · 2014 · Derived
    PubMed: PMID 24146220 · NCT00948935 · Biliary Tract Neoplasms
  12. Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial.
    Ogino S, Liao X, Imamura Y, et al. · J Natl Cancer Inst · 2014 · Derived
    PubMed: PMID 24231454 · NCT00003835 · Colonic Neoplasms
  13. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    Loupakis F, Cremolini C, Masi G, et al. · N Engl J Med · 2014 · Derived
    PubMed: PMID 25337750 · NCT00719797 (TRIBE) · Colorectal Neoplasms
  14. Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study.
    Kubota K, Hida T, Ishikura S, et al. · Lancet Oncol · 2014 · Derived
    PubMed: PMID 24309370 · NCT00144989 · Small Cell Lung Carcinoma
  15. UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabine.
    Goetz MP, McKean HA, Reid JM, et al. · Invest New Drugs · 2014 · Derived
    PubMed: PMID 24114122 · NCT00433550
  16. Peripheral CD45RO, PD-1, and TLR4 expression in metastatic colorectal cancer patients treated with bevacizumab, fluorouracil, and irinotecan (FOLFIRI-B).
    Formica V, Cereda V, di Bari MG, et al. · Med Oncol · 2014 · Derived
    PubMed: PMID 24114613 · NCT01533740 · Colorectal Neoplasms
  17. Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial.
    Ellingson BM, Kim HJ, Woodworth DC, et al. · Radiology · 2014 · Derived
    PubMed: PMID 24475840 · NCT00345163 (BRAIN) · Glioblastoma
  18. Staging classification for cancer of the ovary, fallopian tube, and peritoneum.
    Prat J, FIGO Committee on Gynecologic Oncology · Int J Gynaecol Obstet · 2014 · Background
    PubMed: PMID 24219974 · NCT04789941
  19. Incidence and outcomes of desmoplastic small round cell tumor: results from the surveillance, epidemiology, and end results database.
    Lettieri CK, Garcia-Filion P, Hingorani P, et al. · J Cancer Epidemiol · 2014 · Background
    PubMed: PMID 25431592 · NCT07328425 (ISG-TULIPS) · Desmoplastic Small Round Cell Tumor
  20. Second-line chemotherapy versus supportive cancer treatment in advanced gastric cancer: a meta-analysis.
    Kim HS, Kim HJ, Kim SY, et al. · Ann Oncol · 2014 · Background
    PubMed: PMID 23942775 · NCT04915807 · Stomach Neoplasms
  21. Clinical activity of sunitinib in patients with advanced desmoplastic round cell tumor: a case series.
    Italiano A, Kind M, Cioffi A, et al. · Target Oncol · 2014 · Background
    PubMed: PMID 23292310 · NCT07328425 (ISG-TULIPS) · Desmoplastic Small Round Cell Tumor
  22. Complete cytoreduction and HIPEC improves survival in desmoplastic small round cell tumor.
    Hayes-Jordan A, Green HL, Lin H, et al. · Ann Surg Oncol · 2014 · Background
    PubMed: PMID 24046124 · NCT07328425 (ISG-TULIPS) · Desmoplastic Small Round Cell Tumor
  23. UGT1A1 6/28 polymorphisms could predict irinotecan-induced severe neutropenia not diarrhea in Chinese colorectal cancer patients.
    Gao J, Zhou J, Li Y, et al. · Med Oncol · 2014 · Background
    PubMed: PMID 23686699 · NCT01977235 (TDICC) · Small Cell Lung Carcinoma
  24. Pathological response on surgical samples is an independent prognostic variable for patients with Stage Ib2-IIb cervical cancer treated with neoadjuvant chemotherapy and radical hysterectomy: an Italian multicenter retrospective study (CTF Study).
    Gadducci A, Sartori E, Maggino T, et al. · Gynecol Oncol · 2014 · Background
    PubMed: PMID 24096111 · NCT04789941
  25. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.
    Fuchs CS, Tomasek J, Yong CJ, et al. · Lancet · 2014 · Background
    PubMed: PMID 24094768 · NCT04915807 · Stomach Neoplasms
  26. Trabectedin for desmoplastic small round cell tumours: a possible treatment option?
    Frezza AM, Whelan JS, Dileo P, et al. · Clin Sarcoma Res · 2014 · Background
    PubMed: PMID 24829745 · NCT07328425 (ISG-TULIPS) · Desmoplastic Small Round Cell Tumor
  27. Pazopanib in advanced desmoplastic small round cell tumours: a multi-institutional experience.
    Frezza AM, Benson C, Judson IR, et al. · Clin Sarcoma Res · 2014 · Background
    PubMed: PMID 25089183 · NCT07328425 (ISG-TULIPS) · Desmoplastic Small Round Cell Tumor
  28. Negative feedback and adaptive resistance to the targeted therapy of cancer.
    Chandarlapaty S · Cancer Discov · 2014 · Background
    PubMed: PMID 22576208 · NCT05381038 · Neoplasms
  29. Floxuridine hepatic arterial infusion associated biliary toxicity is increased by concurrent administration of systemic bevacizumab.
    Cercek A, D'Angelica M, Power D, et al. · Ann Surg Oncol · 2014 · Background
    PubMed: PMID 24154839 · NCT03366155 · Colorectal Neoplasms
  30. Third-line trabectedin for a metastatic desmoplastic small round cell tumour treated with multimodal therapy.
    Brunetti AE, Delcuratolo S, Lorusso V, et al. · Anticancer Res · 2014 · Background
    PubMed: PMID 24982387 · NCT07328425 (ISG-TULIPS) · Desmoplastic Small Round Cell Tumor
  31. Conversion to complete resection and/or ablation using hepatic artery infusional chemotherapy in patients with unresectable liver metastases from colorectal cancer: a decade of experience at a single institution.
    Ammori JB, Kemeny NE, Fong Y, et al. · Ann Surg Oncol · 2014 · Background
    PubMed: PMID 23771246 · NCT03366155 · Colorectal Neoplasms
  32. Mutational signatures: the patterns of somatic mutations hidden in cancer genomes.
    Alexandrov LB, Stratton MR · Curr Opin Genet Dev · 2014 · Background
    PubMed: PMID 24657537 · NCT04689347 · Colorectal Neoplasms

2013 (34 papers)

  1. Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility study.
    Zsiros J, Brugieres L, Brock P, et al. · Lancet Oncol · 2013 · Trial result
    PubMed: PMID 23831416 · NCT04478292 · Hepatoblastoma
  2. A phase I study of the combination of temsirolimus with irinotecan for metastatic sarcoma.
    Verschraegen CF, Movva S, Ji Y, et al. · Cancers (Basel) · 2013 · Trial result
    PubMed: PMID 24216984 · NCT00996346 · Sarcoma
  3. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial.
    Seymour MT, Brown SR, Middleton G, et al. · Lancet Oncol · 2013 · Trial result
    PubMed: PMID 23725851 · NCT00389870 · Colorectal Neoplasms
  4. A randomised phase III trial of the pharmacokinetic biomodulation of irinotecan using oral ciclosporin in advanced colorectal cancer: results of the Panitumumab, Irinotecan & Ciclosporin in COLOrectal cancer therapy trial (PICCOLO).
    Middleton G, Brown S, Lowe C, et al. · Eur J Cancer · 2013 · Trial result
    PubMed: PMID 23953030 · NCT00389870 · Colorectal Neoplasms
  5. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial.
    Li J, Qin S, Xu J, et al. · J Clin Oncol · 2013 · Trial result
    PubMed: PMID 23918952 · NCT03116555
  6. Phase II study of induction cisplatin and irinotecan followed by concurrent carboplatin, etoposide, and thoracic radiotherapy for limited-stage small-cell lung cancer, CALGB 30206.
    Kelley MJ, Bogart JA, Hodgson LD, et al. · J Thorac Oncol · 2013 · Trial result
    PubMed: PMID 23196276 · NCT00072527 · Lung Neoplasms
  7. Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design.
    Katz MH, Marsh R, Herman JM, et al. · Ann Surg Oncol · 2013 · Trial result
    PubMed: PMID 23435609 · NCT03167112 (Folfirinox) · Pancreatic Neoplasms
  8. Phase 1 pharmacokinetic study of MK-0646 (dalotuzumab), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in combination with cetuximab and irinotecan in Japanese patients with advanced colorectal cancer.
    Doi T, Muro K, Yoshino T, et al. · Cancer Chemother Pharmacol · 2013 · Trial result
    PubMed: PMID 23921573 · NCT00925015 · Colorectal Neoplasms
  9. Geriatric factors predict chemotherapy feasibility: ancillary results of FFCD 2001-02 phase III study in first-line chemotherapy for metastatic colorectal cancer in elderly patients.
    Aparicio T, Jouve JL, Teillet L, et al. · J Clin Oncol · 2013 · Trial result
    PubMed: PMID 23460711 · NCT00303771 · Colorectal Neoplasms
  10. First-line sunitinib plus FOLFIRI in Japanese patients with unresectable/metastatic colorectal cancer: a phase II study.
    Tsuji Y, Satoh T, Tsuji A, et al. · Cancer Sci · 2013 · Derived
    PubMed: PMID 22537162 · NCT00668863 · Colorectal Neoplasms
  11. Current use and surgical efficacy of laparoscopic colectomy in colon cancer.
    Sticca RP, Alberts SR, Mahoney MR, et al. · J Am Coll Surg · 2013 · Derived
    PubMed: PMID 23623224 · NCT00079274 · Colonic Neoplasms
  12. Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature.
    Stein A, Glockzin G, Wienke A, et al. · BMC Cancer · 2013 · Derived
    PubMed: PMID 22897915 · NCT01321957 (CHARTA) · Colorectal Neoplasms
  13. A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma.
    Roy AC, Park SR, Cunningham D, et al. · Ann Oncol · 2013 · Derived
    PubMed: PMID 23406728 · NCT00813072 · Stomach Neoplasms
  14. Taking into account successive treatment lines in the analysis of a colorectal cancer randomised trial.
    Pénichoux J, Michiels S, Bouché O, et al. · Eur J Cancer · 2013 · Derived
    PubMed: PMID 23490654 · NCT00126256 · Colorectal Neoplasms
  15. Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies.
    Licitra L, Störkel S, Kerr KM, et al. · Eur J Cancer · 2013 · Derived
    PubMed: PMID 23265711 · NCT00154102 (CRYSTAL) · Colorectal Neoplasms
  16. Phase II study of combined chemotherapy with irinotecan and S-1 (IRIS) plus bevacizumab in patients with inoperable recurrent or advanced colorectal cancer.
    Komatsu Y, Yuki S, Sogabe S, et al. · Acta Oncol · 2013 · Derived
    PubMed: PMID 22554343 · NCT00569790 · Colorectal Neoplasms
  17. Gemcitabine and irinotecan as first-line therapy for carcinoma of unknown primary: results of a multicenter phase II trial.
    Holtan SG, Steen PD, Foster NR, et al. · PLoS One · 2013 · Derived
    PubMed: PMID 22815703 · NCT00066781 · Neoplasms, Unknown Primary
  18. An Australian translational study to evaluate the prognostic role of inflammatory markers in patients with metastatic ColorEctal caNcer Treated with bevacizumab (Avastin™) [ASCENT].
    Clarke S, Burge M, Cordwell C, et al. · BMC Cancer · 2013 · Derived
    PubMed: PMID 23497305 · NCT01588990 (ASCENT) · Colorectal Neoplasms
  19. Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial.
    Carrato A, Swieboda-Sadlej A, Staszewska-Skurczynska M, et al. · J Clin Oncol · 2013 · Derived
    PubMed: PMID 23358972 · NCT00457691 · Colorectal Neoplasms
  20. Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study.
    André T, Blons H, Mabro M, et al. · Ann Oncol · 2013 · Derived
    PubMed: PMID 23041588 · NCT00655499 (PIMABI) · Colorectal Neoplasms
  21. Comprehensive analysis of UGT1A1 genetic polymorphisms in Chinese Tibetan and Han populations.
    Zhang X, Meng X, Wang Y, et al. · Biochem Genet · 2013 · Background
    PubMed: PMID 22983686 · NCT01977235 (TDICC) · Small Cell Lung Carcinoma
  22. Feasibility and benefits of second-line chemotherapy in advanced biliary tract cancer: a large retrospective study.
    Walter T, Horgan AM, McNamara M, et al. · Eur J Cancer · 2013 · Background
    PubMed: PMID 22947649 · NCT04059562 (TRITICC) · Cholangiocarcinoma
  23. Effect of bevacizumab added preoperatively to oxaliplatin on liver injury and complications after resection of colorectal liver metastases.
    van der Pool AE, Marsman HA, Verheij J, et al. · J Surg Oncol · 2013 · Background
    PubMed: PMID 22552819 · NCT01858649 (BEV-ONCO2012) · Colorectal Neoplasms
  24. Comparison of in vitro and in vivo biological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis® (PM00104).
    Romano M, Frapolli R, Zangarini M, et al. · Int J Cancer · 2013 · Background
    PubMed: PMID 23588839 · NCT07328425 (ISG-TULIPS) · Desmoplastic Small Round Cell Tumor
  25. Prognostic value of responsiveness of neoadjuvant chemotherapy before surgery for patients with stage IB(2)/IIA(2) cervical cancer.
    Li R, Lu ST, Si JG, et al. · Gynecol Oncol · 2013 · Background
    PubMed: PMID 23146686 · NCT04789941
  26. Phase III randomised controlled trial of neoadjuvant chemotherapy plus radical surgery vs radical surgery alone for stages IB2, IIA2, and IIB cervical cancer: a Japan Clinical Oncology Group trial (JCOG 0102).
    Katsumata N, Yoshikawa H, Kobayashi H, et al. · Br J Cancer · 2013 · Background
    PubMed: PMID 23640393 · NCT04789941
  27. A phase II study of temozolomide in patients with advanced aerodigestive tract and colorectal cancers and methylation of the O6-methylguanine-DNA methyltransferase promoter.
    Hochhauser D, Glynne-Jones R, Potter V, et al. · Mol Cancer Ther · 2013 · Background
    PubMed: PMID 23443801 · NCT05031975 (ERASE-TMZ) · Colorectal Neoplasms
  28. Dacarbazine-mediated upregulation of NKG2D ligands on tumor cells activates NK and CD8 T cells and restrains melanoma growth.
    Hervieu A, Rébé C, Végran F, et al. · J Invest Dermatol · 2013 · Background
    PubMed: PMID 22951720 · NCT04689347 · Colorectal Neoplasms
  29. Stereotactic body radiation therapy with concurrent full-dose gemcitabine for locally advanced pancreatic cancer: a pilot trial demonstrating safety.
    Gurka MK, Collins SP, Slack R, et al. · Radiat Oncol · 2013 · Background
    PubMed: PMID 23452509 · NCT07173387 (RAD-NALIRIFOX) · Pancreatic Neoplasms
  30. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
    Grothey A, Van Cutsem E, Sobrero A, et al. · Lancet · 2013 · Background
    PubMed: PMID 23177514 · NCT03829462 (NEXT-REGIRI) · Colorectal Neoplasms
  31. Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
    Fine RL, Gulati AP, Krantz BA, et al. · Cancer Chemother Pharmacol · 2013 · Background
    PubMed: PMID 23370660 · NCT04689347 · Colorectal Neoplasms
  32. Neutralizing tumor-promoting chronic inflammation: a magic bullet?
    Coussens LM, Zitvogel L, Palucka AK, et al. · Science · 2013 · Background
    PubMed: PMID 23329041 · NCT02021422 · Pancreatic Neoplasms
  33. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.
    Bennouna J, Sastre J, Arnold D, et al. · Lancet Oncol · 2013 · Background
    PubMed: PMID 23168366 · NCT04689347 · Colorectal Neoplasms
  34. Promoter CpG island hypermethylation of the DNA repair enzyme MGMT predicts clinical response to dacarbazine in a phase II study for metastatic colorectal cancer.
    Amatu A, Sartore-Bianchi A, Moutinho C, et al. · Clin Cancer Res · 2013 · Background
    PubMed: PMID 23422094 · NCT05031975 (ERASE-TMZ) · Colorectal Neoplasms

2012 (46 papers)

  1. Radiation Therapy Oncology Group 0247: a randomized Phase II study of neoadjuvant capecitabine and irinotecan or capecitabine and oxaliplatin with concurrent radiotherapy for patients with locally advanced rectal cancer.
    Wong SJ, Winter K, Meropol NJ, et al. · Int J Radiat Oncol Biol Phys · 2012 · Trial result
    PubMed: PMID 21775070 · NCT00081289 · Colorectal Neoplasms
  2. Survival after resection of pancreatic adenocarcinoma: results from a single institution over three decades.
    Winter JM, Brennan MF, Tang LH, et al. · Ann Surg Oncol · 2012 · Trial result
    PubMed: PMID 21761104 · NCT03167112 (Folfirinox) · Pancreatic Neoplasms
  3. Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines.
    Tempero MA, Arnoletti JP, Behrman SW, et al. · J Natl Compr Canc Netw · 2012 · Trial result
    PubMed: PMID 22679115 · NCT03167112 (Folfirinox) · Pancreatic Neoplasms
  4. Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms.
    Satoh T, Ura T, Yamada Y, et al. · Cancer Sci · 2012 · Trial result
    PubMed: PMID 21740478 · NCT01444521 · Stomach Neoplasms
  5. A phase II study of capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancer.
    Renouf DJ, Welch S, Moore MJ, et al. · Cancer Chemother Pharmacol · 2012 · Trial result
    PubMed: PMID 22349811 · NCT00483834 · Colorectal Neoplasms
  6. A weekly combination of carboplatin and irinotecan for previously untreated extensive disease small-cell lung cancer, results of a minimum follow-up of 3 years: a multi-center Phase II trial JMTO LC02-02.
    Okishio K, Mio T, Kawahara M, et al. · Jpn J Clin Oncol · 2012 · Trial result
    PubMed: PMID 22430871 · NCT00104793 · Lung Neoplasms
  7. Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer.
    Meyerhardt JA, Ancukiewicz M, Abrams TA, et al. · PLoS One · 2012 · Trial result
    PubMed: PMID 22701615 · NCT00436072 · Colorectal Neoplasms
  8. Management of patients with pancreatic adenocarcinoma: national trends in patient selection, operative management, and use of adjuvant therapy.
    Mayo SC, Gilson MM, Herman JM, et al. · J Am Coll Surg · 2012 · Trial result
    PubMed: PMID 22055585 · NCT03167112 (Folfirinox) · Pancreatic Neoplasms
  9. Clinical value of circulating endothelial cell levels in metastatic colorectal cancer patients treated with first-line chemotherapy and bevacizumab.
    Malka D, Boige V, Jacques N, et al. · Ann Oncol · 2012 · Trial result
    PubMed: PMID 21825101 · NCT00423696 · Colorectal Neoplasms
  10. Locally advanced breast cancers are more likely to present as Interval Cancers: results from the I-SPY 1 TRIAL (CALGB 150007/150012, ACRIN 6657, InterSPORE Trial).
    Lin C, Buxton MB, Moore D, et al. · Breast Cancer Res Treat · 2012 · Trial result
    PubMed: PMID 21796368 · NCT01042379 (I-SPY) · Neoplasms
  11. A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma.
    Kreisl TN, Zhang W, Odia Y, et al. · Neuro Oncol · 2012 · Trial result
    PubMed: PMID 21865400 · NCT00393094 · Brain Neoplasms
  12. Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status.
    Kang MJ, Hong YS, Kim KP, et al. · Invest New Drugs · 2012 · Trial result
    PubMed: PMID 21706149 · NCT00637091
  13. Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy--results from ACRIN 6657/I-SPY TRIAL.
    Hylton NM, Blume JD, Bernreuter WK, et al. · Radiology · 2012 · Trial result
    PubMed: PMID 22623692 · NCT01042379 (I-SPY) · Neoplasms
  14. Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study).
    Heinrich S, Pestalozzi B, Lesurtel M, et al. · BMC Cancer · 2012 · Trial result
    PubMed: PMID 21831266 · NCT03167112 (Folfirinox) · Pancreatic Neoplasms
  15. Evaluation of efficacy and safety of FOLFIRI for elderly patients with gastric cancer: a first-line phase II study.
    Fonck M, Brunet R, Becouarn Y, et al. · Clin Res Hepatol Gastroenterol · 2012 · Trial result
    PubMed: PMID 21907007 · NCT00210184 (CEPAFIRI) · Stomach Neoplasms
  16. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657.
    Esserman LJ, Berry DA, DeMichele A, et al. · J Clin Oncol · 2012 · Trial result
    PubMed: PMID 22649152 · NCT01042379 (I-SPY) · Neoplasms
  17. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).
    Esserman LJ, Berry DA, Cheang MC, et al. · Breast Cancer Res Treat · 2012 · Trial result
    PubMed: PMID 22198468 · NCT01042379 (I-SPY) · Neoplasms
  18. Phase II and gene expression analysis trial of neoadjuvant capecitabine plus irinotecan followed by capecitabine-based chemoradiotherapy for locally advanced rectal cancer: Hoosier Oncology Group GI03-53.
    Chiorean EG, Sanghani S, Schiel MA, et al. · Cancer Chemother Pharmacol · 2012 · Trial result
    PubMed: PMID 22610353 · NCT00216086 · Rectal Neoplasms
  19. Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale.
    Brock PR, Knight KR, Freyer DR, et al. · J Clin Oncol · 2012 · Trial result
    PubMed: PMID 22547603 · NCT04478292 · Hepatoblastoma
  20. Phase II study of first-line FOLFIRI for progressive metastatic well-differentiated pancreatic endocrine carcinoma.
    Brixi-Benmansour H, Jouve JL, Mitry E, et al. · Dig Liver Dis · 2012 · Trial result
    PubMed: PMID 21831734 · NCT00416767 · Neoplasms
  21. Validation of a prediction rule to maximize curative (R0) resection of early-stage pancreatic adenocarcinoma.
    Bao P, Potter D, Eisenberg DP, et al. · HPB (Oxford) · 2012 · Trial result
    PubMed: PMID 20495714 · NCT03167112 (Folfirinox) · Pancreatic Neoplasms
  22. Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatment for unresectable metastatic colorectal cancer: a phase II trial.
    Assenat E, Desseigne F, Thezenas S, et al. · Oncologist · 2012 · Trial result
    PubMed: PMID 22016477 · NCT00556413 · Colorectal Neoplasms
  23. Immunogenicity of panitumumab in combination chemotherapy clinical trials.
    Weeraratne D, Chen A, Pennucci JJ, et al. · BMC Clin Pharmacol · 2012 · Derived
    PubMed: PMID 22070868 · NCT00332163 (STEPP) · Colorectal Neoplasms
  24. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
    Van Cutsem E, Tabernero J, Lakomy R, et al. · J Clin Oncol · 2012 · Derived
    PubMed: PMID 22949147 · NCT00561470 (VELOUR) · Colorectal Neoplasms
  25. Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC).
    Souglakos J, Ziras N, Kakolyris S, et al. · Br J Cancer · 2012 · Derived
    PubMed: PMID 22240792 · NCT00469443 · Colorectal Neoplasms
  26. The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status.
    Mitchell EP, Piperdi B, Lacouture ME, et al. · Clin Colorectal Cancer · 2012 · Derived
    PubMed: PMID 22000810 · NCT00332163 (STEPP) · Colorectal Neoplasms
  27. A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: the AIO KRK 0110 trial/ML22011 trial.
    Giessen C, von Weikersthal LF, Hinke A, et al. · BMC Cancer · 2012 · Derived
    PubMed: PMID 21861888 · NCT01249638
  28. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial.
    Alberts SR, Sargent DJ, Nair S, et al. · JAMA · 2012 · Derived
    PubMed: PMID 22474202 · NCT00079274 · Colonic Neoplasms
  29. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses.
    Yothers G, O'Connell MJ, Allegra CJ, et al. · J Clin Oncol · 2012 · Background
    PubMed: PMID 21859995 · NCT05031975 (ERASE-TMZ) · Colorectal Neoplasms
  30. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study.
    Tveit KM, Guren T, Glimelius B, et al. · J Clin Oncol · 2012 · Background
    PubMed: PMID 22473155 · NCT01858662 · Colorectal Neoplasms
  31. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research.
    Signorovitch JE, Sikirica V, Erder MH, et al. · Value Health · 2012 · Background
    PubMed: PMID 22999145 · NCT04915807 · Stomach Neoplasms
  32. Cancer treatment and survivorship statistics, 2012.
    Siegel R, DeSantis C, Virgo K, et al. · CA Cancer J Clin · 2012 · Background
    PubMed: PMID 22700443 · NCT05424692 · Rectal Neoplasms
  33. Phase I trial of "bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell" vaccine (FANG) in advanced cancer.
    Senzer N, Barve M, Kuhn J, et al. · Mol Ther · 2012 · Background
    PubMed: PMID 22186789 · NCT02511132 · Sarcoma
  34. Interpreting cancer genomes using systematic host network perturbations by tumour virus proteins.
    Rozenblatt-Rosen O, Deo RC, Padi M, et al. · Nature · 2012 · Background
    PubMed: PMID 22810586 · NCT05381038 · Neoplasms
  35. Cytokeratin-19 and mammaglobin gene expression in circulating tumor cells from metastatic breast cancer patients enrolled in North Central Cancer Treatment Group trials, N0234/336/436/437.
    Reinholz MM, Kitzmann KA, Tenner K, et al. · Clin Cancer Res · 2012 · Background
    PubMed: PMID 21976532 · NCT00275041 · Breast Neoplasms
  36. Cancer immunotherapy via dendritic cells.
    Palucka K, Banchereau J · Nat Rev Cancer · 2012 · Background
    PubMed: PMID 22437871 · NCT02021422 · Pancreatic Neoplasms
  37. Activity of trabectidin in desmoplastic small round cell tumor.
    López-González A, Cantos B, Tejerina E, et al. · Med Oncol · 2012 · Background
    PubMed: PMID 20924717 · NCT07328425 (ISG-TULIPS) · Desmoplastic Small Round Cell Tumor
  38. Complexity in the signaling network: insights from the use of targeted inhibitors in cancer therapy.
    Logue JS, Morrison DK · Genes Dev · 2012 · Background
    PubMed: PMID 22474259 · NCT05381038 · Neoplasms
  39. Enhancement of focused ultrasound with microbubbles on the treatments of anticancer nanodrug in mouse tumors.
    Lin CY, Li JR, Tseng HC, et al. · Nanomedicine · 2012 · Background
    PubMed: PMID 22033084 · NCT07314385
  40. Hospital volume, margin status, and long-term survival after pancreaticoduodenectomy for pancreatic adenocarcinoma.
    La Torre M, Nigri G, Ferrari L, et al. · Am Surg · 2012 · Background
    PubMed: PMID 22369834 · NCT02021422 · Pancreatic Neoplasms
  41. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia.
    Kalos M, Levine BL, Porter DL, et al. · Sci Transl Med · 2012 · Background
    PubMed: PMID 21832238 · NCT02021422 · Pancreatic Neoplasms
  42. Stereotactic body radiation therapy for nonresectable tumors of the pancreas.
    Goyal K, Einstein D, Ibarra RA, et al. · J Surg Res · 2012 · Background
    PubMed: PMID 21937061 · NCT07173387 (RAD-NALIRIFOX) · Pancreatic Neoplasms
  43. Balancing repair and tolerance of DNA damage caused by alkylating agents.
    Fu D, Calvo JA, Samson LD, et al. · Nat Rev Cancer · 2012 · Background
    PubMed: PMID 22237395 · NCT04689347 · Colorectal Neoplasms
  44. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
    Franko J, Shi Q, Goldman CD, et al. · J Clin Oncol · 2012 · Background
    PubMed: PMID 22162570 · NCT00003594 · Colorectal Neoplasms
  45. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials.
    Bokemeyer C, Van Cutsem E, Rougier P, et al. · Eur J Cancer · 2012 · Background
    PubMed: PMID 22446022 · NCT01858649 (BEV-ONCO2012) · Colorectal Neoplasms
  46. Comparison of continuous versus categorical tumor measurement-based metrics to predict overall survival in cancer treatment trials.
    An MW, Mandrekar SJ, Branda ME, et al. · Clin Cancer Res · 2012 · Background
    PubMed: PMID 21880789 · NCT00003594 · Colorectal Neoplasms

2011 (39 papers)

  1. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
    Thuss-Patience PC, Kretzschmar A, Bichev D, et al. · Eur J Cancer · 2011 · Trial result
    PubMed: PMID 21742485 · NCT03116555
  2. Vitamin D status in patients with stage IV colorectal cancer: findings from Intergroup trial N9741.
    Ng K, Sargent DJ, Goldberg RM, et al. · J Clin Oncol · 2011 · Trial result
    PubMed: PMID 21422438 · NCT00003594 · Colorectal Neoplasms
  3. Phase II Study of Biweekly Pemetrexed Plus Irinotecan as Second-Line Therapy for Metastatic Colorectal Cancer.
    Louvet C, André T, Gamelin E, et al. · J Oncol · 2011 · Trial result
    PubMed: PMID 20396391 · NCT00191984 · Colorectal Neoplasms
  4. Global cancer statistics.
    Jemal A, Bray F, Center MM, et al. · CA Cancer J Clin · 2011 · Trial result
    PubMed: PMID 21296855 · NCT03116555
  5. Tumor status at 12 weeks predicts survival in advanced colorectal cancer: findings from NCCTG N9741.
    Heun JM, Grothey A, Branda ME, et al. · Oncologist · 2011 · Trial result
    PubMed: PMID 21632455 · NCT00003594 · Colorectal Neoplasms
  6. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    Conroy T, Desseigne F, Ychou M, et al. · N Engl J Med · 2011 · Trial result
    PubMed: PMID 21561347 · NCT00112658 · Pancreatic Neoplasms
  7. Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children's Oncology Group study.
    Bagatell R, London WB, Wagner LM, et al. · J Clin Oncol · 2011 · Trial result
    PubMed: PMID 21115869 · NCT00311584 · Neuroblastoma
  8. Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.
    Yothers G, Sargent DJ, Wolmark N, et al. · J Natl Cancer Inst · 2011 · Derived
    PubMed: PMID 21997132 · NCT00003835 · Colonic Neoplasms
  9. Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer.
    Villarroel MC, Rajeshkumar NV, Garrido-Laguna I, et al. · Mol Cancer Ther · 2011 · Derived
    PubMed: PMID 21135251 · NCT00276744 · Pancreatic Neoplasms
  10. Phase II study of dose-intense chemotherapy with sequential topoisomerase-targeting regimens with irinotecan/oxaliplatin followed by etoposide/carboplatin in chemotherapy naive patients with extensive small cell lung cancer.
    Rossman J, Reddy V, Cantor A, et al. · Lung Cancer · 2011 · Derived
    PubMed: PMID 20934233 · NCT00240097 · Carcinoma, Non-Small-Cell Lung
  11. The four-herb Chinese medicine PHY906 reduces chemotherapy-induced gastrointestinal toxicity.
    Lam W, Bussom S, Guan F, et al. · Sci Transl Med · 2011 · Derived
    PubMed: PMID 20720216 · NCT00730158 · Colorectal Neoplasms
  12. Pulmonary resection for metastatic gastric cancer.
    Kemp CD, Kitano M, Kerkar S, et al. · J Thorac Oncol · 2011 · Derived
    PubMed: PMID 20881648 · NCT00941655 · Stomach Neoplasms
  13. Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial.
    Ducreux M, Malka D, Mendiboure J, et al. · Lancet Oncol · 2011 · Derived
    PubMed: PMID 21903473 · NCT00126256 · Colorectal Neoplasms
  14. Pancreatic cancer.
    Vincent A, Herman J, Schulick R, et al. · Lancet · 2011 · Background
    PubMed: PMID 21620466 · NCT07173387 (RAD-NALIRIFOX) · Pancreatic Neoplasms
  15. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.
    Van Cutsem E, Köhne CH, Láng I, et al. · J Clin Oncol · 2011 · Background
    PubMed: PMID 21502544 · NCT01858649 (BEV-ONCO2012) · Colorectal Neoplasms
  16. Responsiveness of EORTC QLQ-C30, QLQ-CR38 and FACT-C quality of life questionnaires in patients with colorectal cancer.
    Uwer L, Rotonda C, Guillemin F, et al. · Health Qual Life Outcomes · 2011 · Background
    PubMed: PMID 21859485 · NCT04059562 (TRITICC) · Cholangiocarcinoma
  17. Review of docetaxel in the treatment of gastric cancer.
    Tetzlaff ED, Cheng JD, Ajani JA, et al. · Ther Clin Risk Manag · 2011 · Background
    PubMed: PMID 19209281 · NCT04770623 · Stomach Neoplasms
  18. Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis.
    Roderburg C, Urban GW, Bettermann K, et al. · Hepatology · 2011 · Background
    PubMed: PMID 20890893 · NCT04059562 (TRITICC) · Cholangiocarcinoma
  19. Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth.
    Rocha GZ, Dias MM, Ropelle ER, et al. · Clin Cancer Res · 2011 · Background
    PubMed: PMID 21543517 · NCT01930864 · Colorectal Neoplasms
  20. Intra-tumoral heterogeneity of KRAS and BRAF mutation status in patients with advanced colorectal cancer (aCRC) and cost-effectiveness of multiple sample testing.
    Richman SD, Chambers P, Seymour MT, et al. · Anal Cell Pathol (Amst) · 2011 · Background
    PubMed: PMID 21483104 · NCT00008060 · Colorectal Neoplasms
  21. Thymic stromal lymphopoietin fosters human breast tumor growth by promoting type 2 inflammation.
    Pedroza-Gonzalez A, Xu K, Wu TC, et al. · J Exp Med · 2011 · Background
    PubMed: PMID 21339324 · NCT02021422 · Pancreatic Neoplasms
  22. Pilomyxoid astrocytoma of the cervical spinal cord in a child with rapid progression into glioblastoma: case report and literature review.
    Paraskevopoulos D, Patsalas I, Karkavelas G, et al. · Childs Nerv Syst · 2011 · Background
    PubMed: PMID 20461521 · NCT01837862 · Glioblastoma
  23. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction.
    Mlecnik B, Tosolini M, Kirilovsky A, et al. · J Clin Oncol · 2011 · Background
    PubMed: PMID 21245428 · NCT01858662 · Colorectal Neoplasms
  24. Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors.
    McBride DJ, Orpana AK, Sotiriou C, et al. · Genes Chromosomes Cancer · 2011 · Background
    PubMed: PMID 20725990 · NCT01858649 (BEV-ONCO2012) · Colorectal Neoplasms
  25. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
    Maughan TS, Adams RA, Smith CG, et al. · Lancet · 2011 · Background
    PubMed: PMID 21641636 · NCT01858662 · Colorectal Neoplasms
  26. Cyst fluid interleukin-1beta (IL1beta) levels predict the risk of carcinoma in intraductal papillary mucinous neoplasms of the pancreas.
    Maker AV, Katabi N, Qin LX, et al. · Clin Cancer Res · 2011 · Background
    PubMed: PMID 21266527 · NCT02021422 · Pancreatic Neoplasms
  27. PM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti-tumour activity.
    Leal JF, Martínez-Díez M, García-Hernández V, et al. · Br J Pharmacol · 2011 · Background
    PubMed: PMID 20977459 · NCT07328425 (ISG-TULIPS) · Desmoplastic Small Round Cell Tumor
  28. Tumor promotion via injury- and death-induced inflammation.
    Kuraishy A, Karin M, Grivennikov SI, et al. · Immunity · 2011 · Background
    PubMed: PMID 22035839 · NCT02021422 · Pancreatic Neoplasms
  29. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer.
    Haller DG, Tabernero J, Maroun J, et al. · J Clin Oncol · 2011 · Background
    PubMed: PMID 21383294 · NCT05031975 (ERASE-TMZ) · Colorectal Neoplasms
  30. Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy.
    Halama N, Michel S, Kloor M, et al. · Cancer Res · 2011 · Background
    PubMed: PMID 21846824 · NCT01858662 · Colorectal Neoplasms
  31. Hyaluronan-Irinotecan improves progression-free survival in 5-fluorouracil refractory patients with metastatic colorectal cancer: a randomized phase II trial.
    Gibbs P, Clingan PR, Ganju V, et al. · Cancer Chemother Pharmacol · 2011 · Background
    PubMed: PMID 20333384 · NCT01290783 (FOLF(HA)iri) · Colorectal Neoplasms
  32. Accelerating identification and regulatory approval of investigational cancer drugs.
    Esserman LJ, Woodcock J · JAMA · 2011 · Background
    PubMed: PMID 22187281 · NCT01042379 (I-SPY) · Neoplasms
  33. Mebendazole monotherapy and long-term disease control in metastatic adrenocortical carcinoma.
    Dobrosotskaya IY, Hammer GD, Schteingart DE, et al. · Endocr Pract · 2011 · Background
    PubMed: PMID 21454232 · NCT01837862 · Glioblastoma
  34. Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer.
    De Monte L, Reni M, Tassi E, et al. · J Exp Med · 2011 · Background
    PubMed: PMID 21339327 · NCT02021422 · Pancreatic Neoplasms
  35. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study.
    de Lima M, Giralt S, Thall PF, et al. · Cancer · 2011 · Background
    PubMed: PMID 20672358 · NCT05381038 · Neoplasms
  36. Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers.
    Butterfield LH, Palucka AK, Britten CM, et al. · Clin Cancer Res · 2011 · Background
    PubMed: PMID 21558394 · NCT01858662 · Colorectal Neoplasms
  37. TNM staging in colorectal cancer: T is for T cell and M is for memory.
    Broussard EK, Disis ML · J Clin Oncol · 2011 · Background
    PubMed: PMID 21245434 · NCT01858649 (BEV-ONCO2012) · Colorectal Neoplasms
  38. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans.
    Beatty GL, Chiorean EG, Fishman MP, et al. · Science · 2011 · Background
    PubMed: PMID 21436454 · NCT02021422 · Pancreatic Neoplasms
  39. Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme.
    Bai RY, Staedtke V, Aprhys CM, et al. · Neuro Oncol · 2011 · Background
    PubMed: PMID 21764822 · NCT01837862 · Glioblastoma

2010 (35 papers)

  1. Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium study.
    Wagner LM, Perentesis JP, Reid JM, et al. · Pediatr Blood Cancer · 2010 · Trial result
    PubMed: PMID 20049936 · NCT00138216 · Central Nervous System Neoplasms
  2. Oxaliplatin, irinotecan and capecitabine (OCX) for first-line treatment of advanced/metastatic colorectal cancer: a phase I trial (SAKK 41/03).
    von Moos R, Roth A, Ruhstaller T, et al. · Onkologie · 2010 · Trial result
    PubMed: PMID 20523092 · NCT00217711 · Colorectal Neoplasms
  3. N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial.
    Tan WW, Hillman DW, Salim M, et al. · Ann Oncol · 2010 · Trial result
    PubMed: PMID 19625343 · NCT00079118 · Breast Neoplasms
  4. Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab.
    Spigel DR, Hainsworth JD, Yardley DA, et al. · J Clin Oncol · 2010 · Trial result
    PubMed: PMID 19901100 · NCT00308529 · Small Cell Lung Carcinoma
  5. Phase II trial of irinotecan, carboplatin, and bevacizumab in the treatment of patients with extensive-stage small-cell lung cancer.
    Spigel DR, Greco FA, Zubkus JD, et al. · J Thorac Oncol · 2010 · Trial result
    PubMed: PMID 19875975 · NCT00294931 · Small Cell Lung Carcinoma
  6. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.
    Roth AD, Tejpar S, Delorenzi M, et al. · J Clin Oncol · 2010 · Trial result
    PubMed: PMID 20008640 · NCT00026273 · Colorectal Neoplasms
  7. Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741.
    McLeod HL, Sargent DJ, Marsh S, et al. · J Clin Oncol · 2010 · Trial result
    PubMed: PMID 20530282 · NCT00003594 · Colorectal Neoplasms
  8. Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904.
    Kulke MH, Tempero MA, Niedzwiecki D, et al. · J Clin Oncol · 2010 · Trial result
    PubMed: PMID 19858396 · NCT00012220 · Pancreatic Neoplasms
  9. Phase II NCCTG trial of RT + irinotecan and adjuvant BCNU plus irinotecan for newly diagnosed GBM.
    Jaeckle KA, Ballman KV, Giannini C, et al. · J Neurooncol · 2010 · Trial result
    PubMed: PMID 20063115 · NCT00027612 · Glioblastoma
  10. Paclitaxel/carboplatin/etoposide versus gemcitabine/irinotecan in the first-line treatment of patients with carcinoma of unknown primary site: a randomized, phase III Sarah Cannon Oncology Research Consortium Trial.
    Hainsworth JD, Spigel DR, Clark BL, et al. · Cancer J · 2010 · Trial result
    PubMed: PMID 20164695 · NCT00193596 · Neoplasms, Unknown Primary
  11. Leveraging learning from a phase III colorectal cancer clinical trial: outcomes, methodology, meta-analysis and pharmacogenetics.
    Goldberg RM, Sargent DJ, McLeod H, et al. · Trans Am Clin Climatol Assoc · 2010 · Trial result
    PubMed: PMID 20697547 · NCT00003594 · Colorectal Neoplasms
  12. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study.
    Fernández-Martos C, Pericay C, Aparicio J, et al. · J Clin Oncol · 2010 · Trial result
    PubMed: PMID 20065174 · NCT05868317 · Rectal Neoplasms
  13. Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial.
    Braun MS, Richman SD, Thompson L, et al. · J Clin Oncol · 2010 · Trial result
    PubMed: PMID 19858398 · NCT00008060 · Colorectal Neoplasms
  14. Efficacy and toxicity of chemoradiotherapy with carboplatin and irinotecan followed by consolidation docetaxel for unresectable stage III non-small cell lung cancer.
    Bastos BR, Hatoum GF, Walker GR, et al. · J Thorac Oncol · 2010 · Trial result
    PubMed: PMID 20357618 · NCT00449020 · Lung Neoplasms
  15. Impact of smoking on patients with stage III colon cancer: results from Cancer and Leukemia Group B 89803.
    McCleary NJ, Niedzwiecki D, Hollis D, et al. · Cancer · 2010 · Derived
    PubMed: PMID 20052723 · NCT00003835 · Colonic Neoplasms
  16. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.
    Masi G, Loupakis F, Salvatore L, et al. · Lancet Oncol · 2010 · Derived
    PubMed: PMID 20702138 · NCT01163396 (FOIB)
  17. The GYMSSA trial: a prospective randomized trial comparing gastrectomy, metastasectomy plus systemic therapy versus systemic therapy alone.
    Kerkar SP, Kemp CD, Duffy A, et al. · Trials · 2010 · Derived
    PubMed: PMID 20030854 · NCT00941655 · Stomach Neoplasms
  18. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.
    Valle J, Wasan H, Palmer DH, et al. · N Engl J Med · 2010 · Background
    PubMed: PMID 20375404 · NCT04059562 (TRITICC) · Cholangiocarcinoma
  19. Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept.
    Signorovitch JE, Wu EQ, Yu AP, et al. · Pharmacoeconomics · 2010 · Background
    PubMed: PMID 20831302 · NCT04915807 · Stomach Neoplasms
  20. Pediatric low-grade gliomas.
    Sievert AJ, Fisher MJ · J Child Neurol · 2010 · Background
    PubMed: PMID 19841428 · NCT01837862 · Glioblastoma
  21. Pleomorphic xanthoastrocytoma in children and adolescents.
    Rao AA, Laack NN, Giannini C, et al. · Pediatr Blood Cancer · 2010 · Background
    PubMed: PMID 20582976 · NCT01837862 · Glioblastoma
  22. Unresectable locally advanced pancreatic cancer: a multimodal treatment using neoadjuvant chemoradiotherapy (gemcitabine plus stereotactic radiosurgery) and subsequent surgical exploration.
    Polistina F, Costantin G, Casamassima F, et al. · Ann Surg Oncol · 2010 · Background
    PubMed: PMID 20224860 · NCT07173387 (RAD-NALIRIFOX) · Pancreatic Neoplasms
  23. Immune infiltration in human tumors: a prognostic factor that should not be ignored.
    Pagès F, Galon J, Dieu-Nosjean MC, et al. · Oncogene · 2010 · Background
    PubMed: PMID 19946335 · NCT01858649 (BEV-ONCO2012) · Colorectal Neoplasms
  24. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan.
    Okusaka T, Nakachi K, Fukutomi A, et al. · Br J Cancer · 2010 · Background
    PubMed: PMID 20628385 · NCT04059562 (TRITICC) · Cholangiocarcinoma
  25. Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer.
    Mlecnik B, Tosolini M, Charoentong P, et al. · Gastroenterology · 2010 · Background
    PubMed: PMID 19909745 · NCT01858662 · Colorectal Neoplasms
  26. Tumor thickness at the tumor-normal interface: a novel pathologic indicator of chemotherapy response in hepatic colorectal metastases.
    Maru DM, Kopetz S, Boonsirikamchai P, et al. · Am J Surg Pathol · 2010 · Background
    PubMed: PMID 20697255 · NCT01858662 · Colorectal Neoplasms
  27. Development of personalized tumor biomarkers using massively parallel sequencing.
    Leary RJ, Kinde I, Diehl F, et al. · Sci Transl Med · 2010 · Background
    PubMed: PMID 20371490 · NCT01858662 · Colorectal Neoplasms
  28. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer.
    Lacouture ME, Mitchell EP, Piperdi B, et al. · J Clin Oncol · 2010 · Background
    PubMed: PMID 20142600 · NCT00332163 (STEPP) · Colorectal Neoplasms
  29. Bevacizumab improves pathological response of colorectal cancer liver metastases treated with XELOX/FOLFOX.
    Klinger M, Tamandl D, Eipeldauer S, et al. · Ann Surg Oncol · 2010 · Background
    PubMed: PMID 20177795 · NCT01858662 · Colorectal Neoplasms
  30. Older versus younger patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and stomach: a pooled analysis of eight consecutive North Central Cancer Treatment Group (NCCTG) trials.
    Jatoi A, Foster NR, Egner JR, et al. · Int J Oncol · 2010 · Background
    PubMed: PMID 20126980 · NCT00004235 · Stomach Neoplasms
  31. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
    Folprecht G, Gruenberger T, Bechstein WO, et al. · Lancet Oncol · 2010 · Background
    PubMed: PMID 19942479 · NCT01858649 (BEV-ONCO2012) · Colorectal Neoplasms
  32. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
    Douillard JY, Siena S, Cassidy J, et al. · J Clin Oncol · 2010 · Background
    PubMed: PMID 20921465 · NCT01858662 · Colorectal Neoplasms
  33. Sequential intensified chemotherapy with stem cell rescue for children and adolescents with desmoplastic small round-cell tumor.
    Bisogno G, Ferrari A, Rosolen A, et al. · Bone Marrow Transplant · 2010 · Background
    PubMed: PMID 19802018 · NCT07328425 (ISG-TULIPS) · Desmoplastic Small Round Cell Tumor
  34. Natural immunity to cancer in humans.
    Bindea G, Mlecnik B, Fridman WH, et al. · Curr Opin Immunol · 2010 · Background
    PubMed: PMID 20207124 · NCT01858662 · Colorectal Neoplasms
  35. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Bang YJ, Van Cutsem E, Feyereislova A, et al. · Lancet · 2010 · Background
    PubMed: PMID 20728210 · NCT04915807 · Stomach Neoplasms

2009 (44 papers)

  1. A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802).
    Ychou M, Raoul JL, Douillard JY, et al. · Ann Oncol · 2009 · Trial result
    PubMed: PMID 19179549 · NCT00005979 · Colorectal Neoplasms
  2. Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study.
    Wagner LM, Villablanca JG, Stewart CF, et al. · J Clin Oncol · 2009 · Trial result
    PubMed: PMID 19171709 · NCT00093353 · Neuroblastoma
  3. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3.
    Van Cutsem E, Labianca R, Bodoky G, et al. · J Clin Oncol · 2009 · Trial result
    PubMed: PMID 19451425 · NCT00026273 · Colorectal Neoplasms
  4. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
    Van Cutsem E, Köhne CH, Hitre E, et al. · N Engl J Med · 2009 · Trial result
    PubMed: PMID 19339720 · NCT00154102 (CRYSTAL) · Colorectal Neoplasms
  5. Phase II trial of two different irinotecan schedules with pharmacokinetic analysis in patients with recurrent glioma: North Central Cancer Treatment Group results.
    Santisteban M, Buckner JC, Reid JM, et al. · J Neurooncol · 2009 · Trial result
    PubMed: PMID 19066728 · NCT00003134 · Brain Neoplasms
  6. Racial differences in advanced colorectal cancer outcomes and pharmacogenetics: a subgroup analysis of a large randomized clinical trial.
    Sanoff HK, Sargent DJ, Green EM, et al. · J Clin Oncol · 2009 · Trial result
    PubMed: PMID 19636001 · NCT00003594 · Colorectal Neoplasms
  7. Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741.
    Sanoff HK, Sargent DJ, Campbell ME, et al. · J Clin Oncol · 2009 · Trial result
    PubMed: PMID 19001325 · NCT00003594 · Colorectal Neoplasms
  8. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial.
    Richman SD, Seymour MT, Chambers P, et al. · J Clin Oncol · 2009 · Trial result
    PubMed: PMID 19884549 · NCT00008060 · Colorectal Neoplasms
  9. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.
    Lara PN, Natale R, Crowley J, et al. · J Clin Oncol · 2009 · Trial result
    PubMed: PMID 19349543 · NCT00045162 · Lung Neoplasms
  10. Phase I study of weekly cisplatin, bolus fluorouracil and escalating doses of irinotecan in advanced solid tumors.
    Ku GY, O'Reilly EM, Saltz LB, et al. · Cancer Invest · 2009 · Trial result
    PubMed: PMID 19219674 · NCT00005791
  11. Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine.
    Krishnamurthi SS, Brell JM, Hoppel CL, et al. · Cancer Chemother Pharmacol · 2009 · Trial result
    PubMed: PMID 18414865 · NCT00006465
  12. Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma.
    Katz MH, Wang H, Fleming JB, et al. · Ann Surg Oncol · 2009 · Trial result
    PubMed: PMID 19194760 · NCT03167112 (Folfirinox) · Pancreatic Neoplasms
  13. NCCTG Study N9741: leveraging learning from an NCI Cooperative Group phase III trial.
    Goldberg RM, Sargent DJ, Morton RF, et al. · Oncologist · 2009 · Trial result
    PubMed: PMID 19828593 · NCT00003594 · Colorectal Neoplasms
  14. Plasma insulin-like growth factors, insulin-like binding protein-3, and outcome in metastatic colorectal cancer: results from intergroup trial N9741.
    Fuchs CS, Goldberg RM, Sargent DJ, et al. · Clin Cancer Res · 2009 · Trial result
    PubMed: PMID 19073970 · NCT00003594 · Colorectal Neoplasms
  15. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.
    Friedman HS, Prados MD, Wen PY, et al. · J Clin Oncol · 2009 · Trial result
    PubMed: PMID 19720927 · NCT00345163 (BRAIN) · Glioblastoma
  16. A phase II study of thalidomide and irinotecan for treatment of glioblastoma multiforme.
    Fadul CE, Kingman LS, Meyer LP, et al. · J Neurooncol · 2009 · Trial result
    PubMed: PMID 18661102 · NCT00039468 · Glioblastoma
  17. Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancer.
    Enzinger PC, Ryan DP, Clark JW, et al. · Ann Oncol · 2009 · Trial result
    PubMed: PMID 19139178 · NCT00165464 · Stomach Neoplasms
  18. Utilization and determinants of adjuvant therapy among older patients who receive curative surgery for pancreatic cancer.
    Davila JA, Chiao EY, Hasche JC, et al. · Pancreas · 2009 · Trial result
    PubMed: PMID 18797424 · NCT03167112 (Folfirinox) · Pancreatic Neoplasms
  19. Phase II trial of irinotecan and carboplatin for extensive or relapsed small-cell lung cancer.
    Chen G, Huynh M, Fehrenbacher L, et al. · J Clin Oncol · 2009 · Trial result
    PubMed: PMID 19204194 · NCT00387660 · Small Cell Lung Carcinoma
  20. Tissue biomarker development in a multicentre trial context: a feasibility study on the PETACC3 stage II and III colon cancer adjuvant treatment trial.
    Bosman FT, Yan P, Tejpar S, et al. · Clin Cancer Res · 2009 · Trial result
    PubMed: PMID 19690194 · NCT00026273 · Colorectal Neoplasms
  21. Docetaxel and irinotecan in recurrent or metastatic head and neck cancer: a phase 2 trial of the Eastern Cooperative Oncology Group.
    Argiris A, Buchanan A, Brockstein B, et al. · Cancer · 2009 · Trial result
    PubMed: PMID 19634157 · NCT00040807 · Head and Neck Neoplasms
  22. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study.
    Boku N, Yamamoto S, Fukuda H, et al. · Lancet Oncol · 2009 · Derived
    PubMed: PMID 19818685 · NCT00142350 · Stomach Neoplasms
  23. Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients.
    Yung TK, Chan KC, Mok TS, et al. · Clin Cancer Res · 2009 · Background
    PubMed: PMID 19276259 · NCT01858662 · Colorectal Neoplasms
  24. Management of pilomyxoid astrocytomas: our experience.
    Tsugu H, Oshiro S, Yanai F, et al. · Anticancer Res · 2009 · Background
    PubMed: PMID 19414328 · NCT01837862 · Glioblastoma
  25. Phase I and pharmacokinetic study of cetuximab and irinotecan in children with refractory solid tumors: a study of the pediatric oncology experimental therapeutic investigators' consortium.
    Trippett TM, Herzog C, Whitlock JA, et al. · J Clin Oncol · 2009 · Background
    PubMed: PMID 19770383 · NCT00110357 · Neoplasms
  26. Immunogenic cancer cell death: a key-lock paradigm.
    Tesniere A, Apetoh L, Ghiringhelli F, et al. · Curr Opin Immunol · 2009 · Background
    PubMed: PMID 18573340 · NCT01858649 (BEV-ONCO2012) · Colorectal Neoplasms
  27. Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology.
    Tahara H, Sato M, Thurin M, et al. · J Transl Med · 2009 · Background
    PubMed: PMID 19534815 · NCT01858649 (BEV-ONCO2012) · Colorectal Neoplasms
  28. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial.
    Sebag-Montefiore D, Stephens RJ, Steele R, et al. · Lancet · 2009 · Background
    PubMed: PMID 19269519 · NCT07521605
  29. Vandetanib with FOLFIRI in patients with advanced colorectal adenocarcinoma: results from an open-label, multicentre Phase I study.
    Saunders MP, Wilson R, Peeters M, et al. · Cancer Chemother Pharmacol · 2009 · Background
    PubMed: PMID 19184020 · NCT00507091 · Neoplasm Metastasis
  30. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer.
    Pagès F, Kirilovsky A, Mlecnik B, et al. · J Clin Oncol · 2009 · Background
    PubMed: PMID 19858404 · NCT01858662 · Colorectal Neoplasms
  31. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma.
    Kreisl TN, Kim L, Moore K, et al. · J Clin Oncol · 2009 · Background
    PubMed: PMID 19114704 · NCT00393094 · Brain Neoplasms
  32. Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases.
    Klinger M, Eipeldauer S, Hacker S, et al. · Eur J Surg Oncol · 2009 · Background
    PubMed: PMID 19200687 · NCT01858649 (BEV-ONCO2012) · Colorectal Neoplasms
  33. Combining radiation, immunotherapy, and antiangiogenesis agents in the management of cancer: the Three Musketeers or just another quixotic combination?
    Kamrava M, Bernstein MB, Camphausen K, et al. · Mol Biosyst · 2009 · Background
    PubMed: PMID 19823740 · NCT07521605
  34. Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
    Jimeno A, Li J, Messersmith WA, et al. · J Clin Oncol · 2009 · Background
    PubMed: PMID 18955447 · NCT00861783 · Carcinoma, Hepatocellular
  35. Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay.
    Jimeno A, Chan A, Cusatis G, et al. · Oncogene · 2009 · Background
    PubMed: PMID 19029951 · NCT00861783 · Carcinoma, Hepatocellular
  36. Cancer statistics, 2009.
    Jemal A, Siegel R, Ward E, et al. · CA Cancer J Clin · 2009 · Background
    PubMed: PMID 19474385 · NCT01858662 · Colorectal Neoplasms
  37. Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia.
    Jabbour E, Giralt S, Kantarjian H, et al. · Cancer · 2009 · Background
    PubMed: PMID 19235255 · NCT05381038 · Neoplasms
  38. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer.
    Hecht JR, Mitchell E, Chidiac T, et al. · J Clin Oncol · 2009 · Background
    PubMed: PMID 19114685 · NCT00115765 · Colorectal Neoplasms
  39. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
    Eisenhauer EA, Therasse P, Bogaerts J, et al. · Eur J Cancer · 2009 · Background
    PubMed: PMID 19097774 · NCT01858649 (BEV-ONCO2012) · Colorectal Neoplasms
  40. Coordination of intratumoral immune reaction and human colorectal cancer recurrence.
    Camus M, Tosolini M, Mlecnik B, et al. · Cancer Res · 2009 · Background
    PubMed: PMID 19258510 · NCT01858662 · Colorectal Neoplasms
  41. A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers".
    Butterfield LH, Disis ML, Fox BA, et al. · J Transl Med · 2009 · Background
    PubMed: PMID 19105846 · NCT01858649 (BEV-ONCO2012) · Colorectal Neoplasms
  42. Chronic myeloid leukemia: molecular monitoring in clinical practice.
    Branford S · Hematology Am Soc Hematol Educ Program · 2009 · Background
    PubMed: PMID 18024654 · NCT01858649 (BEV-ONCO2012) · Colorectal Neoplasms
  43. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy.
    Barker AD, Sigman CC, Kelloff GJ, et al. · Clin Pharmacol Ther · 2009 · Background
    PubMed: PMID 19440188 · NCT01042379 (I-SPY) · Neoplasms
  44. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.
    André T, Boni C, Navarro M, et al. · J Clin Oncol · 2009 · Background
    PubMed: PMID 19451431 · NCT05031975 (ERASE-TMZ) · Colorectal Neoplasms

2008 (42 papers)

  1. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head.
    Varadhachary GR, Wolff RA, Crane CH, et al. · J Clin Oncol · 2008 · Trial result
    PubMed: PMID 18640929 · NCT03167112 (Folfirinox) · Pancreatic Neoplasms
  2. A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992).
    Theodore C, Skoneczna I, Bodrogi I, et al. · Ann Oncol · 2008 · Trial result
    PubMed: PMID 18417462 · NCT00066391 · Penile Neoplasms
  3. Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan.
    Sathornsumetee S, Cao Y, Marcello JE, et al. · J Clin Oncol · 2008 · Trial result
    PubMed: PMID 18182667 · NCT00268359 · Glioblastoma
  4. Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients.
    Rouits E, Charasson V, Pétain A, et al. · Br J Cancer · 2008 · Trial result
    PubMed: PMID 18797458 · NCT00559741 · Colorectal Neoplasms
  5. Scheduled administration of low dose irinotecan before gemcitabine in the second line therapy of non-small cell lung cancer: a phase II study.
    Ramnath N, Yu J, Khushalani NI, et al. · Anticancer Drugs · 2008 · Trial result
    PubMed: PMID 18594219 · NCT00182806 · Lung Neoplasms
  6. Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study.
    Loghin ME, Prados MD, Wen P, et al. · Clin Cancer Res · 2008 · Trial result
    PubMed: PMID 18056194 · NCT00006025 · Glioblastoma
  7. Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015.
    Köhne CH, De Greve J, Hartmann JT, et al. · Ann Oncol · 2008 · Trial result
    PubMed: PMID 18065406 · NCT00064181 · Colorectal Neoplasms
  8. Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer.
    Kaufman HL, Lenz HJ, Marshall J, et al. · Clin Cancer Res · 2008 · Trial result
    PubMed: PMID 18676757 · NCT00027833 · Colorectal Neoplasms
  9. Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors.
    Jimeno A, Rudek MA, Purcell T, et al. · Cancer Chemother Pharmacol · 2008 · Trial result
    PubMed: PMID 17429623 · NCT00047242
  10. Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma.
    Haller DG, Rothenberg ML, Wong AO, et al. · J Clin Oncol · 2008 · Trial result
    PubMed: PMID 18824706 · NCT00012389 · Colorectal Neoplasms
  11. Phase II trial of irinotecan plus cisplatin in patients with recurrent or metastatic squamous carcinoma of the head and neck.
    Gilbert J, Cmelak A, Shyr Y, et al. · Cancer · 2008 · Trial result
    PubMed: PMID 18484593 · NCT00639769 · Head and Neck Neoplasms
  12. A Phase I and pharmacokinetic study of selenomethionine in combination with a fixed dose of irinotecan in solid tumors.
    Fakih MG, Pendyala L, Brady W, et al. · Cancer Chemother Pharmacol · 2008 · Trial result
    PubMed: PMID 17989978 · NCT00112892
  13. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head.
    Evans DB, Varadhachary GR, Crane CH, et al. · J Clin Oncol · 2008 · Trial result
    PubMed: PMID 18640930 · NCT03167112 (Folfirinox) · Pancreatic Neoplasms
  14. Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas.
    Desjardins A, Reardon DA, Herndon JE, et al. · Clin Cancer Res · 2008 · Trial result
    PubMed: PMID 18981004 · NCT00268359 · Glioblastoma
  15. Capecitabine and oxaliplatin for advanced esophagogastric cancer.
    Cunningham D, Starling N, Rao S, et al. · N Engl J Med · 2008 · Trial result
    PubMed: PMID 18172173 · NCT03116555
  16. Second-line chemotherapy for patients with advanced gastric cancer: who may benefit?
    Catalano V, Graziano F, Santini D, et al. · Br J Cancer · 2008 · Trial result
    PubMed: PMID 18971936 · NCT03116555
  17. Southwest Oncology Group phase II study of irinotecan in patients with advanced transitional cell carcinoma of the urothelium that progressed after platinum-based chemotherapy.
    Beer TM, Goldman B, Nichols CR, et al. · Clin Genitourin Cancer · 2008 · Trial result
    PubMed: PMID 18501081 · NCT00066612 · Urinary Bladder Neoplasms
  18. A randomized phase II trial evaluating safety and efficacy of an experimental chemotherapy regimen (irinotecan + oxaliplatin, IRINOX) and two standard arms (LV5 FU2 + irinotecan or LV5 FU2 + oxaliplatin) in first-line metastatic colorectal cancer: a study of the Digestive Group of the Fédération Nationale des Centres de Lutte Contre le Cancer.
    Bécouarn Y, Senesse P, Thézenas S, et al. · Ann Oncol · 2008 · Trial result
    PubMed: PMID 17785765 · NCT00066274 · Colorectal Neoplasms
  19. Randomized phase II study of irinotecan, leucovorin and 5-fluorouracil (ILF) versus cisplatin plus ILF (PILF) combination chemotherapy for advanced gastric cancer.
    Park SH, Nam E, Park J, et al. · Ann Oncol · 2008 · Derived
    PubMed: PMID 18083691 · NCT00320294 · Stomach Neoplasms
  20. Broad influenza-specific CD8+ T-cell responses in humanized mice vaccinated with influenza virus vaccines.
    Yu CI, Gallegos M, Marches F, et al. · Blood · 2008 · Background
    PubMed: PMID 18713944 · NCT02021422 · Pancreatic Neoplasms
  21. Circulating tumor antigen-specific regulatory T cells in patients with metastatic melanoma.
    Vence L, Palucka AK, Fay JW, et al. · Proc Natl Acad Sci U S A · 2008 · Background
    PubMed: PMID 18093940 · NCT02021422 · Pancreatic Neoplasms
  22. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
    Saltz LB, Clarke S, Díaz-Rubio E, et al. · J Clin Oncol · 2008 · Background
    PubMed: PMID 18421054 · NCT01858649 (BEV-ONCO2012) · Colorectal Neoplasms
  23. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases.
    Ribero D, Wang H, Donadon M, et al. · Cancer · 2008 · Background
    PubMed: PMID 17960603 · NCT01858662 · Colorectal Neoplasms
  24. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients.
    Rees M, Tekkis PP, Welsh FK, et al. · Ann Surg · 2008 · Background
    PubMed: PMID 18156932 · NCT01858649 (BEV-ONCO2012) · Colorectal Neoplasms
  25. Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases.
    Reddy SK, Morse MA, Hurwitz HI, et al. · J Am Coll Surg · 2008 · Background
    PubMed: PMID 18155574 · NCT01858649 (BEV-ONCO2012) · Colorectal Neoplasms
  26. Design, synthesis, and biological evaluation of (E)-styrylbenzylsulfones as novel anticancer agents.
    Reddy MV, Mallireddigari MR, Cosenza SC, et al. · J Med Chem · 2008 · Background
    PubMed: PMID 18088089 · NCT00861328
  27. Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil.
    Pfeiffer P, Nielsen D, Bjerregaard J, et al. · Ann Oncol · 2008 · Background
    PubMed: PMID 18281264 · NCT04189055 (CETIDYL) · Colonic Neoplasms
  28. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
    Nordlinger B, Sorbye H, Glimelius B, et al. · Lancet · 2008 · Background
    PubMed: PMID 18358928 · NCT01858649 (BEV-ONCO2012) · Colorectal Neoplasms
  29. Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases.
    Kesmodel SB, Ellis LM, Lin E, et al. · J Clin Oncol · 2008 · Background
    PubMed: PMID 18854565 · NCT01858649 (BEV-ONCO2012) · Colorectal Neoplasms
  30. K-ras mutations and benefit from cetuximab in advanced colorectal cancer.
    Karapetis CS, Khambata-Ford S, Jonker DJ, et al. · N Engl J Med · 2008 · Background
    PubMed: PMID 18946061 · NCT04189055 (CETIDYL) · Colonic Neoplasms
  31. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.
    Gruenberger B, Tamandl D, Schueller J, et al. · J Clin Oncol · 2008 · Background
    PubMed: PMID 18398148 · NCT01858662 · Colorectal Neoplasms
  32. Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107.
    Grothey A, Hedrick EE, Mass RD, et al. · J Clin Oncol · 2008 · Background
    PubMed: PMID 18182660 · NCT00003594 · Colorectal Neoplasms
  33. Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease.
    Gralow JR, Burstein HJ, Wood W, et al. · J Clin Oncol · 2008 · Background
    PubMed: PMID 18258991 · NCT01858662 · Colorectal Neoplasms
  34. Mebendazole induces apoptosis via Bcl-2 inactivation in chemoresistant melanoma cells.
    Doudican N, Rodriguez A, Osman I, et al. · Mol Cancer Res · 2008 · Background
    PubMed: PMID 18667591 · NCT01837862 · Glioblastoma
  35. Circulating mutant DNA to assess tumor dynamics.
    Diehl F, Schmidt K, Choti MA, et al. · Nat Med · 2008 · Background
    PubMed: PMID 18670422 · NCT01858649 (BEV-ONCO2012) · Colorectal Neoplasms
  36. A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus.
    Chaussabel D, Quinn C, Shen J, et al. · Immunity · 2008 · Background
    PubMed: PMID 18631455 · NCT02021422 · Pancreatic Neoplasms
  37. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.
    Cassidy J, Clarke S, Díaz-Rubio E, et al. · J Clin Oncol · 2008 · Background
    PubMed: PMID 18421053 · NCT05424692 · Rectal Neoplasms
  38. Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing.
    Campbell PJ, Stephens PJ, Pleasance ED, et al. · Nat Genet · 2008 · Background
    PubMed: PMID 18438408 · NCT01858662 · Colorectal Neoplasms
  39. Cholangiocarcinoma.
    Blechacz BR, Gores GJ · Clin Liver Dis · 2008 · Background
    PubMed: PMID 18242501 · NCT04059562 (TRITICC) · Cholangiocarcinoma
  40. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases.
    Blazer DG, Kishi Y, Maru DM, et al. · J Clin Oncol · 2008 · Background
    PubMed: PMID 18936472 · NCT01858649 (BEV-ONCO2012) · Colorectal Neoplasms
  41. Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4+ T cells that facilitate tumor development.
    Aspord C, Pedroza-Gonzalez A, Gallegos M, et al. · J Exp Med · 2008 · Background
    PubMed: PMID 17438063 · NCT02021422 · Pancreatic Neoplasms
  42. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.
    Amado RG, Wolf M, Peeters M, et al. · J Clin Oncol · 2008 · Background
    PubMed: PMID 18316791 · NCT04189055 (CETIDYL) · Colonic Neoplasms

2007 (46 papers)

  1. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.
    Vredenburgh JJ, Desjardins A, Herndon JE, et al. · Clin Cancer Res · 2007 · Trial result
    PubMed: PMID 17317837 · NCT00268359 · Glioblastoma
  2. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy.
    Varadhachary GR, Tamm EP, Abbruzzese JL, et al. · Ann Surg Oncol · 2007 · Trial result
    PubMed: PMID 16865597 · NCT03167112 (Folfirinox) · Pancreatic Neoplasms
  3. Irinotecan, carboplatin, and imatinib in untreated extensive-stage small-cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
    Spigel DR, Hainsworth JD, Simons L, et al. · J Thorac Oncol · 2007 · Trial result
    PubMed: PMID 17805064 · NCT00193349 · Lung Neoplasms
  4. Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: long-term results of EORTC trial 40891.
    Smeenk HG, van Eijck CH, Hop WC, et al. · Ann Surg · 2007 · Trial result
    PubMed: PMID 17968163 · NCT03167112 (Folfirinox) · Pancreatic Neoplasms
  5. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial.
    Seymour MT, Maughan TS, Ledermann JA, et al. · Lancet · 2007 · Trial result
    PubMed: PMID 17630037 · NCT00008060 · Colorectal Neoplasms
  6. Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: Cancer and Leukemia Group B Study 39902.
    Rocha-Lima CM, Herndon JE, Lee ME, et al. · Ann Oncol · 2007 · Trial result
    PubMed: PMID 17065590 · NCT00005972 · Small Cell Lung Carcinoma
  7. Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma.
    Raut CP, Tseng JF, Sun CC, et al. · Ann Surg · 2007 · Trial result
    PubMed: PMID 17592291 · NCT03167112 (Folfirinox) · Pancreatic Neoplasms
  8. Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group.
    Pappo AS, Lyden E, Breitfeld P, et al. · J Clin Oncol · 2007 · Trial result
    PubMed: PMID 17264331 · NCT00003955 · Sarcoma
  9. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.
    Oettle H, Post S, Neuhaus P, et al. · JAMA · 2007 · Trial result
    PubMed: PMID 17227978 · NCT03167112 (Folfirinox) · Pancreatic Neoplasms
  10. A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer.
    O'connor T, Rustum Y, Levine E, et al. · Cancer Chemother Pharmacol · 2007 · Trial result
    PubMed: PMID 17426973 · NCT00083148 · Breast Neoplasms
  11. Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer.
    Meyerhardt JA, Clark JW, Supko JG, et al. · Cancer Chemother Pharmacol · 2007 · Trial result
    PubMed: PMID 17216531 · NCT00026364 · Colorectal Neoplasms
  12. Phase II trial of oxaliplatin/irinotecan/5-fluorouracil/leucovorin for metastatic colorectal cancer.
    McWilliams RR, Goetz MP, Morlan BW, et al. · Clin Colorectal Cancer · 2007 · Trial result
    PubMed: PMID 17553200 · NCT00080951 · Colorectal Neoplasms
  13. Phase I study of radical thoracic radiation, weekly irinotecan, and cisplatin in locally advanced non-small cell lung carcinoma.
    Langer CJ, Somer R, Litwin S, et al. · J Thorac Oncol · 2007 · Trial result
    PubMed: PMID 17410043 · NCT00022308 · Lung Neoplasms
  14. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial.
    Koopman M, Antonini NF, Douma J, et al. · Lancet · 2007 · Trial result
    PubMed: PMID 17630036 · NCT00312000 · Neoplasms
  15. Randomised study of sequential versus combination chemotherapy with capecitabine, irinotecan and oxaliplatin in advanced colorectal cancer, an interim safety analysis. A Dutch Colorectal Cancer Group (DCCG) phase III study.
    Koopman M, Antonini NF, Douma J, et al. · Ann Oncol · 2007 · Trial result
    PubMed: PMID 16873425 · NCT00312000 · Neoplasms
  16. A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200.
    Giantonio BJ, Levy DE, O'dwyer PJ, et al. · Ann Oncol · 2007 · Trial result
    PubMed: PMID 16873427 · NCT00006786 · Colorectal Neoplasms
  17. Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: results from Intergroup N9741.
    Dy GK, Krook JE, Green EM, et al. · J Clin Oncol · 2007 · Trial result
    PubMed: PMID 17687151 · NCT00003594 · Colorectal Neoplasms
  18. UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan.
    Côté JF, Kirzin S, Kramar A, et al. · Clin Cancer Res · 2007 · Trial result
    PubMed: PMID 17510208 · NCT00005979 · Colorectal Neoplasms
  19. Gemcitabine and irinotecan for patients with untreated extensive stage small cell lung cancer: SWOG 0119.
    Akerley W, McCoy J, Hesketh PJ, et al. · J Thorac Oncol · 2007 · Trial result
    PubMed: PMID 17545848 · NCT00030433 · Lung Neoplasms
  20. Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma.
    Wagner LM, McAllister N, Goldsby RE, et al. · Pediatr Blood Cancer · 2007 · Background
    PubMed: PMID 16317751 · NCT07479732 · Osteosarcoma
  21. Drug-induced expression of the cellular adhesion molecule L1CAM confers anti-apoptotic protection and chemoresistance in pancreatic ductal adenocarcinoma cells.
    Sebens Müerköster S, Werbing V, Sipos B, et al. · Oncogene · 2007 · Background
    PubMed: PMID 17086212 · NCT02021422 · Pancreatic Neoplasms
  22. Desmoplastic small round cell tumor in childhood: the St. Jude Children's Research Hospital experience.
    Saab R, Khoury JD, Krasin M, et al. · Pediatr Blood Cancer · 2007 · Background
    PubMed: PMID 16685737 · NCT07328425 (ISG-TULIPS) · Desmoplastic Small Round Cell Tumor
  23. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery.
    Rubbia-Brandt L, Giostra E, Brezault C, et al. · Ann Oncol · 2007 · Background
    PubMed: PMID 17060484 · NCT01858662 · Colorectal Neoplasms
  24. Gene expression patterns in blood leukocytes discriminate patients with acute infections.
    Ramilo O, Allman W, Chung W, et al. · Blood · 2007 · Background
    PubMed: PMID 17105821 · NCT02021422 · Pancreatic Neoplasms
  25. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.
    Quasar Collaborative Group, Gray R, Barnwell J, et al. · Lancet · 2007 · Background
    PubMed: PMID 18083404 · NCT05031975 (ERASE-TMZ) · Colorectal Neoplasms
  26. Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials.
    Punt CJ, Buyse M, Köhne CH, et al. · J Natl Cancer Inst · 2007 · Background
    PubMed: PMID 17596575 · NCT00026273 · Colorectal Neoplasms
  27. Health utilities using the EQ-5D in studies of cancer.
    Pickard AS, Wilke CT, Lin HW, et al. · Pharmacoeconomics · 2007 · Background
    PubMed: PMID 17488136 · NCT04059562 (TRITICC) · Cholangiocarcinoma
  28. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
    Nicholson HS, Kretschmar CS, Krailo M, et al. · Cancer · 2007 · Background
    PubMed: PMID 17705175 · NCT01837862 · Glioblastoma
  29. Inducible expression of the proallergic cytokine thymic stromal lymphopoietin in airway epithelial cells is controlled by NFkappaB.
    Lee HC, Ziegler SF · Proc Natl Acad Sci U S A · 2007 · Background
    PubMed: PMID 17213320 · NCT02021422 · Pancreatic Neoplasms
  30. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.
    Kuebler JP, Wieand HS, O'Connell MJ, et al. · J Clin Oncol · 2007 · Background
    PubMed: PMID 17470851 · NCT05031975 (ERASE-TMZ) · Colorectal Neoplasms
  31. Modern multimodality approach to hepatic colorectal metastases: solutions and controversies.
    Khatri VP, Chee KG, Petrelli NJ, et al. · Surg Oncol · 2007 · Background
    PubMed: PMID 17532622 · NCT01858662 · Colorectal Neoplasms
  32. Cetuximab for the treatment of colorectal cancer.
    Jonker DJ, O'Callaghan CJ, Karapetis CS, et al. · N Engl J Med · 2007 · Background
    PubMed: PMID 18003960 · NCT04189055 (CETIDYL) · Colonic Neoplasms
  33. Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer.
    Hecht JR, Patnaik A, Berlin J, et al. · Cancer · 2007 · Background
    PubMed: PMID 17671985 · NCT04189055 (CETIDYL) · Colonic Neoplasms
  34. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients.
    Ghiringhelli F, Menard C, Puig PE, et al. · Cancer Immunol Immunother · 2007 · Background
    PubMed: PMID 16960692 · NCT01858662 · Colorectal Neoplasms
  35. The adaptive immunologic microenvironment in colorectal cancer: a novel perspective.
    Galon J, Fridman WH, Pagès F, et al. · Cancer Res · 2007 · Background
    PubMed: PMID 17332313 · NCT01858662 · Colorectal Neoplasms
  36. PIK3CA gene mutations in pediatric and adult glioblastoma multiforme.
    Gallia GL, Rand V, Siu IM, et al. · Mol Cancer Res · 2007 · Background
    PubMed: PMID 17050665 · NCT01574092 · Brain Neoplasms
  37. A general review of the role of irinotecan (CPT11) in the treatment of gastric cancer.
    Farhat FS · Med Oncol · 2007 · Background
    PubMed: PMID 17848736 · NCT04770623 · Stomach Neoplasms
  38. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
    Donson AM, Addo-Yobo SO, Handler MH, et al. · Pediatr Blood Cancer · 2007 · Background
    PubMed: PMID 16609952 · NCT01574092 · Brain Neoplasms
  39. Adjuvant therapy for stage II and III colorectal cancer.
    de Gramont A, Tournigand C, André T, et al. · Semin Oncol · 2007 · Background
    PubMed: PMID 17449351 · NCT01858662 · Colorectal Neoplasms
  40. Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case-control study.
    D'Angelica M, Kornprat P, Gonen M, et al. · Ann Surg Oncol · 2007 · Background
    PubMed: PMID 17103075 · NCT01858649 (BEV-ONCO2012) · Colorectal Neoplasms
  41. The pilomyxoid astrocytoma and its relationship to pilocytic astrocytoma: report of a case and a critical review of the entity.
    Ceppa EP, Bouffet E, Griebel R, et al. · J Neurooncol · 2007 · Background
    PubMed: PMID 16850101 · NCT01837862 · Glioblastoma
  42. Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment.
    Cahill DP, Levine KK, Betensky RA, et al. · Clin Cancer Res · 2007 · Background
    PubMed: PMID 17404084 · NCT04689347 · Colorectal Neoplasms
  43. Congenital glioblastoma: a clinicopathologic and genetic analysis.
    Brat DJ, Shehata BM, Castellano-Sanchez AA, et al. · Brain Pathol · 2007 · Background
    PubMed: PMID 17465990 · NCT01574092 · Brain Neoplasms
  44. Phase II trial of irinotecan in children with refractory solid tumors: a Children's Oncology Group Study.
    Bomgaars LR, Bernstein M, Krailo M, et al. · J Clin Oncol · 2007 · Background
    PubMed: PMID 17925558 · NCT01574092 · Brain Neoplasms
  45. Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer.
    Berlin J, Posey J, Tchekmedyian S, et al. · Clin Colorectal Cancer · 2007 · Background
    PubMed: PMID 17531105 · NCT00111761 · Colorectal Neoplasms
  46. Blood leukocyte microarrays to diagnose systemic onset juvenile idiopathic arthritis and follow the response to IL-1 blockade.
    Allantaz F, Chaussabel D, Stichweh D, et al. · J Exp Med · 2007 · Background
    PubMed: PMID 17724127 · NCT02021422 · Pancreatic Neoplasms

2006 (28 papers)

  1. Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancer.
    Wolpin BM, Clark JW, Meyerhardt JA, et al. · Clin Colorectal Cancer · 2006 · Trial result
    PubMed: PMID 17026790 · NCT00026364 · Colorectal Neoplasms
  2. Phase II trial of gemcitabine plus irinotecan in patients with esophageal cancer: a Southwest Oncology Group (SWOG) trial.
    Williamson SK, McCoy SA, Gandara DR, et al. · Am J Clin Oncol · 2006 · Trial result
    PubMed: PMID 16601427 · NCT00012363 · Stomach Neoplasms
  3. A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study.
    Prados MD, Lamborn K, Yung WK, et al. · Neuro Oncol · 2006 · Trial result
    PubMed: PMID 16533878 · NCT00003616 · Brain Neoplasms
  4. Neoadjuvant chemotherapy, surgery, and adjuvant intraperitoneal chemotherapy in patients with locally advanced gastric or gastroesophageal junction carcinoma: a phase II study.
    Newman E, Potmesil M, Ryan T, et al. · Semin Oncol · 2006 · Trial result
    PubMed: PMID 16399443 · NCT00004103 · Stomach Neoplasms
  5. A Phase II NCCTG study of irinotecan and docetaxel in previously treated patients with non-small cell lung cancer.
    Molina JR, Nikcevich D, Hillman S, et al. · Cancer Invest · 2006 · Trial result
    PubMed: PMID 16777690 · NCT00003900 · Lung Neoplasms
  6. Randomized phase II study of neoadjuvant combined-modality chemoradiation for distal rectal cancer: Radiation Therapy Oncology Group Trial 0012.
    Mohiuddin M, Winter K, Mitchell E, et al. · J Clin Oncol · 2006 · Trial result
    PubMed: PMID 16446336 · NCT00006366 · Colorectal Neoplasms
  7. Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer.
    Meropol NJ, Gold PJ, Diasio RB, et al. · J Clin Oncol · 2006 · Trial result
    PubMed: PMID 16943524 · NCT00022698 · Colorectal Neoplasms
  8. Whole-brain radiotherapy and high-dose methylprednisolone for elderly patients with primary central nervous system lymphoma: Results of North Central Cancer Treatment Group (NCCTG) 96-73-51.
    Laack NN, Ballman KV, Brown PB, et al. · Int J Radiat Oncol Biol Phys · 2006 · Trial result
    PubMed: PMID 16863926 · NCT00003134 · Brain Neoplasms
  9. Potent inhibition of small-cell lung cancer cell growth by simvastatin reveals selective functions of Ras isoforms in growth factor signalling.
    Khanzada UK, Pardo OE, Meier C, et al. · Oncogene · 2006 · Trial result
    PubMed: PMID 16170339 · NCT04985201 · Small Cell Lung Carcinoma
  10. Cancer statistics, 2006.
    Jemal A, Siegel R, Ward E, et al. · CA Cancer J Clin · 2006 · Trial result
    PubMed: PMID 16514137 · NCT03167112 (Folfirinox) · Pancreatic Neoplasms
  11. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer.
    Hanna N, Bunn PA, Langer C, et al. · J Clin Oncol · 2006 · Trial result
    PubMed: PMID 16648503 · NCT00045162 · Lung Neoplasms
  12. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial.
    Goldberg RM, Sargent DJ, Morton RF, et al. · J Clin Oncol · 2006 · Trial result
    PubMed: PMID 16849748 · NCT00003594 · Colorectal Neoplasms
  13. Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children.
    Broniscer A, Chintagumpala M, Fouladi M, et al. · J Neurooncol · 2006 · Trial result
    PubMed: PMID 16200343 · NCT00004068 · Central Nervous System Neoplasms
  14. Phase I and pharmacokinetic study of docetaxel, irinotecan, and celecoxib in patients with advanced non-small cell lung cancer.
    Argiris A, Kut V, Luong L, et al. · Invest New Drugs · 2006 · Trial result
    PubMed: PMID 16096702 · NCT00073866 · Lung Neoplasms
  15. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data.
    Wagner AD, Grothe W, Haerting J, et al. · J Clin Oncol · 2006 · Background
    PubMed: PMID 16782930 · NCT04915807 · Stomach Neoplasms
  16. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG).
    Souglakos J, Androulakis N, Syrigos K, et al. · Br J Cancer · 2006 · Background
    PubMed: PMID 16508637 · NCT02119026 (PASSION) · Colorectal Neoplasms
  17. Pooled analysis of phase II window studies in children with contemporary high-risk metastatic rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
    Soft Tissue Sarcoma Committee of the Children's Oncology Group, Lager JJ, Lyden ER, et al. · J Clin Oncol · 2006 · Background
    PubMed: PMID 16849756 · NCT00003955 · Sarcoma
  18. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
    Rödel C, Martus P, Papadoupolos T, et al. · J Clin Oncol · 2006 · Background
    PubMed: PMID 16246976 · NCT01858662 · Colorectal Neoplasms
  19. Topoisomerase I inhibitors: camptothecins and beyond.
    Pommier Y · Nat Rev Cancer · 2006 · Background
    PubMed: PMID 16990856 · NCT05031975 (ERASE-TMZ) · Colorectal Neoplasms
  20. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    Palucka AK, Ueno H, Connolly J, et al. · J Immunother · 2006 · Background
    PubMed: PMID 16971810 · NCT02021422 · Pancreatic Neoplasms
  21. Prognostic factors for progression of childhood optic pathway glioma: a systematic review.
    Opocher E, Kremer LC, Da Dalt L, et al. · Eur J Cancer · 2006 · Background
    PubMed: PMID 16809032 · NCT01837862 · Glioblastoma
  22. A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients.
    Mabro M, Artru P, André T, et al. · Br J Cancer · 2006 · Background
    PubMed: PMID 16622455 · NCT02119026 (PASSION) · Colorectal Neoplasms
  23. Results of multimodal treatment for desmoplastic small round cell tumors.
    Lal DR, Su WT, Wolden SL, et al. · J Pediatr Surg · 2006 · Background
    PubMed: PMID 15868593 · NCT07328425 (ISG-TULIPS) · Desmoplastic Small Round Cell Tumor
  24. Pilomyxoid astrocytoma: diagnosis, prognosis, and management.
    Komotar RJ, Mocco J, Jones JE, et al. · Neurosurg Focus · 2006 · Background
    PubMed: PMID 16048293 · NCT01837862 · Glioblastoma
  25. Pilomyxoid astrocytoma of the spinal cord: report of three cases.
    Komotar RJ, Carson BS, Rao C, et al. · Neurosurgery · 2006 · Background
    PubMed: PMID 15617606 · NCT01837862 · Glioblastoma
  26. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome.
    Galon J, Costes A, Sanchez-Cabo F, et al. · Science · 2006 · Background
    PubMed: PMID 17008531 · NCT01858649 (BEV-ONCO2012) · Colorectal Neoplasms
  27. A phase I study of irinotecan administered on a weekly schedule in pediatric patients.
    Bomgaars L, Kerr J, Berg S, et al. · Pediatr Blood Cancer · 2006 · Background
    PubMed: PMID 15768380 · NCT01574092 · Brain Neoplasms
  28. Trans-arterial chemoembolization (TACE) of liver metastases from colorectal cancer using irinotecan-eluting beads: preliminary results.
    Aliberti C, Tilli M, Benea G, et al. · Anticancer Res · 2006 · Background
    PubMed: PMID 17094403 · NCT01336985 · Colorectal Neoplasms

2005 (25 papers)

  1. Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial.
    Ramanathan RK, Hwang JJ, Zamboni WC, et al. · Cancer Invest · 2005 · Trial result
    PubMed: PMID 15641483 · NCT00003995 · Colorectal Neoplasms
  2. Phase II trial of induction gemcitabine/CPT-11 followed by a twice-weekly infusion of gemcitabine and concurrent external beam radiation for the treatment of locally advanced pancreatic cancer.
    Mishra G, Butler J, Ho C, et al. · Am J Clin Oncol · 2005 · Trial result
    PubMed: PMID 16062075 · NCT00025168 · Pancreatic Neoplasms
  3. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.
    Louvet C, Labianca R, Hammel P, et al. · J Clin Oncol · 2005 · Trial result
    PubMed: PMID 15908661 · NCT03167112 (Folfirinox) · Pancreatic Neoplasms
  4. Phase 1/11 study of bi-weekly irinotecan plus cisplatin in the treatment of advanced gastric cancer.
    Koizumi W, Kurihara M, Satoh A, et al. · Anticancer Res · 2005 · Trial result
    PubMed: PMID 15865075 · NCT01444521 · Stomach Neoplasms
  5. Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986.
    Köhne CH, van Cutsem E, Wils J, et al. · J Clin Oncol · 2005 · Trial result
    PubMed: PMID 15939923 · NCT00004885 · Colorectal Neoplasms
  6. Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741.
    Delaunoit T, Alberts SR, Sargent DJ, et al. · Ann Oncol · 2005 · Trial result
    PubMed: PMID 15677624 · NCT00003594 · Colorectal Neoplasms
  7. Phase II trial of irinotecan and raltitrexed in chemotherapy-naive advanced colorectal cancer.
    Chiara S, Nobile MT, Tomasello L, et al. · Anticancer Res · 2005 · Trial result
    PubMed: PMID 15865096 · NCT03053167 · Colorectal Neoplasms
  8. UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan.
    Carlini LE, Meropol NJ, Bever J, et al. · Clin Cancer Res · 2005 · Trial result
    PubMed: PMID 15709193 · NCT00022698 · Colorectal Neoplasms
  9. Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children: results of a multiinstitutional study (SJHG-98).
    Broniscer A, Iacono L, Chintagumpala M, et al. · Cancer · 2005 · Trial result
    PubMed: PMID 15565574 · NCT00004068 · Central Nervous System Neoplasms
  10. A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity.
    Borner MM, Bernhard J, Dietrich D, et al. · Ann Oncol · 2005 · Trial result
    PubMed: PMID 15668285 · NCT00030797 · Colorectal Neoplasms
  11. Proposed revision of the esophageal cancer staging system to accommodate pathologic response (pP) following preoperative chemoradiation (CRT).
    Swisher SG, Hofstetter W, Wu TT, et al. · Ann Surg · 2005 · Background
    PubMed: PMID 15849517 · NCT01858649 (BEV-ONCO2012) · Colorectal Neoplasms
  12. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
    Stupp R, Mason WP, van den Bent MJ, et al. · N Engl J Med · 2005 · Background
    PubMed: PMID 15758009 · NCT05031975 (ERASE-TMZ) · Colorectal Neoplasms
  13. Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13.
    Peters WP, Rosner GL, Vredenburgh JJ, et al. · J Clin Oncol · 2005 · Background
    PubMed: PMID 15767638 · NCT05381038 · Neoplasms
  14. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade.
    Pascual V, Allantaz F, Arce E, et al. · J Exp Med · 2005 · Background
    PubMed: PMID 15851489 · NCT02021422 · Pancreatic Neoplasms
  15. A phase II trial of irinotecan, 5-fluorouracil and leucovorin combined with celecoxib and glutamine as first-line therapy for advanced colorectal cancer.
    Pan CX, Loehrer P, Seitz D, et al. · Oncology · 2005 · Background
    PubMed: PMID 16088234 · NCT00040391 · Colorectal Neoplasms
  16. Effector memory T cells, early metastasis, and survival in colorectal cancer.
    Pagès F, Berger A, Camus M, et al. · N Engl J Med · 2005 · Background
    PubMed: PMID 16371631 · NCT01858649 (BEV-ONCO2012) · Colorectal Neoplasms
  17. First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule.
    Masi G, Allegrini G, Cupini S, et al. · Ann Oncol · 2005 · Background
    PubMed: PMID 15550581 · NCT04689347 · Colorectal Neoplasms
  18. Immunotherapy for pancreatic cancer - science driving clinical progress.
    Laheru D, Jaffee EM · Nat Rev Cancer · 2005 · Background
    PubMed: PMID 15905855 · NCT02021422 · Pancreatic Neoplasms
  19. MGMT gene silencing and benefit from temozolomide in glioblastoma.
    Hegi ME, Diserens AC, Gorlia T, et al. · N Engl J Med · 2005 · Background
    PubMed: PMID 15758010 · NCT04689347 · Colorectal Neoplasms
  20. ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent.
    Gumireddy K, Reddy MV, Cosenza SC, et al. · Cancer Cell · 2005 · Background
    PubMed: PMID 15766665 · NCT00861783 · Carcinoma, Hepatocellular
  21. Low grade chiasmatic-hypothalamic glioma-carboplatin and vincristin chemotherapy effectively defers radiotherapy within a comprehensive treatment strategy -- report from the multicenter treatment study for children and adolescents with a low grade glioma -- HIT-LGG 1996 -- of the Society of Pediatric Oncology and Hematology (GPOH).
    Gnekow AK, Kortmann RD, Pietsch T, et al. · Klin Padiatr · 2005 · Background
    PubMed: PMID 15565548 · NCT01574092 · Brain Neoplasms
  22. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies.
    Gerber HP, Ferrara N · Cancer Res · 2005 · Background
    PubMed: PMID 15705858 · NCT02119026 (PASSION) · Colorectal Neoplasms
  23. A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
    Emura T, Suzuki N, Yamaguchi M, et al. · Int J Oncol · 2005 · Background
    PubMed: PMID 15289858 · NCT04059562 (TRITICC) · Cholangiocarcinoma
  24. Galpha13 mediates a signal that is essential for proliferation and survival of thymocyte progenitors.
    Coffield VM, Helms WS, Jiang Q, et al. · J Exp Med · 2005 · Background
    PubMed: PMID 15534370 · NCT04689347 · Colorectal Neoplasms
  25. Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome.
    Ajani JA, Mansfield PF, Crane CH, et al. · J Clin Oncol · 2005 · Background
    PubMed: PMID 15718321 · NCT01858662 · Colorectal Neoplasms

2004 (26 papers)

  1. A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863.
    Venook AP, Enders Klein C, Fleming G, et al. · Ann Oncol · 2004 · Trial result
    PubMed: PMID 14630685 · NCT00003368 · Lymphoma
  2. Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC.
    Rocha Lima CM, Rizvi NA, Zhang C, et al. · Ann Oncol · 2004 · Trial result
    PubMed: PMID 14998842 · NCT00004139 · Lung Neoplasms
  3. Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study.
    Prados MD, Yung WK, Jaeckle KA, et al. · Neuro Oncol · 2004 · Trial result
    PubMed: PMID 14769140 · NCT00003616 · Brain Neoplasms
  4. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.
    Goldberg RM, Sargent DJ, Morton RF, et al. · J Clin Oncol · 2004 · Trial result
    PubMed: PMID 14665611 · NCT00003594 · Colorectal Neoplasms
  5. Irinotecan plus raltitrexed as first-line treatment in advanced colorectal cancer: a phase II study.
    Feliu J, Salud A, Escudero P, et al. · Br J Cancer · 2004 · Trial result
    PubMed: PMID 15083176 · NCT03053167 · Colorectal Neoplasms
  6. Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup Trial N9741.
    Delaunoit T, Goldberg RM, Sargent DJ, et al. · Cancer · 2004 · Trial result
    PubMed: PMID 15470715 · NCT00003594 · Colorectal Neoplasms
  7. Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11.
    Batchelor TT, Gilbert MR, Supko JG, et al. · Neuro Oncol · 2004 · Trial result
    PubMed: PMID 14769136 · NCT00003301 · Glioblastoma
  8. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
    Tournigand C, André T, Achille E, et al. · J Clin Oncol · 2004 · Background
    PubMed: PMID 14657227 · NCT04689347 · Colorectal Neoplasms
  9. Preoperative versus postoperative chemoradiotherapy for rectal cancer.
    Sauer R, Becker H, Hohenberger W, et al. · N Engl J Med · 2004 · Background
    PubMed: PMID 15496622 · NCT07521605
  10. Progress in treatment of small-cell lung cancer: role of CPT-11.
    Saijo N · Br J Cancer · 2004 · Background
    PubMed: PMID 14676791 · NCT00546130 (RNCLC) · Small Cell Lung Carcinoma
  11. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.
    Rubbia-Brandt L, Audard V, Sartoretti P, et al. · Ann Oncol · 2004 · Background
    PubMed: PMID 14998849 · NCT01858649 (BEV-ONCO2012) · Colorectal Neoplasms
  12. Human dendritic cell subsets in NOD/SCID mice engrafted with CD34+ hematopoietic progenitors.
    Palucka AK, Gatlin J, Blanck JP, et al. · Blood · 2004 · Background
    PubMed: PMID 12869510 · NCT02021422 · Pancreatic Neoplasms
  13. Neoadjuvant chemotherapy for locally advanced cervix cancer.
    Neoadjuvant Chemotherapy for Cervical Cancer Meta-Analysis Collaboration (NACCCMA) Collaboration · Cochrane Database Syst Rev · 2004 · Background
    PubMed: PMID 15106161 · NCT04789941
  14. An alternatively spliced cyclin D1 isoform, cyclin D1b, is a nuclear oncogene.
    Lu F, Gladden AB, Diehl JA, et al. · Cancer Res · 2004 · Background
    PubMed: PMID 14612495 · NCT03829462 (NEXT-REGIRI) · Colorectal Neoplasms
  15. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    Hurwitz H, Fehrenbacher L, Novotny W, et al. · N Engl J Med · 2004 · Background
    PubMed: PMID 15175435 · NCT04689347 · Colorectal Neoplasms
  16. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide.
    Hegi ME, Diserens AC, Godard S, et al. · Clin Cancer Res · 2004 · Background
    PubMed: PMID 15041700 · NCT01574092 · Brain Neoplasms
  17. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment.
    Grothey A, Sargent D, Goldberg RM, et al. · J Clin Oncol · 2004 · Background
    PubMed: PMID 15051767 · NCT02119026 (PASSION) · Colorectal Neoplasms
  18. ERBB1 is amplified and overexpressed in high-grade diffusely infiltrative pediatric brain stem glioma.
    Gilbertson RJ, Hill DA, Hernan R, et al. · Clin Cancer Res · 2004 · Background
    PubMed: PMID 14506149 · NCT01574092 · Brain Neoplasms
  19. Irinotecan and cisplatin versus etoposide and cisplatin in small-cell lung cancer: JCOG 9511.
    Fisher MD, D'Orazio A · Clin Lung Cancer · 2004 · Background
    PubMed: PMID 14731333 · NCT00546130 (RNCLC) · Small Cell Lung Carcinoma
  20. Generating mutations but providing chemosensitivity: the role of O6-methylguanine DNA methyltransferase in human cancer.
    Esteller M, Herman JG · Oncogene · 2004 · Background
    PubMed: PMID 14712205 · NCT04689347 · Colorectal Neoplasms
  21. A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells.
    Emura T, Murakami Y, Nakagawa F, et al. · Int J Mol Med · 2004 · Background
    PubMed: PMID 15010854 · NCT04059562 (TRITICC) · Cholangiocarcinoma
  22. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey.
    Dindo D, Demartines N, Clavien PA, et al. · Ann Surg · 2004 · Background
    PubMed: PMID 15273542 · NCT04251715 · Cholangiocarcinoma
  23. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
    Cunningham D, Humblet Y, Siena S, et al. · N Engl J Med · 2004 · Background
    PubMed: PMID 15269313 · NCT04189055 (CETIDYL) · Colonic Neoplasms
  24. Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-STO 22, to assess quality of life in patients with gastric cancer.
    Blazeby JM, Conroy T, Bottomley A, et al. · Eur J Cancer · 2004 · Background
    PubMed: PMID 15454251 · NCT00941655 · Stomach Neoplasms
  25. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.
    André T, Boni C, Mounedji-Boudiaf L, et al. · N Engl J Med · 2004 · Background
    PubMed: PMID 15175436 · NCT01858649 (BEV-ONCO2012) · Colorectal Neoplasms
  26. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival.
    Adam R, Delvart V, Pascal G, et al. · Ann Surg · 2004 · Background
    PubMed: PMID 15383792 · NCT01336985 · Colorectal Neoplasms

2003 (15 papers)

  1. Combined intraperitoneal and intravenous chemotherapy for women with optimally debulked ovarian cancer: results from an intergroup phase II trial.
    Rothenberg ML, Liu PY, Braly PS, et al. · J Clin Oncol · 2003 · Trial result
    PubMed: PMID 12663720 · NCT00539877 · Stomach Neoplasms
  2. A phase II trial of docetaxel and CPT-11 in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and gastric cardia.
    Jatoi A, Tirona MT, Cha SS, et al. · Int J Gastrointest Cancer · 2003 · Trial result
    PubMed: PMID 12794247 · NCT00004235 · Stomach Neoplasms
  3. Phase I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer.
    Ilson DH, Bains M, Kelsen DP, et al. · J Clin Oncol · 2003 · Trial result
    PubMed: PMID 12885811 · NCT00005638 · Stomach Neoplasms
  4. Synergistic interaction of lovastatin and paclitaxel in human cancer cells.
    Holstein SA, Hohl RJ · Mol Cancer Ther · 2003 · Trial result
    PubMed: PMID 12467231 · NCT04985201 · Small Cell Lung Carcinoma
  5. Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumors.
    Goetz MP, Erlichman C, Windebank AJ, et al. · J Clin Oncol · 2003 · Trial result
    PubMed: PMID 12963697 · NCT00005068
  6. CPT-11 for bile-duct and gallbladder carcinoma: a phase II North Central Cancer Treatment Group (NCCTG) study.
    Alberts SR, Fishkin PA, Burgart LJ, et al. · Int J Gastrointest Cancer · 2003 · Trial result
    PubMed: PMID 12794246 · NCT00003276 · Gallbladder Neoplasms
  7. Pharmacogenetics of irinotecan.
    Toffoli G, Cecchin E, Corona G, et al. · Curr Med Chem Anticancer Agents · 2003 · Background
    PubMed: PMID 12769780 · NCT04059562 (TRITICC) · Cholangiocarcinoma
  8. The anthelmintic drug mebendazole induces mitotic arrest and apoptosis by depolymerizing tubulin in non-small cell lung cancer cells.
    Sasaki J, Ramesh R, Chada S, et al. · Mol Cancer Ther · 2003 · Background
    PubMed: PMID 12479701 · NCT01837862 · Glioblastoma
  9. Surgical resection of liver metastases of gastric cancer: an analysis of a 17-year experience with 22 patients.
    Sakamoto Y, Ohyama S, Yamamoto J, et al. · Surgery · 2003 · Background
    PubMed: PMID 12773978 · NCT00941655 · Stomach Neoplasms
  10. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer.
    Ribic CM, Sargent DJ, Moore MJ, et al. · N Engl J Med · 2003 · Background
    PubMed: PMID 12867608 · NCT05031975 (ERASE-TMZ) · Colorectal Neoplasms
  11. Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer.
    Fallik D, Borrini F, Boige V, et al. · Cancer Res · 2003 · Background
    PubMed: PMID 14522894 · NCT01574092 · Brain Neoplasms
  12. Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy.
    Crews KR, Stewart CF, Jones-Wallace D, et al. · Clin Cancer Res · 2003 · Background
    PubMed: PMID 12114421 · NCT01574092 · Brain Neoplasms
  13. A population-based study of the incidence and survival rates in patients with pilocytic astrocytoma.
    Burkhard C, Di Patre PL, Schüler D, et al. · J Neurosurg · 2003 · Background
    PubMed: PMID 12816259 · NCT01837862 · Glioblastoma
  14. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood.
    Bennett L, Palucka AK, Arce E, et al. · J Exp Med · 2003 · Background
    PubMed: PMID 12642603 · NCT02021422 · Pancreatic Neoplasms
  15. Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases.
    Adam R · Ann Oncol · 2003 · Background
    PubMed: PMID 12810452 · NCT01336985 · Colorectal Neoplasms

2002 (14 papers)

  1. Phase I study of weekly oxaliplatin plus irinotecan in previously treated patients with metastatic colorectal cancer.
    Kemeny N, Tong W, Gonen M, et al. · Ann Oncol · 2002 · Trial result
    PubMed: PMID 12196376 · NCT00003427 · Colorectal Neoplasms
  2. Phase I clinical trial of irinotecan with oral capecitabine in patients with gastrointestinal and other solid malignancies.
    Goel S, Jhawer M, Rajdev L, et al. · Am J Clin Oncol · 2002 · Trial result
    PubMed: PMID 12393999 · NCT00003867 · Rectal Neoplasms
  3. Irinotecan and raltitrexed: an active combination in advanced colorectal cancer.
    Carnaghi C, Rimassa L, Garassino I, et al. · Ann Oncol · 2002 · Trial result
    PubMed: PMID 12196368 · NCT03053167 · Colorectal Neoplasms
  4. Multicenter phase I study of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer.
    Aparicio J, de las Peñas R, Vicent JM, et al. · Oncology · 2002 · Trial result
    PubMed: PMID 12187070 · NCT03053167 · Colorectal Neoplasms
  5. Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas.
    Van Glabbeke M, Verweij J, Judson I, et al. · Eur J Cancer · 2002 · Background
    PubMed: PMID 11872347 · NCT07328425 (ISG-TULIPS) · Desmoplastic Small Round Cell Tumor
  6. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer.
    Noda K, Nishiwaki Y, Kawahara M, et al. · N Engl J Med · 2002 · Background
    PubMed: PMID 11784874 · NCT01977235 (TDICC) · Small Cell Lung Carcinoma
  7. Mebendazole elicits a potent antitumor effect on human cancer cell lines both in vitro and in vivo.
    Mukhopadhyay T, Sasaki J, Ramesh R, et al. · Clin Cancer Res · 2002 · Background
    PubMed: PMID 12231542 · NCT01837862 · Glioblastoma
  8. Concurrent cisplatin-based chemotherapy plus radiotherapy for cervical cancer--a meta-analysis.
    Lukka H, Hirte H, Fyles A, et al. · Clin Oncol (R Coll Radiol) · 2002 · Background
    PubMed: PMID 12109823 · NCT04789941
  9. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity.
    Iyer L, Das S, Janisch L, et al. · Pharmacogenomics J · 2002 · Background
    PubMed: PMID 11990381 · NCT00138060 · Colorectal Neoplasms
  10. Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer.
    Falcone A, Masi G, Allegrini G, et al. · J Clin Oncol · 2002 · Background
    PubMed: PMID 12351598 · NCT04689347 · Colorectal Neoplasms
  11. Prognostic factors for cerebellar astrocytomas in children: a study of 102 cases.
    Desai KI, Nadkarni TD, Muzumdar DP, et al. · Pediatr Neurosurg · 2002 · Background
    PubMed: PMID 11786699 · NCT01837862 · Glioblastoma
  12. Irinotecan for pediatric solid tumors: the Memorial Sloan-Kettering experience.
    Cosetti M, Wexler LH, Calleja E, et al. · J Pediatr Hematol Oncol · 2002 · Background
    PubMed: PMID 11990694 · NCT01574092 · Brain Neoplasms
  13. Importance of tumor regression assessment in predicting the outcome in patients with locally advanced rectal carcinoma who are treated with preoperative radiotherapy.
    Bouzourene H, Bosman FT, Seelentag W, et al. · Cancer · 2002 · Background
    PubMed: PMID 11920483 · NCT01858649 (BEV-ONCO2012) · Colorectal Neoplasms
  14. The development of camptothecin analogs in childhood cancers.
    Bomgaars L, Berg SL, Blaney SM, et al. · Oncologist · 2002 · Background
    PubMed: PMID 11743213 · NCT01574092 · Brain Neoplasms

2001 (14 papers)

  1. Irinotecan in the treatment of colorectal cancer: clinical overview.
    Vanhoefer U, Harstrick A, Achterrath W, et al. · J Clin Oncol · 2001 · Background
    PubMed: PMID 11230497 · NCT04059562 (TRITICC) · Cholangiocarcinoma
  2. Optic pathway hypothalamic gliomas in children under three years of age: the role of chemotherapy.
    Silva MM, Goldman S, Keating G, et al. · Pediatr Neurosurg · 2001 · Background
    PubMed: PMID 11096362 · NCT01837862 · Glioblastoma
  3. Reference data for the quality of life questionnaire EORTC QLQ-C30 in the general German population.
    Schwarz R, Hinz A · Eur J Cancer · 2001 · Background
    PubMed: PMID 11435063 · NCT04059562 (TRITICC) · Cholangiocarcinoma
  4. EQ-5D: a measure of health status from the EuroQol Group.
    Rabin R, de Charro F · Ann Med · 2001 · Background
    PubMed: PMID 11491192 · NCT04059562 (TRITICC) · Cholangiocarcinoma
  5. Topoisomerase I-mediated cytotoxicity of N-methyl-N'-nitro-N-nitrosoguanidine: trapping of topoisomerase I by the O6-methylguanine.
    Pourquier P, Waltman JL, Urasaki Y, et al. · Cancer Res · 2001 · Background
    PubMed: PMID 11196197 · NCT05031975 (ERASE-TMZ) · Colorectal Neoplasms
  6. Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice.
    Machiels JP, Reilly RT, Emens LA, et al. · Cancer Res · 2001 · Background
    PubMed: PMID 11325840 · NCT01858662 · Colorectal Neoplasms
  7. Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.
    Houghton PJ, Stewart CF, Cheshire PJ, et al. · Clin Cancer Res · 2001 · Background
    PubMed: PMID 11051264 · NCT05031975 (ERASE-TMZ) · Colorectal Neoplasms
  8. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis.
    Green JA, Kirwan JM, Tierney JF, et al. · Lancet · 2001 · Background
    PubMed: PMID 11564482 · NCT04789941
  9. Oxaliplatin in colorectal cancer: current studies.
    Goldberg R · Oncology (Williston Park) · 2001 · Background
    PubMed: PMID 11204663 · NCT00003594 · Colorectal Neoplasms
  10. Results of a policy of surveillance alone after surgical management of pediatric low grade gliomas.
    Fisher BJ, Leighton CC, Vujovic O, et al. · Int J Radiat Oncol Biol Phys · 2001 · Background
    PubMed: PMID 11597812 · NCT01837862 · Glioblastoma
  11. A phase I study of irinotecan in pediatric patients: a pediatric oncology group study.
    Blaney S, Berg SL, Pratt C, et al. · Clin Cancer Res · 2001 · Background
    PubMed: PMID 11205914 · NCT01574092 · Brain Neoplasms
  12. Carcinogen-specific induction of genetic instability.
    Bardelli A, Cahill DP, Lederer G, et al. · Proc Natl Acad Sci U S A · 2001 · Background
    PubMed: PMID 11296254 · NCT04689347 · Colorectal Neoplasms
  13. Phosphorylation-dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation.
    Alt JR, Cleveland JL, Hannink M, et al. · Genes Dev · 2001 · Background
    PubMed: PMID 11124803 · NCT03829462 (NEXT-REGIRI) · Colorectal Neoplasms
  14. Microsatellite instability occurs in distinct subtypes of pediatric but not adult central nervous system tumors.
    Alonso M, Hamelin R, Kim M, et al. · Cancer Res · 2001 · Background
    PubMed: PMID 11280776 · NCT01574092 · Brain Neoplasms

2000 (12 papers)

  1. Intraperitoneal versus intravenous CPT-11 for peritoneal seeding and liver metastasis.
    Maruyama M, Nagahama T, Yuasa Y, et al. · Anticancer Res · 2000 · Trial result
    PubMed: PMID 10628373 · NCT00539877 · Stomach Neoplasms
  2. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group.
    Klinkenbijl JH, Jeekel J, Sahmoud T, et al. · Ann Surg · 2000 · Trial result
    PubMed: PMID 10615932 · NCT03167112 (Folfirinox) · Pancreatic Neoplasms
  3. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group.
    Young H, Baum R, Cremerius U, et al. · Eur J Cancer · 2000 · Background
    PubMed: PMID 10673991 · NCT01858649 (BEV-ONCO2012) · Colorectal Neoplasms
  4. Effect of mebendazole on human cystic echinococcosis: the role of dosage and treatment duration.
    Vutova K, Mechkov G, Vachkov P, et al. · Ann Trop Med Parasitol · 2000 · Background
    PubMed: PMID 10656037 · NCT01837862 · Glioblastoma
  5. Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group.
    Simmonds PC · BMJ · 2000 · Background
    PubMed: PMID 10968812 · NCT02119026 (PASSION) · Colorectal Neoplasms
  6. Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy.
    Pitot HC, Goldberg RM, Reid JM, et al. · Clin Cancer Res · 2000 · Background
    PubMed: PMID 10873073 · NCT04689347 · Colorectal Neoplasms
  7. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma.
    Middleton MR, Grob JJ, Aaronson N, et al. · J Clin Oncol · 2000 · Background
    PubMed: PMID 10623706 · NCT05031975 (ERASE-TMZ) · Colorectal Neoplasms
  8. Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children.
    Furman WL, Stewart CF, Poquette CA, et al. · J Clin Oncol · 2000 · Background
    PubMed: PMID 10561220 · NCT01574092 · Brain Neoplasms
  9. The impact of extent of resection in the management of malignant gliomas of childhood.
    Finlay JL, Wisoff JH · Childs Nerv Syst · 2000 · Background
    PubMed: PMID 10603023 · NCT01837862 · Glioblastoma
  10. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.
    Esteller M, Garcia-Foncillas J, Andion E, et al. · N Engl J Med · 2000 · Background
    PubMed: PMID 11070098 · NCT01574092 · Brain Neoplasms
  11. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
    Douillard JY, Cunningham D, Roth AD, et al. · Lancet · 2000 · Background
    PubMed: PMID 10744089 · NCT04689347 · Colorectal Neoplasms
  12. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    de Gramont A, Figer A, Seymour M, et al. · J Clin Oncol · 2000 · Background
    PubMed: PMID 10944126 · NCT05424692 · Rectal Neoplasms

1999 (10 papers)

  1. Pediatric astrocytomas with monomorphous pilomyxoid features and a less favorable outcome.
    Tihan T, Fisher PG, Kepner JL, et al. · J Neuropathol Exp Neurol · 1999 · Background
    PubMed: PMID 10515229 · NCT01837862 · Glioblastoma
  2. Successful clinical response to irinotecan in desmoplastic round blue cell tumor.
    Rosoff PM, Bayliff S · Med Pediatr Oncol · 1999 · Background
    PubMed: PMID 10531577 · NCT07328425 (ISG-TULIPS) · Desmoplastic Small Round Cell Tumor
  3. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
    Rose PG, Bundy BN, Watkins EB, et al. · N Engl J Med · 1999 · Background
    PubMed: PMID 10202165 · NCT04789941
  4. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
    Morris M, Eifel PJ, Lu J, et al. · N Engl J Med · 1999 · Background
    PubMed: PMID 10202164 · NCT04789941
  5. Regimen-related toxicity of myeloablative chemotherapy with BCNU, thiotepa, and etoposide followed by autologous stem cell rescue for children with newly diagnosed glioblastoma multiforme: report from the Children's Cancer Group.
    Grovas AC, Boyett JM, Lindsley K, et al. · Med Pediatr Oncol · 1999 · Background
    PubMed: PMID 10398181 · NCT01574092 · Brain Neoplasms
  6. Radiation-induced cerebral vasculopathy in children with neurofibromatosis and optic pathway glioma.
    Grill J, Couanet D, Cappelli C, et al. · Ann Neurol · 1999 · Background
    PubMed: PMID 10072056 · NCT01574092 · Brain Neoplasms
  7. Pleomorphic xanthoastrocytoma: what do we really know about it?
    Giannini C, Scheithauer BW, Burger PC, et al. · Cancer · 1999 · Background
    PubMed: PMID 10223246 · NCT01837862 · Glioblastoma
  8. Long-term follow up of 69 patients treated for optic pathway tumours before the chemotherapy era.
    Cappelli C, Grill J, Raquin M, et al. · Arch Dis Child · 1999 · Background
    PubMed: PMID 9875044 · NCT01837862 · Glioblastoma
  9. Selective modulation of collagenase 1 gene expression by the chemotherapeutic agent doxorubicin.
    Benbow U, Maitra R, Hamilton JW, et al. · Clin Cancer Res · 1999 · Background
    PubMed: PMID 9918220 · NCT02119026 (PASSION) · Colorectal Neoplasms
  10. Pretreatment factors predict overall survival for patients with low-grade glioma: a recursive partitioning analysis.
    Bauman G, Lote K, Larson D, et al. · Int J Radiat Oncol Biol Phys · 1999 · Background
    PubMed: PMID 10571199 · NCT01837862 · Glioblastoma

1998 (7 papers)

  1. Adjuvant intraperitoneal chemotherapy with carbon-adsorbed mitomycin in patients with gastric cancer: results of a randomized multicenter trial of the Austrian Working Group for Surgical Oncology.
    Rosen HR, Jatzko G, Repse S, et al. · J Clin Oncol · 1998 · Trial result
    PubMed: PMID 9704725 · NCT00539877 · Stomach Neoplasms
  2. Comparison of the pharmacokinetics and efficacy of irinotecan after administration by the intravenous versus intraperitoneal route in mice.
    Guichard S, Chatelut E, Lochon I, et al. · Cancer Chemother Pharmacol · 1998 · Trial result
    PubMed: PMID 9654118 · NCT00539877 · Stomach Neoplasms
  3. Current neurosurgical management and the impact of the extent of resection in the treatment of malignant gliomas of childhood: a report of the Children's Cancer Group trial no. CCG-945.
    Wisoff JH, Boyett JM, Berger MS, et al. · J Neurosurg · 1998 · Background
    PubMed: PMID 9647172 · NCT01837862 · Glioblastoma
  4. Human deoxyribonucleic acid topoisomerases: molecular targets of anticancer drugs.
    Holden JA · Ann Clin Lab Sci · 1998 · Background
    PubMed: PMID 9433537 · NCT04789941
  5. Using reference data on quality of life--the importance of adjusting for age and gender, exemplified by the EORTC QLQ-C30 (+3).
    Hjermstad MJ, Fayers PM, Bjordal K, et al. · Eur J Cancer · 1998 · Background
    PubMed: PMID 9849421 · NCT04059562 (TRITICC) · Cholangiocarcinoma
  6. The relationship between high-dose treatment and combination chemotherapy: the concept of summation dose intensity.
    Frei E, Elias A, Wheeler C, et al. · Clin Cancer Res · 1998 · Background
    PubMed: PMID 9748116 · NCT05381038 · Neoplasms
  7. Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents.
    Coggins CA, Elion GB, Houghton PJ, et al. · Cancer Chemother Pharmacol · 1998 · Background
    PubMed: PMID 9554593 · NCT01574092 · Brain Neoplasms

1997 (6 papers)

  1. Fluorouracil in colorectal cancer--a tale of two drugs: implications for biochemical modulation.
    Sobrero AF, Aschele C, Bertino JR, et al. · J Clin Oncol · 1997 · Background
    PubMed: PMID 8996164 · NCT04689347 · Colorectal Neoplasms
  2. Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas.
    Packer RJ, Ater J, Allen J, et al. · J Neurosurg · 1997 · Background
    PubMed: PMID 9126887 · NCT01837862 · Glioblastoma
  3. The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30.
    King MT · Qual Life Res · 1997 · Background
    PubMed: PMID 8993101 · NCT04059562 (TRITICC) · Cholangiocarcinoma
  4. Hepatic resection for metastatic colorectal cancer results in cure for some patients.
    Jamison RL, Donohue JH, Nagorney DM, et al. · Arch Surg · 1997 · Background
    PubMed: PMID 9161393 · NCT01858662 · Colorectal Neoplasms
  5. Low-grade astrocytoma: a decade of experience at St. Jude Children's Research Hospital.
    Gajjar A, Sanford RA, Heideman R, et al. · J Clin Oncol · 1997 · Background
    PubMed: PMID 9256121 · NCT01837862 · Glioblastoma
  6. Etoposide and thiotepa followed by ABMT (autologous bone marrow transplantation) in children and young adults with high-grade gliomas.
    Bouffet E, Mottolese C, Jouvet A, et al. · Eur J Cancer · 1997 · Background
    PubMed: PMID 9071906 · NCT01574092 · Brain Neoplasms

1996 (1 paper)

  1. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Française de Chirurgie.
    Nordlinger B, Guiguet M, Vaillant JC, et al. · Cancer · 1996 · Background
    PubMed: PMID 8608500 · NCT01858649 (BEV-ONCO2012) · Colorectal Neoplasms

1995 (5 papers)

  1. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis.
    Warren RS, Yuan H, Matli MR, et al. · J Clin Invest · 1995 · Background
    PubMed: PMID 7535799 · NCT02119026 (PASSION) · Colorectal Neoplasms
  2. Low-grade gliomas of the cerebral hemispheres in children: an analysis of 71 cases.
    Pollack IF, Claassen D, al-Shboul Q, et al. · J Neurosurg · 1995 · Background
    PubMed: PMID 7897512 · NCT01837862 · Glioblastoma
  3. Optic pathway and hypothalamic/chiasmatic gliomas in children younger than age 5 years with a 6-year follow-up.
    Janss AJ, Grundy R, Cnaan A, et al. · Cancer · 1995 · Background
    PubMed: PMID 7842408 · NCT01837862 · Glioblastoma
  4. Low-grade astrocytoma with neuraxis dissemination at diagnosis.
    Gajjar A, Bhargava R, Jenkins JJ, et al. · J Neurosurg · 1995 · Background
    PubMed: PMID 7782852 · NCT01837862 · Glioblastoma
  5. Pre-irradiation chemotherapy in children with high-grade astrocytoma: tumor response to two cycles of the '8-drugs-in-1-day' regimen. A Childrens Cancer Group study, CCG-945.
    Finlay JL, Geyer JR, Turski PA, et al. · J Neurooncol · 1995 · Background
    PubMed: PMID 7699420 · NCT01574092 · Brain Neoplasms

1994 (5 papers)

  1. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations.
    Mandard AM, Dalibard F, Mandard JC, et al. · Cancer · 1994 · Background
    PubMed: PMID 8194005 · NCT01858649 (BEV-ONCO2012) · Colorectal Neoplasms
  2. Treatment options and prognosis for multicentric juvenile pilocytic astrocytoma.
    Mamelak AN, Prados MD, Obana WG, et al. · J Neurosurg · 1994 · Background
    PubMed: PMID 8207524 · NCT01837862 · Glioblastoma
  3. Gliomas of the anterior visual pathway.
    Dutton JJ · Surv Ophthalmol · 1994 · Background
    PubMed: PMID 8009427 · NCT01837862 · Glioblastoma
  4. Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients.
    de Forni M, Bugat R, Chabot GG, et al. · Cancer Res · 1994 · Background
    PubMed: PMID 8044782 · NCT00001495 · Neoplasms
  5. Topoisomerase I inhibitors. An overview of the camptothecin analogs.
    Burris HA, Fields SM · Hematol Oncol Clin North Am · 1994 · Background
    PubMed: PMID 8040144 · NCT04059562 (TRITICC) · Cholangiocarcinoma

1993 (6 papers)

  1. Resection margins in carcinoma of the head of the pancreas. Implications for radiation therapy.
    Willett CG, Lewandrowski K, Warshaw AL, et al. · Ann Surg · 1993 · Trial result
    PubMed: PMID 8094952 · NCT03167112 (Folfirinox) · Pancreatic Neoplasms
  2. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo.
    Kim KJ, Li B, Winer J, et al. · Nature · 1993 · Background
    PubMed: PMID 7683111 · NCT02119026 (PASSION) · Colorectal Neoplasms
  3. Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors.
    Duffner PK, Horowitz ME, Krischer JP, et al. · N Engl J Med · 1993 · Background
    PubMed: PMID 8388548 · NCT01837862 · Glioblastoma
  4. Chemotherapy for pilocytic astrocytomas.
    Brown MT, Friedman HS, Oakes WJ, et al. · Cancer · 1993 · Background
    PubMed: PMID 8490847 · NCT01837862 · Glioblastoma
  5. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.
    Brodeur GM, Pritchard J, Berthold F, et al. · J Clin Oncol · 1993 · Background
    PubMed: PMID 8336186 · NCT07334301 (BEACON2) · Neuroblastoma
  6. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.
    Aaronson NK, Ahmedzai S, Bergman B, et al. · J Natl Cancer Inst · 1993 · Background
    PubMed: PMID 8433390 · NCT00941655 · Stomach Neoplasms

1992 (2 papers)

  1. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
    Newlands ES, Blackledge GR, Slack JA, et al. · Br J Cancer · 1992 · Background
    PubMed: PMID 1739631 · NCT04689347 · Colorectal Neoplasms
  2. Treatment of children with progressive or recurrent brain tumors with carboplatin or iproplatin: a Pediatric Oncology Group randomized phase II study.
    Friedman HS, Krischer JP, Burger P, et al. · J Clin Oncol · 1992 · Background
    PubMed: PMID 1732426 · NCT01837862 · Glioblastoma

1991 (3 papers)

  1. Management of chiasmal and hypothalamic gliomas of infancy and childhood with chemotherapy.
    Petronio J, Edwards MS, Prados M, et al. · J Neurosurg · 1991 · Background
    PubMed: PMID 1901597 · NCT01837862 · Glioblastoma
  2. Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer.
    Negoro S, Fukuoka M, Masuda N, et al. · J Natl Cancer Inst · 1991 · Background
    PubMed: PMID 1653362 · NCT00001495 · Neoplasms
  3. Importance of histologic condition and treatment of pediatric cerebellar astrocytoma.
    Conway PD, Oechler HW, Kun LE, et al. · Cancer · 1991 · Background
    PubMed: PMID 1851047 · NCT01837862 · Glioblastoma

1989 (1 paper)

  1. Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity.
    Hertzberg RP, Caranfa MJ, Holden KG, et al. · J Med Chem · 1989 · Background
    PubMed: PMID 2537428 · NCT01574092 · Brain Neoplasms

1988 (3 papers)

  1. Treatment results of juvenile pilocytic astrocytoma.
    Wallner KE, Gonzales MF, Edwards MS, et al. · J Neurosurg · 1988 · Background
    PubMed: PMID 3392563 · NCT01837862 · Glioblastoma
  2. Treatment of chiasmatic/hypothalamic gliomas of childhood with chemotherapy: an update.
    Packer RJ, Sutton LN, Bilaniuk LT, et al. · Ann Neurol · 1988 · Background
    PubMed: PMID 3345069 · NCT01837862 · Glioblastoma
  3. Results of the treatment of children with recurrent gliomas with lomustine and vincristine.
    Lefkowitz IB, Packer RJ, Sutton LN, et al. · Cancer · 1988 · Background
    PubMed: PMID 3338054 · NCT01837862 · Glioblastoma

1987 (1 paper)

  1. Gene for von Recklinghausen neurofibromatosis is in the pericentromeric region of chromosome 17.
    Barker D, Wright E, Nguyen K, et al. · Science · 1987 · Background
    PubMed: PMID 3107130 · NCT00393094 · Brain Neoplasms

1986 (3 papers)

  1. The Norton-Simon hypothesis revisited.
    Norton L, Simon R · Cancer Treat Rep · 1986 · Background
    PubMed: PMID 3510732 · NCT05381038 · Neoplasms
  2. Occupational exposure and brain tumors.
    Moss AR · J Toxicol Environ Health · 1986 · Background
    PubMed: PMID 4093991 · NCT00393094 · Brain Neoplasms
  3. DNA content and chromosomal composition of malignant human gliomas.
    Bigner SH, Bjerkvig R, Laerum OD, et al. · Neurol Clin · 1986 · Background
    PubMed: PMID 3001489 · NCT00393094 · Brain Neoplasms

1985 (2 papers)

  1. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.
    Kalser MH, Ellenberg SS · Arch Surg · 1985 · Trial result
    PubMed: PMID 4015380 · NCT03167112 (Folfirinox) · Pancreatic Neoplasms
  2. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I.
    Hsiang YH, Hertzberg R, Hecht S, et al. · J Biol Chem · 1985 · Background
    PubMed: PMID 2997227 · NCT04789941

1983 (1 paper)

  1. Treatment of liver hydatid disease with mebendazole: a prospective study of thirteen cases.
    Gil-Grande LA, Boixeda D, Garcia-Hoz F, et al. · Am J Gastroenterol · 1983 · Background
    PubMed: PMID 6613972 · NCT01837862 · Glioblastoma

1980 (1 paper)

  1. Pleomorphic xanthoastrocytoma: a distinctive meningocerebral glioma of young subjects with relatively favorable prognosis. A study of 12 cases.
    Kepes JJ, Rubinstein LJ, Eng LF, et al. · Cancer · 1980 · Background
    PubMed: PMID 498051 · NCT01837862 · Glioblastoma

1971 (1 paper)

  1. Cytotoxicity and mode of action of 5-azacytidine on L1210 leukemia.
    Li LH, Olin EJ, Buskirk HH, et al. · Cancer Res · 1971 · Background
    PubMed: PMID 5487063 · NCT05381038 · Neoplasms

1967 (1 paper)

  1. [Documentation of forensic-chemical studies on punched cards].
    Müller RK · Dtsch Z Gesamte Gerichtl Med · 1967 · Background
    PubMed: PMID 5966423 · NCT04059562 (TRITICC) · Cholangiocarcinoma

Sources and methodology

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).